Loyola University Chicago

Loyola eCommons
Dissertations

Theses and Dissertations

1996

Characterization of Central Serotonergic Alterations in Male Rats
Following Prenatal Exposure to Fluoxetine
Theresa M. Cabrera
Loyola University Chicago

Follow this and additional works at: https://ecommons.luc.edu/luc_diss
Part of the Pharmacology Commons

Recommended Citation
Cabrera, Theresa M., "Characterization of Central Serotonergic Alterations in Male Rats Following Prenatal
Exposure to Fluoxetine" (1996). Dissertations. 3403.
https://ecommons.luc.edu/luc_diss/3403

This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons.
It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 1996 Theresa M. Cabrera

LOYOLA UNIVERSITY CHICAGO

CHARACTERIZATION OF CENTRAL SEROTONERGIC ALTERATIONS IN
MALE RATS FOLLOWING PRENATAL EXPOSURE TO FLUOXETINE

A DISSERTATION SUBMITTED TO
THE FA CUL TY OF THE GRADUATE SCHOOL
IN PARTIAL FULFILLMENT OF THE REQUIREMENT
FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY

DEPARTMENT OF PHARMACOLOGY
AND EXPERIMENTAL THERAPEUTICS

BY
THERESA M. CABRERA

CHICAGO, ILLINOIS
JANUARY, 1996

lOYOLA U

NIVERSITY MEDICAL CENTER LIBRARY

Copyright by Theresa M. Cabrera, 1995
All rights reserved

ii

ACKNOWLEDGEMENTS

I would like to thank my advisors Drs. George Battaglia and Louis D. Van de
Kar for the enormous amount of time and resources they have given me during my
tenure as a graduate student. In addition to my edification in all aspects of the
scientific process and experimental technique, my mentors have instilled in me
what I hope is the right combination of confidence and trepidation that I need to
succeed in whatever lies ahead in my career. I am especially grateful to Dr.
Battaglia for his unwavering support, collegiality and friendship. I am deeply
indebted to my laboratory colleagues Wilfred Pinto and Francisca Garcia for
generously and consistently offering a helping hand when I needed it the most. In
addition, as is the nature of the experiments described in this dissertation, these
studies could not have been carried out without the cooperation of many people
from different laboratories. Namely, I would like to thank Qian Li, Kayoko
Kunimoto, Frank Tung, Wilfred Pinto, Francisca Garcia, Christopher Chambers, Dr.
Nancy Muma, Hans Kusters, David Guran, and Dr. Andrew Levy; all of whom
participated to varying degrees with the work presented in this dissertation.
I am grateful to my dissertation committee Drs. Lydia Don Carlos, Robert J.
Handa, and Israel Hanin for all their helpful comments and insightful discussion
during the course of this dissertation work. In addition, I would like to thank Dr.
Robert Handa and for generously donating his time to provide me with some of my
initial training in the developmental field and for providing our laboratory with some
iii

necessary resources; Dr. Lydia Don Carlos for helping me struggle through the
neuroanatomy; Dr. Stanley Lorens for supporting me in my endeavor to go to
graduate school and for providing me with my initial research opportunities in
Pharmacology; and Dr. Israel Hanin for his support in my professional endeavors,
and for helping me develop the plethora of skills that I needed to "survive"
graduate school, and that I will use for the rest of my career.
I gratefully acknowledge the support of the faculty, students and staff, of
the Department of Pharmacology; and the financial support supplied by Loyola
University and the National Science Foundation.

I am especially grateful to Mrs.

Corrine Arthur for her assistance in the preparation of this dissertation.
A special word of thanks goes to my sister Michelle for giving freely of her
time to ease my burden and ensure that my dissertation was formatted properly so
that I could make it through these last few months a little bit more smoothly.
Lastly, I am grateful to my entire family, especially my parents and my husband
Paul, for all the unending support and sacrifices that they have made to ensure that
I was successful in this endeavor.

iv

ABSTRACT

Fluoxetine (Prozac®) is an antidepressant which selectively inhibits the
reuptake of serotonin (5-HT) into presynaptic nerve terminals. Limited preclinical
studies suggest that prenatal exposure to fluoxetine may affect progeny brain
neurochemistry at doses which do not alter the physical development of the
offspring. The dissertation objective was to identify and characterize
neurochemical and functional changes in central serotonergic systems in
prepubescent and adult male rat progeny produced by prenatal exposure to
fluoxetine.
Pregnant rats were administered saline or fluoxetine (10 mg/kg, s.c.) daily
from gestational day 13 through 20. Neurochemical parameters assessed in the
brains of offspring include: (1) 5-HT and 5-hydroxy indoleacetic acid (5-HIAA)
content; (2) the density of 5-HT uptake sites; and (3) 5-HT 1 A and 5-HT2 A receptors
in specific neuroanatomic loci. The functional status of brain 5-HT pathways was
assessed by investigating: (1) the ability of the 5-HT releasing drug pchloroamphetamine (PCA) to reduce 5-HT content and (2) the ability of the 5-HT,A
agonist 8-0H-DPAT and the 5-HT 2 A12 c agonist DOI to elicit increases in plasma
levels of adrenocorticotropic hormone (ACTH), corticosterone, and renin.
Site-specific alterations in the density of 5-HT uptake sites were observed
only in prepubescent offspring prenatally exposed to fluoxetine. In contrast, in
both prepubescent and adult progeny prenatally exposed to fluoxetine, select

v

regional decreases were observed in brain 5-HT content. Basal 5-HIAA content
was not altered by prenatal fluoxetine exposure. However, the magnitude of the
PCA-induced reduction in midbrain 5-HT content was significantly attenuated in
fluoxetine-exposed adult progeny, suggesting some alteration in uptake or release
mechanisms.
With respect to functional indices, basal levels of plasma hormones (ACTH,
corticosterone and renin) were not altered by prenatal fluoxetine exposure.
However, the ACTH response to DOI was significantly attenuated in adult but not
in prepubescent progeny prenatally exposed to fluoxetine. In contrast, the
neuroendocrine responses to 8-0H-DPAT were not affected by prenatal exposure
to fluoxetine. Likewise, while numerous site-specific alterations in 5-HT 2 A
receptors were observed in offspring prenatally exposed to fluoxetine, 5-HT,A
receptors were minimally affected by the prenatal treatment.
In summary, prenatal exposure to fluoxetine results in site-specific and agedependent alterations in brain 5-HT pathways in offspring in the absence of
physical abnormalities. As dysfunction of 5-HT pathways is implicated in the
etiology of various psychiatric disorders, these observed alterations may be of
some clinical significance to human offspring prenatally exposed to fluoxetine.
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CHAPTER I
INTRODUCTION

Fluoxetine (Prozac ®i is a member of the class of antidepressants known as
Selective Serotonin Reuptake Inhibitors (SSRl's) as it preferentially inhibits the
transport of serotonin (5-HT) into presynaptic nerve terminals without blocking the
uptake of norepinephrine or dopamine. In addition, fluoxetine has negligible
affinity for brain serotonergic, catecholaminergic, histaminergic, GABAergic,
muscarinic, benzodiazepine, and opiate receptors (Peroutka and Snyder, 1980;
Thomas et al., 1987; Fuller et al., 1991; Wong et al., 1991 ). Acutely, blockade of
the 5-HT uptake site increases synaptic concentrations of 5-HT. Subchronic
blockade of the 5-HT transporter in adult rats has been reported to result in a
desensitization of inhibitory somatodendritic autoreceptors, thus enhancing
serotonergic neurotransmission (Blier et al., 1990; de Montigny et al., 1990). This
enhancement of serotonergic neurotransmission is linked to fluoxetine' s
therapeutic efficacy. In addition, repeated administration of fluoxetine to adult
male rats has been reported to alter the density and sensitivity of postsynaptic
brain 5-HT receptors (e.g. 5-HT,, 5-HT,M and 5-HT 2 A12c; Wong and Bymaster,
1981; Dumbrille-Ross and Tang, 1983; Wong et al., 1985; Welner et al., 1989; Li

et al., 1993a, b), as well as to alter the concentration of brain 5-HT and 5-HIAA
(5-hydroxy indoleacetic acid; a 5-HT metabolite; Hrdina, 1987; Baron et al., 1988;
Sarkissian et al., 1990; Caccia et al., 1992). Thus, fluoxetine can markedly alter
serotonergic neurotransmission in adult animals.
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In humans, the high degree of selectivity of this drug for the 5-HT
transporter produces less of the side effects commonly encountered with the
tricyclic antidepressants and, in part, accounts for the widespread use of this drug
as well as other similarly selective reuptake inhibitors such as paroxetine {Paxil®),
sertraline (Zoloft®), and fluvoxamine (Luvox®). Although initially indicated for the
treatment of depression, in recent years fluoxetine has been assessed for
therapeutic efficacy in a variety of psychiatric conditions including obsessivecompulsive (Fontaine and Chouinard, 1986, 1989; Pigott et al., 1990) and eating
disorders (Pijl et al., 1991; Walsh and Devlin, 1992; Wise, 1992; Yen and Fuller,
1992; Wood A., 1993), as well as a potential treatment for cocaine and alcohol
abuse (Batki et al., 1993; Messiha , 1993). Because of fluoxetine's widespread
use, it is likely that a large percentage of the population of patients taking this
medication will be women of child bearing age. Yet, despite the potential for the
exposure of human offspring to fluoxetine (or other SSRl's), to date, only a few
studies have been published investigating the teratogenic potential of this widely
prescribed medication.
In humans, prenatal fluoxetine exposure did not result in an increased risk
of malformations (Pastuszak et al., 1993). Studies in rats and rabbits also indicate
that prenatal exposure to moderate doses (i.e. doses that were not toxic to the
maternal animal) of fluoxetine does not produce any gross physical abnormalities in
the offspring, nor does it affect fetal viability or litter size (Stanford and Patton,
1993; Byrd and Markham, 1994; Cabrera and Battaglia, 1994; Vorhees et al.,
1994). In addition, two laboratories have examined the behavior of rat offspring
prenatally exposed to fluoxetine in a variety of paradigms and found no adverse
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consequences of fluoxetine exposure (Hoyt et al., 1989; Vorhees et al., 1994). In
contrast to the absence of physical terata following prenatal fluoxetine exposure,
other evidence indicates that prenatal exposure to fluoxetine can produce
neurochemical alterations in offspring. Montero et al. (1990) reported that prenatal
exposure to fluoxetine decreased [ 3 H]imipramine binding to 5-HT uptake sites in
the cortex of prepubescent rat offspring. Likewise, Romero et al. (1994)
demonstrated that prenatal exposure to fluoxetine reduced cortical 5-HT 2 A
receptor-stimulated phosphoinositide hydrolysis in prepubescent, but not adult,
progeny. These studies are consistent with data demonstrating that both
fluoxetine and its active metabolite, norfluoxetine, cross the placenta and enter
fetal brain tissue (Pohland et al., 1989). After infiltrating fetal brain tissue,
fluoxetine may alter extracellular concentrations of 5-HT by interacting with 5-HT
transporters present on developing neurons and glia.
In fetal rats, 5-HT uptake sites have been demonstrated to be present as
early as embryonic day 1 5 and evidence suggests that these sites may be hyperfunctional during brain development (Whitaker-Azmitia and Azmitia, 1986;
Mercado and Hernandez-A., 1992; lvgy-May et al., 1994). In addition, several 5HT receptors (5-HT,A, 5-HT, 8 , 5-HT 2 A and 5-HT 2 cl have been reported to be
present in fetal rat brain (Uzbekov et al., 1979; Bruinink et al., 1983;
Whitaker-Azmitia et al., 1990a; Roth et al., 1991; Voigt et al., 1991; Hellendall et

al., 1993; Hillion et al., 1993). The presence of 5-HT (Lidov and Molliver, 1982;
Wallace and Lauder, 1983) and a variety of central 5-HT recognition sites during
fetal rat development suggests that drugs which interact with, and modulate 5-HT
systems in adults, also have potential sites of action in the fetus. Consistent with
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this idea, several studies have demonstrated that during pregnancy, the
administration of drugs which modulate serotonergic neurotransmission produce
neurochemical alterations in brain 5-HT pathways in offspring. For example,
alterations in pre- and/or postsynaptic components of brain 5-HT pathways have
been reported following maternal administration of the 5-HT precursor L-tryptophan
(Hernandez-Rodriguez and Chagoya, 1986), the serotonin synthesis inhibitor pchlorophenylalanine (Whitaker-Azmitia et al., 1987), directly acting serotonin
agonists (Whitaker-Azmitia et al., 1987; Whitaker-Azmitia et al., 1990b), or
monoamine oxidase inhibitors (Whitaker-Azmitia et al., 1994). Therefore, our
hypothesis is that disruption of the regulation of 5-HT concentrations during fetal
brain development by the administration of fluoxetine will result in neurochemical
and functional alterations in brain 5-HT pathways in offspring.
The objective of this dissertation is to identify and characterize
neurochemical and functional alterations in central serotonergic systems in
prepubescent (postnatal day 28; PD 28) and adult (PD 70) male rat progeny
prenatally exposed to fluoxetine. Male animals were chosen for these experiments
in order to prevent any confounding influence of hormonal cycling in
postpubescent females. The characterization of fluoxetine-induced alterations at
two developmental time points (PD 28 and PD 70) allowed for the determination of
whether any observed alterations were limited to prepubescent progeny (i.e.
present at PD 28, but not at PD 70), or persisted into adulthood (i.e. present at PD
28 and PD 70). Alternatively, fluoxetine-induced alterations may become apparent
only after the progeny mature (i.e. not present at PD 28, but present at PD 70).
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The consequences of prenatal fluoxetine exposure on brain 5-HT pathways
in progeny were assessed by determining the functional status of ( 1 ) presynaptic
5-HT neurons and (2) postsynaptic 5-HT target tissues, and by (3) assessing the
presence of alterations in the density of 5-HT recognition sites in specific
neuroanatomic loci. The functional status of presynaptic 5-HT terminals was
assessed by measuring basal levels of 5-HT and 5-HIAA, and by investigating the
ability of the 5-HT releasing drug p-chloroamphetamine (PCA) to reduce 5-HT
content. PCA enters the serotonergic nerve terminals via the 5-HT uptake site and
then blocks 5-HT synthesis and stimulates the release of 5-HT, resulting in a
significant decrease in regional 5-HT content (Fuller et al., 1965; Fuller, 1980,
1992; Kuhn et al., 1985; Adell et al., 1989; Fattaccini et al., 1991; Rudnick and
Wall, 1992). Differences in the magnitude of the reductions in regional 5-HT
content, in control versus fluoxetine-exposed offspring, following PCA
administration would indicate differences in the functional integrity of either the 5HT transport mechanism and/or the neurotransmitter release process. On the other
hand, similar decreases in regional 5-HT content in control versus fluoxetineexposed offspring would indicate that prenatal fluoxetine does not produce global
changes in 5-HT transport mechanisms or release processes in specific brain
regions. In addition, the ratio of 5-HT:5-HIAA levels was determined as an index
of serotonin turnover.
The functional status of postsynaptic 5-HT,A and 5-HT 2 A receptors was
assessed by measuring the ability of the selective 5-HT,A agonist 8-0H-DPAT (8hydroxy dipropylaminotetraline) and the 5-HT 2 A12 c agonist DOI ( ± 4-iodo,2,5
dimethoxy phenylisopropylamine) to elicit increases in plasma levels of
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adrenocorticotropic hormone (ACTH), corticosterone, and renin the secretion of
which can be regulated by central 5-HT pathways. 5-HT fibers which originate in
the dorsal and median raphe nuclei innervate a number of forebrain areas and send
collaterals to certain hypothalamic nuclei including the paraventricular nucleus
(appendix 3). Some of these hypothalamic serotonergic nerve terminals stimulate
ACTH and renin secretion (Karteszi et al., 1982; Van de Kar et al., 1985a). For
example, the activation of hypothalamic 5-HT,A and 5-HT 2 A12 c receptors has been
reported to increase plasma ACTH and corticosterone levels (Koenig et al., 1987;
Lorens and Van de Kar, 1987; Gilbert et al., 1988a,b; Calogero et al., 1989;
Przegalinski et al., 1989; Alper, 1990; Fuller, 1990; Van de Kar, 1991 ), while the
stimulation of central 5-HT 2 A receptors has been reported to elevate plasma renin
levels (Van de Kar et al., 1985b; Rittenhouse et al., 1990; Van de Kar, 1991 ).
The ability of the selective 5-HT,A agonist 8-0H-DPAT and the 5-HT 2 A12 c agonist
DOI to elicit increases in plasma levels of ACTH, corticosterone, and renin provides
an index of the functional status of hypothalamic 5-HT receptor subtypes. These
studies may provide a peripheral marker of central serotonergic dysfunction in
association with in utero exposure to fluoxetine.
Lastly, the effect of prenatal exposure to fluoxetine on the regional
innervation of 5-HT neurons, as well as on the density of 5-HT 1 A and 5-HT 2 A
receptor subtypes was determined by quantitative in vitro autoradiography.

These

studies can provide a comprehensive map of fluoxetine-induced alterations in preand postsynaptic 5-HT recognition sites. All neurochemical parameters were
assessed in brain regions receiving varying degrees of serotonergic innervation, as
well as those brain regions rich in 5-HT immunoreactive perikarya. Herein we
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report that prenatal exposure to fluoxetine produces site-specific and agedependent alterations in the neurochemical and functional status of both pre- and
postsynaptic components of brain serotonin systems in male offspring.

CHAPTER II
REVIEW OF RELATED LITERATURE

Ontogeny of the Serotonergic System in Rat Brain
Cell Bodies

The development of the serotonergic system in the rat embryo was first
described using fluorescence histochemistry (Levitt and Moore, 1978; Olsen and
Seiger, 1972; Seiger and Olsen, 1973). However, the fluorophore formed from 5HT photodecomposes rapidly, and a significant portion of the serotonergic
innervation was not visualized with the histofluorescence method (Lidov et al.,
1980; Lidov and Molliver, 1982a,b). Subsequently, immunocytochemical
procedures that provided more reliable and sensitive visualization were employed
and form the basis of our current knowledge of the development of the
serotonergic system in rat brain (Steinbusch et al., 1978; Lidov and Molliver,
1982a,b; Wallace et al., 1982; Aitken and Tork, 1988; Konig et al., 1988).
Overall, during the gestational period from GD 12-18, 5-HT immunoreactive cells
will proliferate, form complex dendritic trees, and migrate to their permanent
positions (Aitken and Tork, 1988). These changes are described briefly below.
Serotonergic neurons first appear at GD 12 as a bilateral rostral cluster of
cells just caudal to the mesencephalic flexure (Aitken and Tork, 1988). At this
immature stage, the neurons are smooth, round, and have no dendrites (Lidov and
Molliver, 1982a). By GD 14 the rostral cluster of cells enlarges and a caudal
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cluster of scattered 5-HT immunoreactive neurons first appears in the medulla
caudal to the pontine flexure (Lidov and Molliver, 1982a; Aitken and Tork, 1988).
At GD 13-14 the serotonergic neurons no longer appear immature. During this
stage, the neurons are sending out numerous dendritic processes away from the
ventricular surface (Lidov and Molliver, 1982a; Wallace and Lauder, 1983; Aitken
and Tork, 1988), and fine axonal processes cross the midline and may serve as a
commissural connection between the bilateral 5-HT cell groups (Lidov and Molliver,
1982a; Wallace and Lauder, 1983; Aitken and Tork, 1988). By GD 15, the
genesis of the neurons in the B7-9 complex is essentially complete (Wallace and
Lauder, 1983). At this stage, the 5-HT immunoreactive neurons can still be seen
as two distinct groups, but they have increased in size and number. At this point
there are also prominent bilateral bundles of ascending and descending 5-HT axons
emerging from the rostral and caudal cell groups respectively (Lidov and Molliver,
1982a; Aitken and Tork, 1988). By GD 16, 5-HT immunoreactive cells have
become more numerous and less compact. Aggregations of cells within the rostral
and caudal cell groups begin to form and are the first signs of the neuronal subsets
that will later form distinct raphe nuclei (Lidov and Molliver, 1982a). For example,
four subdivisions of the superior group are apparent: ( 1 ) the dorsal group will form
the dorsal raphe; (2) the medial group, will form the median raphe and may
contribute some neurons to the nucleus pontine centralis oralis and to the B9 cell
group; (3) the transient lateral; and (4) ventro-lateral groups will form the B9 group
and contribute to the raphe magnus. In addition, two divisions are now apparent
in the inferior group which will form the raphe pallidus and obscurus (Lidov and
Molliver, 1982a). At GD 17, the formation of a fused 5-HT immunoreactive

10
nucleus becomes apparent (Jacobs and Azmitia, 1992), and by GD 19 the
distribution of serotonergic neurons in the brainstem is similar to that found in the
adult (Lidov and Molliver, 1982a; for review see Tork, 1990). The development of
serotonergic cell bodies is essentially complete by GD 19 (Lidov and Molliver,
1982a). From GD 19 through the first postnatal week, there is a rapid growth of
5-HT dendrites and a decrease in cellular packing density in individual nuclei but
the overall morphology of the cell groups in the brainstem does not change (Lidov
and Molliver, 1982a).

Axonal Projections

Since the caudal group of raphe nuclei primarily innervate the spinal cord,
only the ascending projections from the rostral nuclei will be discussed. Similar to
the development of the 5-HT cell bodies, the development of the ascending
projections has been studied primarily using immunocytochemical techniques
(Lidov and Molliver, 1982b; Wallace and Lauder, 1983; D' Amato et al., 1987;
Aitken and Tork, 1988; Wallace and Lauder, 1992).
As mentioned above, the first axonal projections are those which cross the
midline and link the bilateral groups of rostral nuclei at about 12-13 days of
gestation (Wallace and Lauder, 1983). At GD 14-15 axons have extended rostrally
to the mesencephalic flexure. At this stage the serotonergic axons are
unbranched, relatively uniform and have few varicosities; unlike the axons seen in
adults which are finer, more varicose and twisted (Lidov and Molliver, 1982b).
Growth cones stain intensely for 5-HT at this stage. By GD16, bilateral bundles of
ascending 5-HT axons pass completely through the mesencephalon and can be
seen at the border of the diencephalon and telencephalon (Lidov and Molliver,

11
1982b; Wallace and Lauder, 1983; Aitken and Tork, 1988). At this stage the
number of 5-HT immunoreactive fibers increases in the lateral hypothalamus,
reaching as far rostrally as the supraoptic region (Lauder, 1990). By GD 17, the
ascending 5-HT axons in the medial forebrain bundle (MFB) innervate the basal
forebrain and the rostral pole of the telencephalon (Lidov and Molliver, 1982b;
Wallace and Lauder, 1983; Aitken and Tork, 1988). Although 5-HT fibers reach
the frontal cortex by GD 17 (Lidov and Molliver, 1982a; Blue and Molliver, 1985),
the adult cortical laminar pattern is not complete until approximately two weeks
postnatally (Jacobs and Azmitia, 1992). The signals for terminal sprouting are not
known, but have been suggested to be a function of the target cells rather than
the 5-HT afferents themselves (Jacobs and Azmitia, 1992). At GD 18, there is an
increase in 5-HT immunoreactivity in several areas of the hypothalamus (e.g. the
mammillary complex, and the anterior hypothalamus; Wallace and Lauder, 1983),
and by GD 19, the serotonergic pathways to all major divisions of the forebrain
have been established. The layout of 5-HT projections is similar to GD 17,
however, the axon density at GD 19 has increased (Lidov and Molliver, 1982b).
At this stage, 5-HT fibers leaving the MFB form branches in which serotonergic
axons travel along specific fiber bundles such as the fasciculus retroflexus,
mammillotegmental tract, stria medullaris, supracallosal stria and external capsule.
5-HT fibers have been suggested to use these other fibers as mechanical guides to
innervate a target area; a process termed "epiphytic guidance" (Azmitia, 1978;
Jacobs and Azmitia, 1992). At GD 19, synapses have been observed on dorsal
raphe neurons which increase in number for several weeks postnatally (Lauder and
Bloom, 1975). Axon density continues to increase through GD 21, and new
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subcortical and hippocampal terminal fields develop. At GD 21, 5-HT axons can
be seen in the cerebellum; the amygdala, as well as the paraventricular nucleus of
the hypothalamus are densely innervated. In general, most areas of the brainstem
are densely innervated by this stage (Lidov and Molliver, 1982b). 5-HT terminal
field formation continues postnatally especially in the telencephalon, tectum and
cerebellum (Lidov and Molliver, 1982b).
In summary, the ontogeny of 5-HT axonal projections has been described
by Lidov and Molliver (1982b) as occurring in 3 stages: (1) Initial axon elongation
(GD 13-16). This phase overlaps considerably with the formation of raphe nuclei
described above and ends when axons in the medial forebrain bundle first enter the
basal forebrain; (2) The development of selective pathways (GD 15-19), which
begins with the appearance of 5-HT fibers in the mamillo-tegmental tract and the
fasciculus retroflexus at about GD 15, and ends when axons have reached the
vicinity of all the structures in the brain that are to receive 5-HT innervation; and
(3) terminal field development (GD 19-PD 21). In general, the development of
terminal innervation is region specific (Lidov and Molliver, 1982b). Brain areas
rostral to the pons develop terminal arborizations primarily postnatally, indicating
that 5-HT axons do not innervate immature, primarily proliferative neuronal
populations (Lidov and Molliver, 1982b). The rapid and dramatic development of
serotonergic cell bodies and axonal projections from GD 13 through birth make this
period of development particularly sensitive to perturbations in the serotonergic
system.
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Serotonin Recognition Sites, Synthesis and Degradation Enzymes
Relatively few studies have investigated the presence of 5-HT receptors
during perinatal development of the rat brain. Most of these studies have
employed radioligand binding analysis in homogenates or synaptosomes.

In 1979,

Uzbekov et al. reported a high density of [ 3 HJ5-HT binding sites in rat brain
immediately postnatally. This finding was later confirmed by Fillion et al. (1982)
and by Whitaker-Azmitia et al. (1987). Around the same time, Daval et al. (1987)
demonstrated that 5-HT,A receptors were expressed in fetal rat brain in excess of
adult levels. Similarly, high levels of 5-HT,A receptors were reported in human
fetal brain in excess of adult levels (Bar-Peled et al., 1991 ). More recently, using
more sensitive molecular biological techniques, Hillian et al., (1993) detected 5HT,A receptor mRNA in rat brain as early as GD 12. This group also noted that the
concentration of 5-HT,A transcripts reached a maximum at GD 15 and then
progressively decreased to low levels before birth. Interestingly, this peak in 5HT,A mRNA occurs at a time when target cells of 5-HT neurons are undergoing
differentiation (Lauder and Krebs, 1978). Subsequently, Hillian et al. (1994)
reported that 5-HT,A receptors were detectable in embryonic brain stem cultures 2
days after mRNA was initially detected. In addition, 5-HT,A receptor protein and
mRNA were localized to neuron-like cells but not in glial cells in brainstem cultures
taken from GD 14-GD 16 rats (Hillian et al., 1994). The apparently selective
localization of 5-HT,A receptors to neuronal cells is contradictory to previous
reports (Whitaker-Azmitia and Azmitia, 1989; Hellendall et al., 1992). 5-HT 18
mRNA has also been identified in rat brain as early as GD 17 (Voigt et al., 1991 ).
With respect to the 5-HT 2 receptor family, Bruinink et al. (1983) identified
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3

H]spiperone binding to 5-HT 2 A receptors as early as GD 15-16 in rat forebrain

homogenates. In addition, Roth et al. (1991) demonstrated that 5-HT 2 A receptors
increased 8-fold between GD 17 and PD 13, while 5-HT 2 c receptors increased only
2-fold between GD 17 and PD 27. This increase in 5-HT 2 A and 5-HT 2 c receptor
number was also accompanied by increases in the level of mRNA for each receptor
subtype. Consistent with these data, Pranzatelli (1993) also reported an increase
in 5-HT 2 c receptors in rat cortex and diencephalon during the preweanling period.
Interestingly, the rank order of the density of 5-HT 2 c receptors shifted from
postnatal day 1 (brainstem
diencephalon

>

spinal cord

>
=

cortex

>

spinal cord) to postnatal day 28 (cortex

brainstem

=

hippocampus).

5-HT 3 receptors have

been reported to be present during brain development in mice (Shtrom et al.,
1993). However, 5-HT 3 receptors have not been identified in fetal rat brain. In
addition, some indirect evidence (i.e. profile of 5-HT stimulation of adenylyl
cyclase) suggests that 5-HT 4 receptors may be present and functional in fetal
mouse and rat brain (Dumuis et al., 1988a,b; Enjalbert et al., 1978). However, no
studies have definitively demonstrated the presence of 5-HT 4 receptors in fetal rat
brain.
In 1987, Whitaker-Azmitia et al. investigated the functional status of fetal
rat 5-HT receptors by testing their ability to regulate in response to serotonergic
perturbing agents. This group treated pregnant rats with either p-chlorophenylalanine (PCPA; a tryptophan hydroxylase inhibitor) or 5-methoxytryptamine
(5-MT; a nonselective 5-HT agonist) and examined [ 3 H]5-HT binding in forebrain
and brain stem homogenates of postnatal progeny. The administration of PCPA
increased [ 3 H]5-HT binding in the forebrain and brain stem at PD 1 while 5-MT
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administration decreased [ 3 HJ5-HT binding in both areas at PD 1 . The
demonstration that forebrain and brain stem 5-HT receptors respond to alterations
in the serotonergic system during development indicates that fetal 5-HT receptors
appear to be functional and capable of playing a role in neuronal development
(Whitaker-Azmitia et al., 1987). This study also demonstrates that prenatal
perturbation of the serotonergic system can result in postnatal alterations in
progeny brain 5-HT systems. Further evidence of functional 5-HT 1 A receptors in
fetal rat brain includes a study by Becquet et al. (1992) in which they reported that
the 5-HT lA agonist 8-0H-DPAT inhibited the spontaneous and K +-evoked release of
[

3

HJ5-HT in primary cultures from GD 14 rat raphe nuclei.
In addition to 5-HT receptors, 5-HT uptake sites are present and functional

in fetal rats. Whitaker-Azmitia and Azmitia (1986) demonstrated active 5-HT
uptake in cultures composed of mesencephalic raphe cells (GD 14) and
hippocampal cells (GD 18). More recently, Mercado and Hernandez (1992)
isolated prenatal growth cone particles and found that fetal growth cone particles
take up more [ 3 H]5-HT per unit time than PD 5 growth cone particles. This
apparent hyperactivity of prenatal 5-HT uptake systems in brain supports the
importance of critically regulating extracellular 5-HT concentrations during the
development of fetal rat brain. Consistent with this idea, lvgy-May et al. ( 1994),
demonstrated that the 5-HT transporter is present on growth cones prior to
synapse formation. In addition, this group reported that active 5-HT uptake into
growth cone fractions (prepared from GD 20 rats) could be inhibited by fluoxetine.
Other components of the serotonergic system that have been detected prior
to birth include 5-hydroxytryptophan decarboxylase activity (Bennett and Giarman,
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1965), monoamine oxidase activity (Shimizu and Morikawa, 1959; Nachmias,
1960; Karki et al., 1962; Kurzepa and Bojanek, 1965), tryptophan 5-hydroxylase
(Baker and Quay, 1969), and tryptophan (Hamon and Bourgoin, 1979; Blue and
Molliver, 1987).
The presence of functional central 5-HT recognition sites during fetal rat
development suggests that drugs which interact with 5-HT systems in adults have
potential sites of action in the fetus.

Serotonin as a Developmental Signal
In the 1960-70's Buznikov et al. measured 5-HT levels in non-mammalian
species during the initial stages of embryogenesis and demonstrated that 5-HT
concentrations fluctuate during the cell division cycle (Buznikov et al., 1964;
Buznikov et al., 1972; Buznikov, 1973). Their study was one of the earliest
reports to suggest that 5-HT might have a role in the regulation of development.
Since these initial reports, many studies have detected high concentrations of 5-HT
during development of the central nervous system prior to assuming its role as a
neurotransmitter (for review see Buznikov, 1984). These and other more recent
studies support a role for 5-HT as a developmental signal and/or trophic factor in
several animal species. Some of the key reports on this topic are discussed below.
In 1984, Haydon et al. reported that when 5-HT is placed directly adjacent
to a growth cone of the pond snail Helisoma, a reversible retraction of the growth
cone filopodia and lamellipodia was observed, as well as a decrease in the growth
cone surface area and motility. By inhibiting neurite outgrowth, 5-HT was
demonstrated to prevent the formation of electrical connections with other
competent neurons. Similar results were reported by Davila-Garcia et al. in which
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cultured raphe neurons of the rat exposed to 5-HT exhibited an inhibition of neurite
outgrowth (Davila-Garcia et al., 1985). Conflicting reports on the role of 5-HT in
development include a report by Liu and Lauder (1991 ). In this study, the
presence of nialamide (a monoamine oxidase inhibitor) in cultures of rat embryonic
neurons increased the neuronal soma area, the number of neurites, and neurite
branching in 5-HT immunoreactive cells; although there was some evidence that 5HT inhibited the effects of nialamide. Other reports in vertebrate neuronal cultures
report concentration dependent effects of 5-HT on neuronal outgrowth. WhitakerAzmitia et al., (1990b) demonstrated that in neuronal cultures derived from GD 1314 rat pups, low concentrations of a non-selective 5-HT agonist (5-MT; 1-100 nM)
inhibited growth of 5-HT neurons. However, higher concentrations ( > 1,000 nM)
stimulated growth (Whitaker-Azmitia et al., 1990b). Similarly, when 5-MT was
given to pregnant rats from GD 12 to birth, there was an increase in terminal
outgrowth in the forebrain (as measured by [ 3 H]5HT uptake) at high doses but
inhibited growth at low doses. These reports suggest that 5-HT may also act as a
trophic stimulus for survival and growth of 5-HT cell bodies.
In addition to its role in the growth of the pre-synaptic neuron, serotonin
has also been demonstrated to initiate and amplify its own synthesis, as well as
affect 5-HT target area development, and cellular proliferation. A stimulatory role
of 5-HT on the expression of neurochemical markers of serotonergic neurons was
reported in 1986 by De Vitry et al.. This group demonstrated that incubation of
mouse embryonic hypothalamic cells with 8-0H-DPAT increased the intensity of 5HT immunoreactive staining and the number of 5-HT immunoreactive cells. The
proposed autocrine stimulation was shown to be receptor-mediated as this effect
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was blocked by co-incubation with the non-selective 5-HT antagonist, metergoline.
In 1992, Chubakov et al. demonstrated that the morphological and functional
development of hippocampal explants could be stimulated by the exogenous
administration of 5-HT or by co-culture of hippocampal neurons with raphe nuclei.
Likewise, the absence of 5-HT has been shown to result in an altered morphology
of 5-HT target regions and retarded cell proliferation (Lauder and Krebs, 1978;
Goldberg and Kater, 1989).
Although the site(s) of action for serotonin's effects on developing nerve
cells is(are) unknown, evidence suggests that serotonin's effects during
development are regulated within growth cones and/or glial cells (Haydon et al.,
1984; Mattson and Kater, 1987; Aitken and Tork, 1988) presumably by activation
of one or more 5-HT receptor subtypes. The evidence in support of growth cone
regulation includes studies which demonstrated a high degree of 5-HT
immunoreactivity in the growth cones of developing 5-HT neurons (Aitken and
Tork, 1988). Also, when Helisoma growth cones are physically isolated they
continue motile and elongation behaviors and remain sensitive to neurotransmitters
(Haydon et al., 1984; Mattson and Kater, 1987). The report by Haydon et al.
( 1 984) in Helisoma cultures also demonstrated that the focal application of 5-HT to
either the neurite or the soma did not result in any inhibitory effects.
Other evidence suggests an involvement of 5-HT,A receptors on glial cells in
the role of 5-HT as a developmental signal. Glial cells have an active uptake
system for 5-HT and contain 5-HT receptors, MAO, and other catabolizing and
synthesizing enzymes and may be capable of releasing neurotransmitter (Katz and
Kimelberg, 1985; Whitaker-Azmitia and Azmitia, 1986; Hansson et al., 1987).
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Whitaker-Azmitia and Azmitia ( 1989) demonstrated that the stimulation of rat
astroglial cells in culture with either 8-0H-DPAT or ipsapirone (selective 5-HT 1 A
agonists) produces a conditioned medium which when used as an incubation
medium for primary 5-HT neuron cultures increases serotonergic neuronal
membrane surface area (as reflected by increased [ 3 H]5HT uptake;
Whitaker-Azmitia and Azmitia, 1989; Whitaker-Azmitia et al., 1990a,b). In
contrast, TFMPP (trifluoro-methyl-phenyl-piperazine; a 5-HT 18 agonist) did not
produce a conditioned medium capable of altering neuronal membrane area. It has
been suggested that, in vivo, astrocytes may be in contact with 5-HT cell bodies
or terminals and may produce a factor which is important for neuronal survival or
growth (Whitaker-Azmitia and Azmitia, 1989). The substance believed to be
produced by the astrocytes is S-100 8 protein (Azmitia et al., 1990; Jacobs and
Azmitia, 1992).
8-0H-DPAT has been shown to stimulate astrocytes to release S-100 8
which promotes growth of embryonic 5-HT neurons (Whitaker-Azmitia and
Azmitia, 1989; Azmitia et al., 1990; Whitaker-Azmitia et al., 1990a). In addition,
inactivation of S-100 8 prevents the growth-stimulating effects of ipsapirone
(Whitaker-Azmitia et al., 1990). It has recently been proposed that S-100 8
mediates the growth of serotonergic neurons by inhibiting the phosphorylation of
the neuron-specific protein F1 /GAP 43 (Sheu et al., 1994). This protein is highly
expressed in brain during periods of normal growth and is present in large
quantities in midbrain rap he serotonergic neurons (Skene, 1989; Bendetti et al.,
1991; Meberg and Routtenberg, 1991). Based on their investigations, WhitakerAzmitia et al. (1990b) have speculated that the development of 5-HT neurons is
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dependent on the balance between two high affinity 5-HT receptors one of which
is localized on 5-HT neurons and regulates 5-HT release; stimulation of this
unidentified 5-HT receptor subtype results in stunting of neurites or abnormal
morphology. The second receptor is a 5-HT,A receptor localized on astroglial cells;
stimulation of which results in the production of "factors" regulating the
development of 5-HT neurons {Whitaker-Azmitia et al., 1990b).
In addition to the controversy concerning the site of action of 5-HT, the
signal transduction mechanism is unknown as well. Several second messenger
systems {Ca+ 2 , cyclic nucleotides, phosphoinositides) have been suggested to be
involved in mediating the effects of neurotransmitters on neurite outgrowth. For
example, in the He/isoma neuron 819, 5-HT has been demonstrated to increase
ca+ 2 influx into growth cones {Cohan et al., 1987), and the outgrowth inhibitory
effects of 5-HT could be prevented by application of ca+ 2 blockers {Mattson and
Kater, 1987). Other reports indicate that high ca+ 2 levels result in neurite
retraction and eventual death {Choi, 1985; Cohan et al., 1987). In contrast,
Nyakas et al. (1989) have reported that serotonergic neurons grown in low ca+ 2
medium have smaller somas and fewer processes after 3 days in culture.
Although cAMP {Shapiro, 1973; Schubert et al., 1978; Nirenberg and
Wilson, 1984; Taylor-Hunter et al., 1987; Mattson et al., 1988) and inositol
phospholipids {Spinelli and Ishii, 1983; Traynor, 1984; Reboulleau, 1986;
Taylor-Hunter et al., 1987) have been implicated in the regulation of neuronal
outgrowth and synaptogenesis, the reports have been conflicting. Some studies
show that increases in intracellular cAMP levels enhance neurite extension in PC
12 cells {Schubert et al., 1978), embryonic rat cortical cells {Shapiro, 1973), and
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hippocampal pyramidal neurons (Mattson, 1988). On the other hand, in He/isoma
B 1 9 neurons, elevations in cAMP inhibited neurite elongation and growth cone
motility (Mattson, 1988). Similarly, phorbol activators have been found to
promote neurite outgrowth (Spinelli and Ishii, 1983) in neuroblastoma cells, as well
as cause a retraction of filopodia and lamellipodia (Taylor-Hunter et al., 1987).
Outgrowth of neurites can also be affected by electrical activity (Marsh and
Beams, 1946; Patel and Pao, 1982). Filopodia and lamellipodia of He/isoma
neurons retracted and ceased elongation when action potentials were induced in
these neurons (Cohan and Kater, 1986). Also, depolarization of Helisoma neurons
by acetylcholine prevented the 5-HT induced inhibition of neurite outgrowth in B19
neurons (McCobb and Kater, 1986; Mattson, 1988).
Although there currently is no consensus on the exact role of 5-HT in
development (trophic or inhibitory) nor the specific mechanisms involved or site(s)
of action, it is clear that changes in 5-HT levels can result in alterations in the
development of 5-HT axons and target areas. Therefore, the critical regulation of
brain 5-HT levels during the development of central 5-HT systems is important to
maintaining its integrity.

The Administration of Selective Serotonin Reuptake
Inhibitors to Adult Rats Alters Brain Neurochemistry
Fluoxetine was first described in the scientific literature as a selective 5-HT
uptake inhibitor in 1974 (Fuller et al., 1974). In 1988, fluoxetine (Prozac®) was
approved for clinical use in the United States as a treatment for depression. To
date, fluoxetine is currently being investigated for therapeutic efficacy in a variety
of psychiatric disorders known to involve dysfunctional 5-HT systems. Because
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fluoxetine is a highly selective compound, patients experience fewer side effects
following a therapeutic regimen of fluoxetine versus those observed for nonselective tricyclic antidepressants, and consequently compliance is generally
greater for fluoxetine than for the tricyclic antidepressants. In addition, fluoxetine
is less toxic (especially when taken in overdose) than its predecessors the tricyclic
antidepressants. However, similar to the tricyclic antidepressants, fluoxetine (and
other SSRls) requires at least 2 weeks of daily administration prior to the onset of
significant clinical efficacy. Therefore, preclinical studies have investigated the
consequences of acute (single administration), sub-chronic ( ~ 14 d), and chronic
(;;::::: 21 d) administration of fluoxetine (and other SSRls) on brain monoamine
systems. Some of the key studies will be described below. Most of the research
has focused on understanding fluoxetine-induced alterations in brain 5-HT
pathways in an attempt to elucidate fluoxetine's mechanism(s) of action, and
achieve an understanding of the neurochemical processes involved in the etiology
of depression and other psychiatric disorders.

Acute Effects of Selective Serotonin Reuptake Inhibitors
Recent microdialysis studies have revealed that the acute peripheral
administration of the 5-HT uptake inhibitors citalopram ( 1 or 10 mg/kg),
clomipramine (20 mg/kg) or fluvoxamine (10 mg/kg) results in a 2-6 fold increase
in extracellular 5-HT concentrations in the dorsal raphe nucleus (lnvernizzi et al.,
1992; Bel and Artigas, 1992; Adell and Artigas, 1991 ). In contrast, the
administration of a low (1 mg/kg) dose of citalopram did not alter extracellular
levels of 5-HT in the frontal cortex (lnvernizzi et al., 1992). However, extracellular
5-HT was significantly elevated in the frontal cortex following a high dose (10
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mg/kg) of citalopram (lnvernizzi et al., 1992). Dose-dependent responses in
extracellular 5-HT content were also observed in other brain regions innervated by
5-HT neurons. For example, low doses of the 5-HT uptake inhibitors citalopram or
paroxetine (0.5 mg/kg) decreased extracellular 5-HT concentrations in the
hippocampus (Hjorth and Auerbach, 1994). However, higher doses of citalopram
(5 mg/kg) or fluoxetine (10 mg/kg) increased extracellular 5-HT in the hippocampus
(Hjorth, 1993; Sabol et al., 1992). Following a single administration of fluoxetine
( 10 mg/kg) increases in extracellular 5-HT concentration have been reported in the
striatum (Perry and Fuller, 1992; Rutter and Auerbach, 1993) and diencephalon
(Rutter and Auerbach, 1993). The differential response of 5-HT cell body regions
(e.g dorsal raphe) and terminal regions (e.g. cortex) to peripherally administered 5HT uptake inhibitors was unexpected as both cell body and terminal regions were
equally sensitive to local administration of SSRls. Together, these studies
suggested that the increase in extracellular 5-HT levels by low doses of SSRls in
the dorsal raphe prevented the increase in 5-HT expected in terminal regions.
Consistent with this hypothesis, Hutson et al., 1989 demonstrated that 8-0HDPAT applied locally to the dorsal raphe decreased extracellular 5-HT in the
hippocampus. Therefore, it has been hypothesized that activation of 5-HT,A
receptors in the dorsal raphe may mediate the inhibitory effect of SSRls on
extracellular 5-HT in terminal regions. Subsequently, further evidence to support
this theory was put forth using 5-HT 1 antagonists. For example, lnvernizzi et al.
( 1992) observed that increases in extracellular cortical 5-HT concentrations after
peripheral citalopram administration could be elicited if rats were pretreated with
methiothepin (a non-selective 5-HT 1 antagonist). Using a more selective 5-HT 1 A
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antagonist, Hjorth and Auerbach ( 1994) demonstrated that (-)WAY 100135
abolished the decrease in 5-HT observed in the hippocampus following systemic
injection of low doses of citalopram or paroxetine. Thus, low doses of SSRls
increase extracellular 5-HT in cell body regions which activates presynaptic
autoreceptors, inhibits neuronal firing, and inhibits the subsequent release of 5-HT
into terminal areas. Thus, following acute administration of low doses of 5-HT
uptake inhibitors, there is no significant elevation of extracellular 5-HT in terminal
regions. However, the inhibitory effects of SSRls, mediated by the activation of 5HT 1A autoreceptors, can be overcome by the administration of higher doses of the
uptake inhibitor. In summary, the nature of the effect of uptake inhibitors on
extracellular 5-HT concentrations is region- and dose-specific.
In contrast to the complexity of changes in extracellular 5-HT
concentrations, extracellular 5-HIAA concentration is consistently reduced
following acute SSRI administration. For example, 5-HIAA extracellular 5-HIAA
concentrations were significantly reduced in the diencephalon following acute
fluoxetine administration ( 10 mg/kg; Rutter and Auerbach, 1993). The reduction in
extracellular 5-HIAA has also been reported to occur in the hippocampus following
acute sertraline (11 mg/kg) administration (Manfridi et al., 1992).

Subchronic and Chronic Effects of Selective Serotonin Reuptake Inhibitors
In addition to investigating the effects of acute administration of SSRls,
several studies have investigated the effects of subchronic and chronic
administration of 5-HT uptake inhibitors such as fluoxetine on various aspects of
brain serotonin systems in the rat. Similar to observations made following acute
SSRI administration, the most consistent finding following subchronic and chronic
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SSRI exposure is a reduction in regional brain 5-HIAA content. For example, a
single administration of either citalopram or fluoxetine decreases brain 5-HIAA
content as measured by HPLC analysis {Baker and Goodrich, 1982; Baker and
Hoff, 1987; Hyttel, 1977b; Caccia et al., 1992). The reduction in 5-HIAA persists
throughout the duration of the treatment (as long as 21 d; Caccia et al.,
1992;Hrdina, 1987; Baron, 1988) and can return to control values upon
discontinuation of the drug {Caccia et al., 1992). The reduction in 5-HIAA content
following acute, subchronic or chronic SSRI administration is believed to be the
result of blockade of 5-HT reuptake and a consequent reduction in the reuptake of
5-HT and its metabolism by intracellular monoamine oxidase (Beasley et al., 1992;
Rutter and Auerbach, 1993; Frankfurt et al., 1994). In contrast to the consistent
decrease in 5-HIAA observed after SSRI administration, brain 5-HT levels have
been reported to either decrease or remain constant following subchronic or
chronic SSRI administration. Some researchers have reported decreased brain 5HT content after a single dose of fluoxetine (20 mg/kg, i.p.; Savage, 1980) while
others report no change in cortical 5-HT content following either 4, 7, or 16 day
fluoxetine ( 10 mg/kg; Hrdina, 1987; Savage, 1980) administration but a reduction
in 5-HT content after 21 days (Hrdina, 1987). In contrast, Caccia et al. ( 1992)
reported decreased hippocampal and cortical 5-HT concentrations after 7 days of
fluoxetine administration (15 mg/kg, i.p.). Thus, changes in brain 5-HT
concentration following SSRls may be region and dose-dependent and appear to be
dependent on the treatment regimen employed.
With respect to changes in 5-HT receptors following subchronic and chronic
administration of SSRls, results are dependent on the duration of the treatment and
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the particular SSRI investigated. Some studies have reported that the
administration of fluoxetine ( 10 mg/kg/day, i.p. or via minipump) or citalopram
(dose, p.o.) for 14 days did not alter the density of 5-HT 2 A receptors (Baron et al.,
1988; Hyttel et al., 1984; Goodnough and Baker, 1994) in rat cortical
homogenates. However, Eison et al. (1991), reported that the continuous
administration of fluoxetine (20 mg/kg/day) via osmotic minipump for 14 days
decreased 5-HT 2 A receptors in rat cortex. Longer administration of fluoxetine ( 10
mg/kg/day for 21-28 days) has been reported to result increased 5-HT 2 A receptors
in rat cortical homogenates (Dumbrille-Ross and Tang, 1983) and increase 5HT 2 A 12c receptors in the hypothalamus (Li et al, 1993a). Other reports using the
same dose of fluoxetine, indicate a lack of changes in 5-HT 2 A receptors in cortical
homogenates after 21 days of fluoxetine treatment (Peroutka and Snyder, 1980;
Snyder and Peroutka, 1982). Similarly, Hyttel et al. (1984) reported a lack of
changes in 5-HT 2 A receptors in various brain regions after the administration of
citalopram (dose, p.o. x 14d). Still other studies reported that paroxetine
administration (5 mg/kg, i.p. x 21 d) decreased 5-HT 2 A receptors. With respect to
the sensitivity of the 5-HT 2 receptor subtypes, Kennet et al. ( 1994) reported that
chronic administration of either fluoxetine or paroxetine ( 10 mg/kg, p.o.)
attenuated the ability of mCPP to produce hypolocomotion suggesting a reduced
responsivity of 5-HT 2 c128 receptor subtypes.
No clear pattern of 5-HT, receptor changes following repeated SSRI
exposure has emerged from the literature. A reduction in 5-HT, receptors has
been observed after as few as three daily injections of fluoxetine (10 mg/kg, i.p.;
Wong et al., 1985) and following longer administration of fluoxetine ( 10 mg/kg/day
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for 24-28 days) in rat cortical homogenates (Dumbrille-Ross and Tang, 1983;
Wong et al., 1985). In addition, using in vitro autoradiography, decreased 5-HT 1 A
receptor density in the dorsal raphe nucleus was observed after long-term
treatment (21 d) with fluoxetine (Welner et al., 1989). However, 5-HT 1 A receptors
were not altered in either the hippocampus or temporal cortex (Welner et al.,
1989), regions containing 5-HT 1 A receptors on non-serotonergic neurons. Other
reports using the same dose of fluoxetine (10 mg/kg/day, i.p.) indicate a lack of
change in 5-HT 1 receptors in cortical homogenates after 21 days of fluoxetine
treatment (Peroutka and Snyder, 1980; Snyder and Peroutka, 1982). Likewise,
data from our laboratory (Li et al., 1993b) indicate a lack of alterations in the
density of 5-HT 1 A receptors in both the cortex and hypothalamus (Li et al., 1993a),
following long-term (21 d) administration of fluoxetine (10 mg/kg, i.p.). However,
a reduced neuroendocrine responsiveness of hypothalamic 5-HT 1 A receptors was
observed following long-term (21 d) administration of fluoxetine to adult male rats.
Likewise, in humans, chronic administration of fluoxetine resulted in an attenuated
5-HT 1 A-mediated increase in ACTH/cortisol release and hypothermic response.
Alterations in the density of 5-HT uptake sites have also been reported
following repeated administration of SSRls. Brunelle et al. ( 1987) reported that
citalopram administration ( 10 mg/kg/day) for 15 days decreased the number of
imipramine binding sites in rat cerebral cortex. In contrast, Hrdina and Vu (1993)
using a more selective ligand ([ 3 H]paroxetine) and more detailed autoradiographic
techniques reported that chronic administration of fluoxetine ( 10 mg/kg) increased
the density of 5-HT uptake sites in the frontoparietal cortex, striate cortex, CA 1
area of the hippocampus and in the superior colliculus. In general, however, the
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changes in 5-HT uptake sites following fluoxetine administration are small in
magnitude.
Other effects on brain 5-HT systems that have been associated with 5-HT
uptake blockers include a reduction in 5-HT 7 receptors in the hypothalamus
following 21 d administration of fluoxetine (5 mg/kg, p.a.; sleight et al., 1995). In
addition, short-term administration of fluoxetine (10 mg/kg, i,p. x 4d) has been
reported to result in a decrease in 5-HT turnover in the ventromedial nucleus and
an increase in 5-HT turnover in the median raphe (Frankfurt et al., 1994). Lastly,
chronic administration of fluoxetine has been reported to result in a decrease in the
maximal rate of 5-HT uptake into cortical synaptosomes (Hrdina, 1987).
Effects on other neurotransmitter systems include reports indicating that the
administration of citalopram ( 15 d, 1Omg/kg) increased alpha-1 receptors, and
decreased beta-2 receptors in rat cerebral cortex (Brunello et al., 1987; Milne and
Goa, 1991). These studies are in contrast to other reports with either citalopram
or paroxetine which indicate either no change or a decrease in cortical adrenergic
receptors (Hyttel et al., 1984; Nelson et al., 1989, 1990). In addition to changes
in receptor density following 5-HT uptake blockers, Baron et al. (1 988) reported a
decrease in beta adrenergic receptor-mediated cAMP production after subchronic
fluoxetine administration ( 10 mg/kg, i.p., bid x 14 d). Other reports indicate no
changes in beta receptor sensitivity (Schmidt and Thornberry, 1977; Mishra et al.,
1979) following a similar paradigm. In addition, Fluoxetine ( 10 to 30 mg/kg)
administration for 21 days decreased dopamine content in the striatum and
nucleus accumbens (Gardier et al., 1993; Caccia et al., 1992). Frankfurt et al.
( 1994) administered fluoxetine ( 10 mg/kg, i.p.) for 4 days and observed an
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increase in norepinephrine in the dorsomedial nucleus of the hypothalamus, the
dorsal raphe nucleus and the parietal motor cortex.
Other effects that have been associated with 5-HT uptake blockers include
increased activity of metabolizing enzymes in astrocytes (Bal-Klara, 1989),
increased corticotropin releasing hormone mRNA in the paraventricular nucleus and
increased mineralocorticoid receptor mRNA in the hippocampus after 8 weeks but
not 2 weeks of administration (Brady et al., 1992). Decreased plasma
corticosterone levels have also been observed after 2 week of fluoxetine (5mg/kg,
i.p.; Brady et al., 1992).
In summary, these observations indicate that repeated administration of
fluoxetine (and other SSRls) can markedly alter serotonergic neurotransmission in
adult rats and may indirectly effect other neurotransmitter systems as well.

Prenatal Exposure to Serotonin Uptake Inhibitors
Unfortunately, there is currently a paucity of information available on the
effects of prenatal exposure to 5-HT uptake inhibitors. One study in humans
suggests that prenatal fluoxetine exposure does not result in an increased risk of
malformations in the offspring at birth (Pastuszak et al., 1993). Other data, in
humans (provided by officials at the Eli Lilly Company) are anecdotal and
inconclusive (Shader, 1992a,b). Animal studies in rats and rabbits indicate that
prenatal exposure to moderate doses of fluoxetine (i.e. doses which are not toxic
to the maternal animal) does not result in any visually apparent physical
abnormalities in offspring, nor does it affect fetal viability or litter size (Stanford
and Patton, 1993; Byrd and Markham, 1994; Cabrera and Battaglia, 1994;
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Vorhees et al., 1994). However, an increased frequency of skin hematomas was
observed in fluoxetine-exposed rat offspring at birth (Stanford and Patton, 1993).
The hematomas were absorbed within 3-5 days after birth and no other adverse
vascular effects were observed in fluoxetine-exposed offspring. In mice, the
administration of fluoxetine from GD 9 - 12 did not result in any evidence of
embryotoxicity or growth retardation, however craniofacial abnormalities were
prevalent (Shuey et al., 1992).
A variety of behavioral measurements have also been assessed in
fluoxetine-exposed rat offspring and include locomotor activity, acoustic startle
response, passive avoidance responding, water maze task performance, nose-poke
activity, and onset of cliff avoidance behavior (Hoyt et al., 1989; Vorhees et al.,
1994). No significant pattern of treatment-related changes was observed in
fluoxetine-exposed offspring in any of the behavioral paradigms tested. In
addition, Hoyt et al. (1989) did not find any adverse effects of fluoxetine-exposure
on mating or fertility in rats.
In contrast to the absence of physical terata or neurobehavioral toxicity in
rats prenatally exposed to fluoxetine, other evidence indicates that prenatal
exposure to fluoxetine can produce neurochemical alterations in offspring.
Montero et al. (1990) reported that prenatal exposure to fluoxetine decreased
[

3

H]imipramine binding to 5-HT uptake sites in the cortex of prepubescent rat

offspring. Likewise, Romero et al. (1994) demonstrated that prenatal exposure to
fluoxetine reduced cortical 5-HT 2A receptor-stimulated phosphoinositide hydrolysis
in prepubescent, but not adult, progeny. These studies are consistent with data
demonstrating that both fluoxetine and its active metabolite, norfluoxetine, cross
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the placenta and enter fetal brain tissue (Pohland et al., 1 989). After infiltrating
fetal brain tissue, fluoxetine may alter extracellular concentrations of 5-HT by
interacting with 5-HT transporters present on developing neurons and glia. This
disruption of 5-HT regulation during fetal development may be responsible for the
neurochemical alterations observed in brain 5-HT pathways in offspring.
Similar to the data reported above, prenatal exposure to a low dose of the
5-HT uptake inhibitor zimelidine (3-5 mg/kg) did not alter litter size, progeny birth
weight, or open field behavior (Grimm and Frieder, 1987; Del Rio et al., 1988).
Likewise, no signs of pathological or morphological changes were observed in
various internal organs in adult progeny prenatally exposed to zimelidine (Grimm
and Frieder, 1987). However, early motor performance was altered by prenatal
zimelidine exposure (Grimm and Frieder, 1987). This same group of researchers
also reported a lack of effect of prenatal zimelidine exposure on active 5-HT uptake
and spontaneous 5-HT release in frontal cortical synaptosomal preparations made
from adult offspring. Consistent with these data, Del Rio et al. (1988) reported a
lack of effect of prenatal zimelidine exposure on the density of cortical 5-HT
uptake sites. Lastly, in rats and rabbits, prenatal exposure to moderate doses of
the 5-HT uptake inhibitor paroxetine (4.3 mg/kg) did not produce any physical
signs of teratogenicity. However, in rats, embryotoxicity was observed following
prenatal exposure to high doses of paroxetine (43 mg/kg; Baldwin et al., 1989).
To date, an extensive literature search of this area has revealed no other studies
investigating the effects of prenatal administration of fluoxetine (Prozac®),
paroxetine (Paxil®), sertraline (Zolott®), fluvoxamine (Luvox®), zimelidine or
citalopram. Some data are available, however, on prenatal exposure to
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clomipramine a tricyclic antidepressant with a high affinity for the 5-HT
transporter. Although direct comparisons between prenatal exposure to
clomipramine and the other aforementioned 5-HT uptake blockers is not possible,
as clomipramine is metabolized to a compound which has norepinephrine uptake
blocking activity, the effects of prenatal exposure to clomipramine serve to further
illustrate that alterations in 5-HT systems during pregnancy can produce long-term
changes in progeny in the absence of physical terata.
De Ceballos et al. (1985) administered clomipramine (10 mg/kg/day, s.c.) to
rats from GD 6 through pregnancy. While they did not observe any physical terata
at birth, in prepubescent rats, the density of beta receptors in the cortex was
decreased by 27%. With a similar treatment paradigm, Montero et al. (1991)
found no changes in 5-HT 18 receptor density while Del Rio et al. (1988) reported a
30 % decrease in 5-HT 2 A receptor density in the cortex, and De Ceballos et al.
( 1985) reported no change in D2 receptor binding in the striatum following prenatal
clomipramine. Likewise, preliminary data from our laboratory indicate that prenatal
exposure to clomipramine (10 mg/kg, s.c., GD 13-20) did not alter male:female
ratios per litter, or the total litter size. However, there was a 25 % decrease in
hypothalamic 5-HT 2 A 12c receptors in adult male progeny (unpublished observations).
In general, human case studies report that in utero exposure to clomipramine
results in only minor transient symptoms and an absence of physical terata (Cowe

et al., 1982; Ostergaard and Pedersen, 1982; Misri and Sivertz, 1991; Schimmel!
et al., 1 991). No neurochemical data are available following in utero exposure to
clomipramine or any other 5-HT uptake inhibitors in humans. While the detection
of physical teratogenesis is important, elucidating the neurochemical teratogenic
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potential of the SSRls may be important with respect to clinical disorders
associated with dysfunction of brain neurotransmitter systems.

CHAPTER Ill
MATERIALS AND METHODS

Animals

Pregnant Sprague-Dawley rats weighing 280-320 g were obtained from Zivic
Miller {Zelienople, PA) and were maintained in a temperature (22-24 ° C)-, humidity
(50-55%)- and illumination (12:12 hr light/dark cycle, lights on at 07:00)-controlled
facility. The determination of gestational day zero was carried out by the supplier,
and was defined by the presence of a copulatory plug.

All procedures were

conducted in accordance with the NIH Guide for the Care and Use of Laboratory
Animals and approved by the Loyola University Institutional Animal Care and Use
Committee.

Dams

Pregnant rats arrived in the laboratory on either gestational day 5
{experimental animals) or 7 {foster rats). In order to monitor nutritional intake,
starting on gestational day 8 {GD 8), and continuing throughout the injection
period, all experimental animals were placed on a nutritionally balanced liquid diet
consisting of Vitamin Diet Fortification Mixture {ICN Nutritional Biochemicals,
Cleveland, Ohio), Salt Mixture XIV {ICN Nutritional Biochemicals, Cleveland, Ohio),
chocolate flavored Sustacal {Mead Johnson, Evansville, Ind.) and water {Riley et
al., 1979). The foster rats had ad libitum access to rat chow {Teklab rodent lab
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blocks, Harlan Teklab, Bartonville, IL) and water. Foster dams were weighed and
received animal care identical to the experimental dams, but were not subjected to
any experimental procedures. Experimental dams received injections of either
0.9% saline (2ml/kg, s.c.) or fluoxetine (10 mg/kg/2ml, s.c.) daily (09:00)
beginning on GD 13, and ending on GD 20. After termination of the injection
paradigm, all animals had free access to food and water.

Offspring
At birth (i.e. postnatal day 0, PD 0), all offspring from each of the
experimental groups were fostered to untreated, lactating dams in order to
eliminate the possible influence of drug-induced differences in nurturing. At the
time of fostering, the litters were culled to no more than 9 pups per litter (5 males,
4 females). All pups were weaned on PD 21. Males and females were
subsequently housed separately in groups of 2 or 3 rats per cage, and had free
access to food and water. Only male animals were used for the remainder of the
experimental protocols. The number of samples (N) for each postnatal treatment
group was obtained by using a single pup from each of the litters. Progeny were
sacrificed by decapitation as described below at PD 28 or at PD 70. These ages
represent pre- and postpubescent time points, respectively.

Postnatal Experimental Protocols
Assessment of the Neurochemical and Functional Status of Serotonergic Neurons
Offspring were sacrificed 1 hr after receiving a single injection of either
saline or the 5-HT releaser p-chloroamphetamine (PCA; 5 mg/kg, i.p.). The brains
were quickly removed, placed on a cold petri dish and the hypothalamus, striatum,
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hippocampus, midbrain and frontal cortex dissected as described below.
These brain regions were chosen to represent: ( 1) areas which complete synapse
formation at differing postnatal ages (Lauder et al., 1982; Lidov and Molliver,
1982a,b; Wallace and Lauder, 1983; D' Amato et al., 1987); and/or (2) areas
receiving varying degrees of serotonergic innervation from the dorsal and median
raphe nuclei, in order to assess whether prenatal fluoxetine exposure may disrupt
select brain 5-HT pathways which follow differential developmental time courses.
The brain regions were immediately placed in cryovials, frozen in liquid nitrogen,
and then placed in a -70 • C freezer until analyzed for 5-HT and 5-HIAA content by
high performance liquid chromatography (HPLC; appendix 1 ). Basal levels of 5-HT
and 5-HIAA were determined in each brain region from animals receiving the saline
injection prior to sacrifice. As an index of "5-HT turnover", the ratio of 5-HT to 5HIAA values was calculated in individual animals in each prenatal treatment group.
This index provides rudimentary information regarding the turnover process (i.e.
synthesis, release, reuptake and degradation of the neurotransmitter). A detailed
investigation of these neuronal processes are beyond the scope of this
dissertation.
The functional status of presynaptic serotonergic terminals was assessed by
measuring the ability of the serotonin releaser PCA to reduce 5-HT content in
various brain regions. PCA enters the serotonergic nerve terminals via the 5-HT
uptake site, and then inhibits 5-HT synthesis and stimulates the release of 5-HT,
resulting in a significant decrease in regional 5-HT content (Fuller et al., 1965;
Fuller, 1980, 1992; Kuhn et al., 1985; Adell et al., 1989; Fattaccini et al., 1991;
Rudnick and Wall, 1992). Therefore, differences in the magnitude of the
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reductions in regional 5-HT content, in control versus fluoxetine-exposed offspring,
following PCA administration would indicate differences in the functional integrity
of either the 5-HT transport mechanism and/or the neurotransmitter release
process. On the other hand, similar decreases in regional 5-HT content, in control
versus fluoxetine-exposed offspring, would indicate the inability of prenatal
fluoxetine to produce global changes in 5-HT transport mechanisms or release
processes in specific brain regions (appendix 2).

Dissection Technique

Rats were killed by decapitation, their brains removed and rinsed in ice cold
saline then placed on a cold glass plate kept on ice. The brains were dissected
according to a modification of the procedure outlined by Glowinski and Iversen
( 1966). Briefly, the olfactory bulbs were removed with fine forceps and the brain
was placed on its dorsal surface. Next, the hypothalamus was delineated rostrally
by the fusion of the optic chiasm and caudally by the mammillary bodies and was
excised with the use of curved, fine forceps. After the removal of the hypothalamus, the brain was placed on its ventral surface, and a vertical cut was made,
with a thin steel razor blade, anterior to the corpus callosum. The area rostral to
the cut was taken as frontal cortex. The cortical hemispheres, including the
striatum and hippocampus, were dissected free from the remainder of the brain.
Using a gentle rocking motion, the striatum was dissected with curved forceps
using the external walls of the lateral ventricles as an internal boundary and the
corpus callosum as an external boundary. The hippocampus was removed from
the cortex by blunt dissection with a spatula. Finally, two vertical cuts were
required for the removal of the midbrain. First, a vertical cut was made with a
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steel razor blade rostral of the superior colliculi, and then the midbrain was
separated from the pons by a vertical cut just rostral to the cerebellum.

Assessment of the Functional Status of 5-HT 1A and 5-HT 2 A 12c Receptor Systems
Neuroendocrine Challenge Tests
Functional alterations in postsynaptic components of serotonergic systems
were determined at PD 28 or PD 70 by measuring the 5-HT receptor-mediated
stimulation of plasma hormones following a single s.c. injection of either saline, the
5-HT 1A agonist 8-0H-DPAT (0.5 mg/kg) or the 5-HT 2 A12 c agonist DOI (2 mg/kg) (see
appendices 3 and 4). The rats were sacrificed 30 min post-injection by
decapitation, and trunk blood was collected into centrifuge tubes containing 0.5 ml
of 0.3 M EDTA (pH 7.4) for subsequent analyses of plasma ACTH, corticosterone
and renin levels. The doses of 8-0H-DPA T and DOI were chosen based on
previous reports that 0.5 mg/kg 8-0H-DPAT and 2 mg/kg DOI elicit maximal
increases in plasma ACTH and corticosterone (Li et al., 1993a,b). In addition, 2
mg/kg DOI maximally increases plasma renin (Li et al., 1993a). The brains from
saline-challenged rats were removed and the hypothalamus and frontal cortex
dissected as previously described, placed in cryovials, frozen in liquid nitrogen, and
then placed in a -70 ° C freezer until used for radio ligand binding assays.

Percentage of High Affinity 5-HT 2 A Receptors
5-HT 1A and 5-HT 2 A receptors belong to a family of membrane-bound
receptors which interact with guanine nucleotide regulatory proteins (G-proteins)
as the initial phase in the activation of second messenger systems. These Gprotein linked receptors have been demonstrated to exist in 2 states; one state of
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the receptor is coupled to the G-protein while the other state of the receptor is
uncoupled from the G-protein (appendix 5). Because agonists interact with the
receptor and subsequently promote the formation of the agonist-receptortransducer complex, agonists exhibit differential affinities for these two states of
the receptor. Agonists exhibit a high affinity for the coupled state of the receptor
and a low affinity for the uncoupled state of the receptor. In contrast, antagonists
do not promote the formation of the ternary complex and therefore antagonists
interact with these receptors as a homogenous population of intermediate affinity.
Since agonists exhibit a high affinity for only one state of the receptor (the coupled
state), radiolabelled agonists (such as [ 125 1)001 and [ 3 H]8-0H-DPAT) will only label
the high affinity state of the receptor within the concentration range employed in
saturation studies. In other words, the density of agonist-labelled receptors
represents only a portion of the total population of receptors present in a given
brain region. In contrast, radiolabelled antagonists will label the total population of
receptors present in a given tissue. An alteration in the maximal density of
agonist-labelled (high affinity) receptors would be indicative of an alteration in the
number of receptors coupled to G-proteins. Changes in the number of G-protein
coupled receptors could occur as a result of 2 distinct mechanisms. The treatment
could have produced: (1) an alteration in the coupling efficiency of the receptors in
the absence of any changes in the total number of receptors present; or (2) an
alteration in the number of coupled receptors as a consequence of an alteration in
the total number of receptors present in a given tissue. The percentage of high
affinity labelled receptors would be altered in the first situation, and the percentage
would remain constant in the second scenario. Alternatively, it is theoretically
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possible for a given drug treatment to change the total number of receptors
without affecting the number of receptors coupled to the G-protein. In this case,
the percentage of high affinity receptors to the total population would also be
altered. In order to provide a comprehensive examination of changes in G-protein
linked receptors following a given drug treatment, the densities of both the agonist
and antagonist labelled receptors need to be determined. Because commercially,
radiolabelled 5-HT,A antagonists are currently not available, only the density of the
high affinity state of the 5-HT,A receptor could be examined autoradiographically in
the present studies. In contrast, radiolabelled 5-HT 2 A agonists and antagonists are
commercially available. Therefore, the present studies utilize both a radiolabelled
agonist and antagonist to determine whether changes in 5-HT 2 A receptor densities
(as determined by receptor autoradiography) reflect changes in the total receptor
density or the number of high affinity G-protein coupled receptors. In addition, as
an index of the ability of 5-HT 2 A receptors to couple to their respective G-proteins
(Gq/G 11 ), the percentage of high affinity agonist ([1 25 1]001) labelled 5-HT 2 A receptors
was calculated for each animal and in each brain region by dividing the maximal
density of [ 125 1)001 labelled receptors by the maximal density of the total (high and
low affinity) 5-HT 2 A receptor population and multiplying by 100. As the receptor
must couple to the G-protein in order to activate second messenger systems,
changes in either the absolute number or in the percentage of high affinity
receptors may have functional consequences for the organism.
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Determination of Site-Specific Alterations in 5-HT Recognition Sites
For all autoradiographic determinations, rats were killed by decapitation at
either PD 28 or PD 70, their brains were quickly removed, frozen on powdered dry
ice, secured with parafilm and plastic wrap then stored at -70 • C until sectioned for

in vitro autoradiography.

Neurochemical Determinations
High Performance Liquid Chromatography
HPLC determination of brain biogenic amines was carried out as described
by Saller et al. (1984) with some modifications. Brain regions were sonicated in
10 volumes of ice-cold 0.1 N perchloric acid containing 0.5 µM
dihydroxybenzylamine (DHBA) as the internal standard used to calculate the
recovery of the biogenic amines. The homogenate was then centrifuged at 20,000
x G for 15 min at 4 • C. Fifty micro liter aliquots of the supernatant were injected
onto an HPLC system. The HPLC system consisted of a delivery pump (Model
Waters 501, Waters, Marlbourgh, MA) in conjunction with a Waters 717
autosampler (Waters, Marlbourgh, MA) and analytical column (Microsorb C 18 5 µm,
150 mm X 4.6 mm, Rainin, Woburn, MA) protected by a guard column (Microsorb
C 18 5 µm, 150 mm X 4.6 mm, Rainin, Woburn, MA). An electrochemical detector
(Model LC-4C, Bioanalytical Systems West Lafayette, IN) with a glassy carbon
electrode was used at a voltage setting of

+ 0. 75 V versus an Ag/AgCI reference

electrode. The mobil phase was composed of 9 g/L monochloracetic acid, 0.25
mM EDTA, 0.375 g/L 1-octanesulfonic acid, and 1 % tetrahydrofuran (pH 3.0).
The solvent flow was maintained at 2.0 ml/min.

Standard solutions of 5-HT and

5-HIAA were prepared in ice-cold 0.1 N perchloric acid containing 0.5 µM DHBA.

42
The system was run by Millennium 2010 Chromatography Manager, a computer
program that performs data acquisition, processing and management of
chromatographic information (Waters, Marlbourgh, MA). Tissue precipitates were
resuspended in 0. 1 N NaOH to achieve a tissue concentration of approximately 30
mg/ml, then 20 µI aliquots were taken for protein determination according to the
method of Lowry et al. (1951 ). For each brain region, samples from prepubescent
and adult progeny were assayed simultaneously for brain monoamine content.

Radioimmunoassay of Plasma Hormones
Plasma ACTH
Radioimmunoassay of ACTH was performed on unextracted plasma samples
according to a previously published protocol (Carnes et al., 1986). Briefly, the
ACTH antiserum was obtained from lgG Corp (Nashville TN). ACTH (1-39)
standards were obtained from Calbiochem and

125

1-ACTH from INCSTAR

(Stillwater, MN). The sequence recognition of the antiserum is amino acids 5-18
of ACTH. In addition, this antiserum does not significantly recognize a-MSH,

P-

MSH, P-endorphin, P-lipotropin, ACTH 11-24 or ACTH 1-16-amide. In this double
antibody radioimmunoassay, samples or standards were incubated with the ACTH
antibody (final dilution 1 :30,000, 22% total binding) at 4 ° C for 24 hr in a 0.01 M
phosphate buffer (PBS, pH 7.6) containing 1 % bovine serum albumin (Sigma, St.
Louis, MO), 0.025 M EDTA, 0.5% normal rabbit serum (CalBiochem, San Diego,
CA) and 25 KIU/ml aprotinin (Sigma Chemical Co, St. Louis, MO).

125

1-ACTH (2000

cpm, INCSTAR, Stillwater, MN) was added and incubated for 24 hr at 4 ° C in a
total volume of 0.3 ml. The second antibody (goat anti-rabbit-v-globulin,
CalBiochem, San Diego, CA) was added at a final dilution of 1 :50 and incubated
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overnight at 4 ° C. 1.5 ml of cold PBS was added to the tubes and they were then
centrifuged at 15,000 X G at 4 ° C for 40 min. The radioactivity of the pellet
containing the antibody bound ligands was counted by a Micromedic 4/200 plus
counter. The sensitivity of the assay was 0.25 pg/tube and the intra- and interassay variations were 4.2% and 14.6% respectively.

Plasma Corticosterone

Radioimmunoassay of corticosterone was performed on unextracted plasma
samples as previously described {Van de Kar et al., 1985b). Antiserum was
obtained from ICN Biochemicals {Costa Mesa, CA). The assay buffer was 0.05 M
sodium phosphate {pH 7.0) containing 0.16 M sodium chloride, 0.015 M sodium
azide and 2.0 g/L gelatin to prevent adsorption to glassware. Plasma samples (2 µI
or 5 µI) or standard solutions containing 0 - 5 ng corticosterone per tube were
placed in a water bath at 80 ° C for 20 min to denature binding proteins. After the
tubes were cooled to room temperature, the plasma samples were incubated with
the tracer {[ 3 H]corticosterone; 5,000 to 6,000 cpm) and the antibody (1 :5600) at
4 ° C for 24 hr. The total volume of the assay was 0. 7 ml. To separate the bound
from the free tracer, the tubes were subsequently incubated for 10 min at 4 ° C
with 0.2 ml of a cold Dextran T70-charcoal suspension then centrifuged (15,000 X
G) for 20 min at 4 ° C. The supernatant containing the antibody-ligand complexes
was decanted into scintillation vials, and 5 ml of Omnifluor scintillation fluid was
added to each vial. After shaking the vials, the amount of free [ 3 H]corticosterone
present in the supernatant was counted on a Hewlett Packard MINAXY scintillation
counter for 2 min. The sensitivity limit was 0.02 ng/tube and the intra- and interassay variations were 4.5% and 11.9% respectively.
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Plasma Renin

Plasma renin concentration, assayed by generating angiotensin I (ANG I) in
the presence of a saturating concentration of exogenous renin substrate
(angiotensinogen), provides a measure for renin secretion. Plasma renin was
assayed according to a previously published protocol (Richardson-Morton et al.,
1989). Briefly, renin substrate was added to the plasma along with 0.5 M
phosphate buffer pH 6.0, phenylmethyl-sulfonyl fluoride (2.5 mM) and 8hydroxyquinoline (3.4 mM). The mixture was incubated at 37°C for 1 hour, and
the incubation was terminated by immersion of the samples in boiling water for 3
min. The radioimmunoassay of ANG I was performed using an antiserum (vdk2)
generated in New Zealand rabbits against angiotensin I at a dilution of 1: 16,000.
The cross reactivity of the antibody for angiotensin II is 0.0001 %; and for
neurotensin, bombesin, oxytocin, Leu 5 -enkephalin, Arg 8 -vasopressin, and ~
lipotropin, the cross reactivity is less than 0.0006%. The bound tracer (125 1-ANG I)
was separated from free tracer by the addition of a Dextran T500-charcoal
suspension followed by centrifugation. The pellet containing the unbound ANGI
and tracer was counted by a Micromedic 4/200 plus counter. The assay
sensitivity limit of the radioimmunoassay was 10 pg ANG I per tube and the intraassay variability was 4.4%. The inter-assay variation was 12.6%.

Radioligand Binding Assays in Homogenates
Tissue Preparation

Brain tissues were prepared according to a previously described protocol
(Leonhardt et al., 1992). Briefly, frozen tissue was weighed and placed in. a
minimum of 10 volumes of ice cold 50 mM Tris-HCI (pH 7.7, 25°C) containing 0.5
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mM EDTA and 10 mM MgS0 4 and homogenized using a Tekmar Tissumizer (2 x 5
sec). The homogenate was centrifuged at 30,000 X G for 1 5 min at 4 • C. Tissue
was resuspended in 30 volumes of buffer, homogenized, incubated at 37 ° C for 15
min, and then centrifuged at 30,000 X G for 10 min. Tissue was washed and
centrifuged once more. Finally, the tissue was resuspended to a volume of 20 30 mg wet wt./ml in cold 50 mM Tris-HCI (pH 7.7, 25 °C).

5-HT Uptake Sites
5-HT uptake sites were measured in homogenates of the frontal cortex,
hypothalamus, hippocampus, striatum and midbrain according to a previously
published protocol (Battaglia et al., 1987). [ 3 H]Paroxetine binding to 5-HT uptake
sites was carried out in 5.0 ml total volume containing 1 mg wet wt. of tissue and
a saturating concentration (0.4 nM) of [ 3 H]paroxetine (20 Ci/mmol) in 50 mM TrisHCI (pH 7. 7, 25 ° C), 120 mM NaCl and 5 mM KCI. Nonspecific binding was
determined by the addition of 1 .0 µM citalopram to a parallel set of tubes. Tubes
containing drugs and tissue were incubated for 120 min at room temperature, then
filtered rapidly using a Brandel Harvester fitted with Whatman GF/C filters that had
been presoaked in 0.5% polyethylenimine. The samples were next washed with
20 ml of 50 mM Tris-HCI (pH 7.7, 25°C). Filters were then added to scintillation
vials containing 5 ml of Ultima Gold (Packard Instrument Co., Inc., Downers Grove,
IL) scintillation fluid. The vials were shaken for 60 min and samples counted for
2.5 min on a Beckman LS5000TD scintillation counter at an efficiency of 60%.
For each brain region, samples from prepubescent and adult progeny were assayed
simultaneously.
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5-HT 2 A 12c Receptors
5-HT 2 A 12 c receptors were labelled in general accordance with the protocol by
Leonhardt et al., (1 99 2). Saturation studies were carried out in the hypothalamus
by incubating 1 .0 mg wet wt. of brain tissue with increasing concentrations of
[

125

1]001 ranging from 0.15 nM to 0.6 nM in 50 mM Tris-HCI, 10 mM MgS0 4 , 0.5

mM EOTA, 0.02% ascorbate, and 10µM pargyline (pH 7.7, 25°C) for 90 min at
room temperature. Nonspecific binding was defined in the presence of 10 µM 5HT. For comparative purposes only, 5-HT 2 A 12c receptor sites were also measured in
cortical tissue using a single concentration of radioligand (0.05 nM) below its Kd
value (0.4 nM) to screen for any detectable change in binding. This approach
renders radioligand binding sensitive to changes in either the affinity and/or density
of cortical 5-HT 2 A 12 c receptors. Briefly, 0.05 nM [ 125 1]001 in 50 mM Tris-HCI, 10
mM MgS0 4 , 0.5 mM EOTA, 0.02% ascorbate, and 10µM pargyline (pH 7.7,
25 ° Cl was incubated with 1.5 mg wet wt. of cortical tissue for 90 min at room
temperature. Nonspecific binding was defined in the presence of 10 µM 5-HT.
Following incubation, tubes containing drugs and tissue were filtered rapidly using
a Brandel Harvester fitted with Whatman GF/C filters. All the samples were
washed with 15 ml of 50 mM Tris-HCI (pH 7. 7, 25 ° C). Filters were then added to
75 x 12 mm plastic test tubes and counted in a Micromedic 4/200 Plus Automatic
Gamma Counter for 3 min each at an efficiency of 82%. For each brain region,
samples from prepubescent and adult progeny were analyzed simultaneously.
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Autoradiographic Analysis of Serotonin Recognition Sites
General Procedures

Fifteen micron thick coronal sections of brains were obtained at -20 ° C
using a cryostat (Hacker Instruments, Inc.). Sections were thaw-mounted onto
chrome alum/gelatin-coated microscope slides, and stored at -20 ° C until used for
autoradiographic analysis of 5-HT recognition sites. Coronal sections were taken at
the following levels according to the rat atlas by Paxinos and Watson (1986):
Bregma

+ 3.70 mm, + 1.00 mm, -0.30 mm, -1.80 mm, -2.80mm, -3.14 mm,

- 4.80 mm, -8.00 mm (figure 1 ). Prior to autoradiographic analysis, slide-mounted
brain sections were brought to room temperature.
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Figure 1 . Schematic drawings representing the levels of rat brain used in the
autoradiographic analysis of 5-HT recognition sites.
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Figure 1 Continued. Schematic drawings representing the levels of rat brain used
in the autoradiographic analysis of 5-HT recognition sites.
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Figure 1 Continued. Schematic drawings representing the levels of rat brain used
in the autoradiographic analysis of 5-HT recognition sites.
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G.

H.

Figure 1 Continued. Schematic drawings representing the levels of rat brain used in
the autoradiographic analysis of 5-HT recognition sites. Cross-hatched areas indicate
brain regions where the density of 5-HT recognition sites was determined. Bregma
+ 3.70 mm (A), + 1.00 mm(~), - 0.30 mm (C), - 1.80 mm (0), - 2.80 mm (~),
-3.14 mm (f), - 4.80 mm (G), - 8.00 mm (H). Abbreviation: cc, corpus callosum. The
remainder of the abbreviations are described in Table 10. All the data analysis was
carried out using the rat atlas by Paxinos and Watson (1986). However, for
illustrative purposes only, the above drawings were adapted from the computer
generated atlas by Swanson (1992) and chosen to represent levels which correspond
to appropriate Paxinos and Watson (1986) levels as stated in the Materials and
Methods section.
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Following the in vitro labelling of 5-HT recognition sites, the slides were
allowed to dry overnight in slide boxes containing desiccant before apposing them
to Hyperfilm-3H (Amersham Corporation, Arlington Heights, IL) at 4 ° C for 4 days
with [ 125 1]001, 30 days with [ 3 H]citalopram, or 60 days with [ 3 H]ketanserin and
[3H]8-0H-DPA T to generate the autoradiograms. Slides containing tritium or [ 125 1]
standards (Amersham Corporation) were included with each film to control for
exposure differences between films. The films were developed by placing them in
Kodak Developer D-19 for 5 min, then in Kodak Indicator Stop Bath solution for
30 sec, followed by 5 min in Kodak Fixer. The films were subsequently placed in a
running water bath containing Kodak Photo-Flo 200 Solution for 1 5 min, then air
dried. Autoradiograms were quantitated on a Macintosh Quadra 950 computer
using the public domain NIH Image program (developed at the U.S. National
Institutes of Health and available from the Internet by anonymous FTP from
zippy.nimh.nih.gov).

The amount of radioactivity present in each layer of the

standard polymers was carried out by the supplier (Amersham Corporation). In
addition, the supplier generated optical density vs. radioactivity curves using both
brain paste and polymer standards in order to determine the amount of
radioactivity present in each lay of the polymer standards per mg tissue equivalent.
Radioactive standards expressed as nCi/mg tissue equivalent (corrected for
radioactive decay) were converted to fmol of sites/mg tissue equivalent according
to following equations:

( 1)

[nCi/mg tissue equivalent]* [ 1 µCi/1000 nCi] * [2 .22E6 DPM/1 µCi] =
DPM/mg tissue equivalent
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(2)

[DPM/mg tissue equivalent] I [specific activity of radioligand * 2.221
fmol sites/mg tissue equivalent

Best-fit standard curves of film grey scale values generated by tritium or
[

125

1] standards co-exposed with labelled slides resulted when an exponential

function was used to describe the relationship between radioactive standards and
grey scale value. For each brain region and for each radioligand, a mean
determination of the fmol of sites labelled per mg tissue equivalent was carried out
by averaging the values obtained from 3-4 adjacent sections (measurements were
taken from both the right and left sides of the autoradiograms where applicable).
The determination of nonspecific binding was carried out in duplicate adjacent
sections from each animal and for each autoradiographic assay. Nonspecific
binding was subtracted from the total signal. For assays using [ 125 1], final values
were corrected for differences between the tissue section and standard polymer
thickness.

5-HT Uptake Sites
Autoradiographic localization of 5-HT uptake sites was determined
according to a modification of the protocol by D'Amato et al. (1987). Slide
mounted sections were preincubated at room temperature for 15 min in 50 mM
Tris HCI containing 120 mM NaCl and 5 mM KCI (pH 7.7 at 25 °C). Sections were
then incubated at room temperature in 0. 7 nM [ 3 H]citalopram (specific activity 81
Ci/mmol; Kct = 0.84 nM) in the absence or presence of 1 µM paroxetine to
determine nonspecific binding. Following incubation, sections were washed twice
in ice cold 50 mM Tris HCI containing 120 mM NaCl and 5 mM KCI (pH 7. 7 at
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25 ° C) for ten minutes each time then dipped in ice cold deionized water, and dried
rapidly under a stream of cold dry air.

High Affinity 5-HT,A Receptors
Autoradiographic localization of 5-HT 1A receptors was determined according
to a modification of the protocol by Pazos and Palacios (1985). The assay buffer
consisted of 0.17 M Tris HCI containing 4 mM CaCl 2 , 10 µM pargyline and 0.01 %
ascorbic acid (pH 7.6). Slide mounted sections were incubated at room
temperature for 1 hr in assay buffer containing 2 nM [3H]8-0H-DPAT (specific
activity 129.5 Ci/mmol) in the absence or presence of 1 µM 5-HT to determine
nonspecific binding. Following incubation, sections were washed twice in ice cold
assay buffer for ten minutes each time then dipped in ice cold deionized water, and
dried rapidly under a stream of cold dry air.

High Affinity 5-HT 2 A Receptors
Autoradiographic localization of high affinity 5-HT 2 A receptors was
determined according to a modification of the protocol by Appel et al. (1990). The
assay buffer consisted of 50 mM Tris HCI, 0.5 mM EDTA, 10 mM MgS04, 0.1 %
ascorbic acid, and 10 µM pargyline (pH 7. 7, 25 ° C). Slide mounted sections were
incubated at room temperature for 90 min in 0.2 nM [ 125 1]001 (specific activity
2200 Ci/mmol) in the absence or presence of 100 nM spiperone to determine
nonspecific binding. Following incubation, sections were washed twice in ice cold
assay buffer for ten minutes each time then dipped in ice cold deionized water, and
dried rapidly under a stream of cold dry air.
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The affinity of [ 125 1)001 for 5-HT 2 A receptors was determined in slide
mounted cortical sections in order to obtain Kd values for [ 125 1)001 so that
autoradiographic data could be extrapolated to 100 % fractional occupancy. Slide
mounted sections were incubated with concentrations of [ 125 1)001 ranging from 0.2
nM to 2.3 nM for 90 min at room temperature. 100 nM spiperone was used to
define nonspecific binding. Following incubation, sections were washed twice in
ice cold assay buffer for ten minutes each time then dipped in ice cold deionized
water. Each section was wiped from the slides using a Whatman GF/C filter,
placed in a test tube, then counted with a gamma counter for 3 min. The affinity
of the radioligand was determined using the lnPlot computer program {GraphPad
Software Inc., SanOiego, CA).

Total (High and Low) 5-HT 2 A Receptors

Autoradiographic localization of total 5-HT 2 A receptors was determined
according to a modification of the protocol by Pazos and Palacios (1985). The
assay buffer consisted of 0.17 M Tris HCI {pH 7. 7, 25 ° CJ. Slide mounted sections
were preincubated in assay buffer for 15 min at room temperature. The sections
were then incubated for 2 hr at room temperature in 0.4 nM [ 3 H]ketanserin
(specific activity 77. 1 Ci/mmol) in the presence of 30 nM prazosin to preclude
binding to alpha-1 receptors. Nonspecific binding was determined in the presence
of 1 µM cinanserin. Following incubation, sections were washed twice in ice cold
assay buffer for ten minutes each time then dipped in ice cold deionized water, and
dried rapidly under a stream of cold dry air.
The affinity of [ 3 H]ketanserin for 5-HT 2 A receptors was determined in slide
mounted cortical sections in order to obtain Kd values for [ 3 H]ketanserin so that
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autoradiographic data could be extrapolated to 100 % fractional occupancy. Slide
mounted sections were preincubated in assay buffer for 1 5 min at room
temperature. Sections were then incubated with concentrations of [ 3 H]ketanserin
ranging from 0.4 nM to 2.4 nM for 2 hr at room temperature in the presence of 30
nM prazosin to preclude binding to alpha-1 receptors. Nonspecific binding was
determined in the presence of 1 µM cinanserin. Following incubation, sections
were washed twice in ice cold assay buffer for ten minutes each time then dipped
in ice cold deionized water. Each section was wiped from the slides using a
Whatman GF/C filter, placed in a scintillation vial with scintillation fluid, shaken for
60 min, then counted in a scintillation counter for 2.5 min. The affinity of the
radioligand was determined using the lnPlot computer program (GraphPad
Software Inc., SanDiego, CA).

Drugs and Chemicals

Prazosin, 8-0H-DPAT, DOI, spiperone, serotonin creatinine sulfate, and 5hydroxy indoleacetic acid were obtained from Research Biochemicals International
(Natick, MA). Monochloroacetic acid, 1-octanesulfoneic acid sodium salt and
tetrahydrofuran were obtained from J.T.Baker (Phillpsburg,NJ).
[

3

[ 3 H]Citalopram,

H]Paroxetine, [ 3 H]8-0H-DPAT, [ 3 H]ketanserin, and [ 125 l]DOI were obtained from

New England Nuclear (Boston, MA). Citalopram was provided by Lundbeck
(Copenhagen, Denmark). Fluoxetine was generously provided by the Eli Lilly
Company (Indianapolis, IN). Paroxetine was obtained from Smith Kline Beecham
Pharmaceuticals (Philadelphia, PA). PCA and all other chemicals were obtained
from Sigma Chemical Company (St. Louis, MO).
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Statistics
Statistical analysis of maternal weight gain was performed using a 1-way
analysis of variance (ANO VA). Statistical analyses of Male:Female ratio and litter
size were performed by Student's t-test. Statistical analyses of endocrine data
were carried out by using a three-way ANOVA. All other data were analyzed using
a 2-way ANOVA unless otherwise indicated (appendix 13). If the F values from
the ANOV A indicated significant differences, individual group means were then
compared by a Student-Newman-Keuls' test (Steel and Torrie, 1960) using a
computer program (SigmaStat, San Rafael, CA).

CHAPTER IV
RESULTS

Growth Parameters

The administration of fluoxetine to pregnant dams from GD 13-20 did not
significantly alter maternal weight gain during the course of the treatment (vehicle:
112.0 ± 8.3 g; fluoxetine: 103.9 ± 8.4 g; Fig. 2). Likewise, the administration of
a liquid diet did not alter the nutritional intake of pregnant dams as indicated by a
lack of difference in maternal weight gain between foster (102.5 ± 2.5 g) and
vehicle (112.0 ± 8.3 g) treated dams during the treatment period. As shown in
Table 1, despite the lack of effect on maternal weight gain, prenatal exposure to
fluoxetine resulted in a small (-8%) but statistically significant (p < 0.05) decrease
in male progeny birth weight. By PD 28, male progeny of fluoxetine-treated dams
exhibited body weights which were similar to control values. However, at PD 70,
male progeny of fluoxetine-treated dams again exhibited a significant decrease in
body weight (-14%; p < 0.05) compared to control animals. As indicated in Table
2, there were no differences in either the gender distribution per litter or in the
total progeny number per litter between prenatal treatment groups. In addition,
there were no between group differences in either the crown-rump lengths or
anogenital distances (Table 3) in either male or female progeny.
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Figure 2. Total amount of weight gained by the maternal animals during the course
of the treatment paradigm. Data represent group means ± SEM from 10-21 rats per
group. The administration of 10 mg/kg/2ml fluoxetine from GD 13-20 did not
significantly alter maternal weight gain during this period.
In addition, the
administration of a liquid diet had no effect on maternal weight gain as weight gain
in chow-fed foster dams was not significantly different from either VEH or FLX dams.
Abbreviations: FSTR, foster dams; VEH, saline dams; FLX, fluoxetine dams.
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TABLE 1

MALE PROGENY BODY WEIGHT

Prenatal Exposure
Group

Body Weight (g)
PD 0

PD 28

PD 70

Control

6.7 ± 0.1

105.5 ± 7.1

486.6 ± 6.6

Fluoxetine

6.2 ± 0.2 *

103.3 ± 2.9

418.9 ± 18.5 *

At PD 0 data represent the litter mean ± SEM from 10 control and 11 fluoxetine
exposed litters per group. At PD 28 and PD 70, data represent the mean ± SEM
from 6-8 rats per postnatal experimental group with each rat within a group being
obtained from a different litter. A small (-8%) but significant decrease in birth weight
(PD 0) was observed in progeny prenatally exposed to fluoxetine ( 10 mg/kg/2ml, s.c.,
to dams from GD 13-20). By PD 28 there were no significant weight differences
between saline and fluoxetine-exposed progeny. However, at PD 70, progeny of
fluoxetine treated dams exhibited a significant decrease (-14%) in body weight in
comparison with their age matched controls. Data were analyzed by Student's t-test.
* Significantly different (p < 0.05) from corresponding controls.

TABLE 2

PROGENY NUMBER AND GENDER DISTRIBUTION WITHIN LITTERS
(N)

Male:Female

Litter Size

Control

(10)

0.97 ± 0.11

13 ± 1

Fluoxetine

( 11)

1.00 ± 0.16

12 ± 1

Prenatal Exposure
Group

Data represent the mean ± SEM
group. Litters were composed
administration of fluoxetine from
or the gender distribution within
Student's t-test.

from 10-11 litters (N) per treatment
of 8-18 rats prior to culling. The
GD 13-20 did not alter the litter size
the litters. Data were analyzed by
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TABLE 3

PROGENY GROWTH PARAMETERS

Prenatal
Exposure
Group

Crown-Rump
Length (mm)

Anogenital
Distance (mm)

Males

Females

Males

Females

Control

47.01 ± 0.38

46.46 ± 0.54

2.57 ± 0.08

1.27 ± 0.05t

Fluoxetine

46.83 ± 0.58

45.95 ± 0.50

2.66 ± 0.09

1.39 ± 0.04t

Data represent the mean ± SEM from 10 control and 11 fluoxetine exposed litters per
group. Litters were composed of 2-11 rats per gender prior to culling. Data were
analyzed by a 2-way ANOVA followed by a Newman-Keuls post-hoc test. Prenatal
exposure to fluoxetine did not alter the crown-rump length or anogenital distance of
either male or female offspring. t Significantly different (p < 0.05) than corresponding
male progeny.

Site-Specific Reductions in 5-HT Content in Fluoxetine-Exposed Offspring

Table 4 reports basal 5-HT levels in several brain regions in prepubescent
and adult male progeny prenatally exposed to either saline or fluoxetine. Prenatal
exposure to fluoxetine significantly reduced cortical 5-HT content (-28%) only in
the frontal cortex of prepubescent male progeny.

5-HT content was not altered in

either the hypothalamus, hippocampus, striatum or midbrain of fluoxetine-exposed
offspring at PD 28. In contrast, in adult animals, basal 5-HT content was
significantly reduced only in the midbrain (-28%) of fluoxetine-exposed offspring
(Table 4). Adult control and fluoxetine-exposed offspring exhibited similar levels of
5-HT in cortex, hypothalamus, hippocampus, and striatum.

TABLE 4
SEROTONIN LEVELS IN PREPUBESCENT AND ADULT MALE PROGENY

Prenatal
Exposure
Group

Brain Region
Midbrain

Frontal Cortex

Hypothalamus

Hippocampus

Striatum

Saline

23.4 ± 1.1 (7)

45.5 ± 1.8 (8)

14.9 ± 0.8 (7)

20.1 ± 2.4 (8)

40.6 ± 1.8 (7)

Fluoxetine

16.8 ± 1.5 * (7)
(-28%)

45.3 ± 2.8 (7)

13.1 ± 0.6 (8)

19.2 ± 1.6 (8)

45.5 ± 4.7 (8)

Saline

27.3 ± 1.8 (7)

49.5 ± 3.0 (8)

18.0 ± 0.8 (8)

22.2 ± 1.2 (8)

65.6 ± 8.2

Fluoxetine

31.1 ± 2.3

48.2 ± 3.0 (8)

18.3 ± 1.7 (8)

20.8 ± 1.7 (8)

47.1 ± 2.3 * (8)
(-28%)

Pregubescent

Adult

t

(8)

t

(8)

Data are expressed as pmol 5-HT/mg protein and represent the means ± SEM from 7-8 rats per group with each rat within a group
being obtained from a different litter. The number of rats per group is shown in parentheses. In prepubescent progeny, prenatal
exposure to fluoxetine (10 mg/kg/2ml s.c., to dams from GD 13-20) significantly reduced basal 5-HT levels only in the frontal
cortex (-28 %). In adult progeny, prenatal exposure to fluoxetine produced a significant reduction only in midbrain 5-HT content
(-28%). Hypothalamic, hippocampal, and striatal 5-HT concentrations were not altered by fluoxetine exposure in either
prepubescent or adult offspring. Data from each brain region were analyzed separately using a two-way ANOVA followed by a
Newman-Keuls post-hoc test. *Significantly different from age-matched control values within the respective brain region (p < 0.05).
t Significantly different from the respective values obtained in prepubescent progeny (p<0.05).

TABLE 5

5-HYDROXY INDOLEACETIC ACID LEVELS IN PREPUBESCENT AND ADULT MALE PROGENY

Prenatal
Exposure
Group

Brain Region
Frontal Cortex

Hypothalamus

Hippocampus

Striatum

Midbrain

Saline

23.6 ± 2.1 (8)

36.2 ± 0.9 (8)

21.3 ± 1.0 (7)

37.2 ± 2.8 (8)

52.5 ± 2.4 (8)

Fluoxetine

23.6 ± 2.1 (8)

35.3 ± 2.6 (7)

20.5 ± 1.0 (8)

32.9 ± 1.9 (8)

51.2 ± 3.6(7)

Saline

20.0 ± 1.5 (8)

28.5 ± 2.4 t (8)

14.9 ± 0.8 t (8)

23.0 ± 1.7 t (8)

34.4 ± 3.3 t (7)

Fluoxetine

22.0 ± 1.5 (8)

27.6 ± 1.5t(8)

14.0 ± 0.9 t (8)

22.1 ± 1.4 t (8)

33.3 ± 3.0 t (8)

Pre12ubescent

Adult

Data are expressed as pmol 5-HIAA/mg protein and represent the means ± SEM from 7-8 rats per group with each rat within a group
being obtained from a different litter. The number of rats per group is shown in parentheses. Prenatal exposure to fluoxetine ( 10
mg/kg/2ml s.c., to dams from GD 13-20) did not alter basal 5-HIAA content in the frontal cortex, hypothalamus, hippocampus,
striatum, or midbrain of prepubescent male progeny. Likewise, 5-HIAA content was not altered in adult male progeny across any
of the brain regions examined. Data from each brain region were analyzed separately using a two-way ANOVA followed by a
Newman-Keuls post-hoc test. t Significantly different from the respective values obtained in prepubescent progeny (p<0.05).
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TABLE 6
5-HT/5HIAA RATIO IN PREPUBESCENT AND ADULT MALE PROGENY

Prenatal
Exposure
Group

Brain Region
Frontal Cortex

Hypothalamus

Hippocampus

Striatum

Midbrain

Saline

1.01 ± 0.11 (8)

1.26 ± 0.05 (8)

0.86 ± 0.14 (7)

0.54 ± 0.04 (8)

0. 79 ± 0.02 (7)

Fluoxetine

0. 78 ± 0.06 (8)

1 .31 ± 0.10 (7)

0.65 ± 0.04 (8)

0.60 ± 0.07 (8)

0.81 ± 0.04 (8)

Saline

1.50 ± o.o9r (8l

1 .80 ± 0.15 t (8)

1.28 ± 0.06t (7)

o.99 ± o.o5r (8l

1.70 ± 0.15t (8)

Fluoxetine

1.45 ± 0.14t (8)

1. 75 ± o.o8r (8l

1.23 ± 0.11 t (7)

0.94 ± 0.04t (8)

1 .45 ±

Pre12ubescent

Adult

o.or (8l

Data represent the means ± SEM of 5-HT/5-HIAA ratios from 7-8 rats per group with each rat within a group being obtained from
a different litter. The number of rats per group is shown in parentheses. Prenatal exposure to fluoxetine (10 mg/kg/2ml s.c., to dams
from GD 13-20) did not alter basal 5-HT turnover in the frontal cortex, hypothalamus, hippocampus, striatum, or midbrain of
prepubescent male progeny. Likewise, in adult male progeny, 5-HT turnover was not altered across any of the brain regions
examined. Data from each brain region were analyzed separately using a two-way ANOVA followed by a Newman-Keuls post-hoc
test. t Significantly different than the respective values obtained in prepubescent progeny (p < 0.05).
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In contrast to the reduction in cortical 5-HT content observed in prepubescent
fluoxetine-exposed progeny, basal 5-HIAA content was not altered in any of the brain regions
examined (Table 5) at PD 28.

Likewise, 5-HIAA content was similar in control and

fluoxetine-exposed adult progeny in the cortex, hypothalamus, hippocampus, striatum and
midbrain (Table 5).
In addition to the determination of regional basal 5-HT and 5-HIAA content, the ratio
of 5-HT:5-HIAA levels was calculated as an index of 5-HT turnover (Table 6). Despite some
reduction in basal 5-HT content in fluoxetine-exposed progeny, serotonin turnover was not
significantly altered by prenatal fluoxetine exposure in either 5-HT target areas (cortex,
hypothalamus, hippocampus, and striatum) or in a brain region containing 5-HT cell bodies
(midbrain) regardless of the age of the animal.

Prenatal Fluoxetine Exposure Alters the Ability
of a 5-HT Releasing Drug to Reduce 5-HT Content
PCA administration significantly reduced 5-HT content across all brain regions
examined {see appendix 6 for statistical analysis). The reduction in 5-HT content ranged
from approximately 21 - 67 % in control progeny.

In fluoxetine-exposed progeny, the

reduction in 5-HT content ranged from 20 - 59% in different brain regions {Fig. 3). At PD
28, PCA administration reduced hypothalamic 5-HT content by 21 % in saline-exposed
progeny and 34% in fluoxetine-exposed offspring in comparison to their respective basal 5HT values (Fig. 3A).

However, this 13% difference in the magnitude of the reduction

between prenatal treatment groups did not reach statistical significance.

PCA produced

similar reductions in 5-HT content in both control and fluoxetine-exposed offspring in the
cortex, hippocampus, striatum and midbrain at PD 28 (Fig. 3A). In adult offspring, PCA
significantly reduced midbrain 5-HT content in both progeny groups.

However, the
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magnitude of the reduction in 5-HT content in fluoxetine-exposed animals was significantly
less than observed in saline-treated progeny (Figure 38). PCA reduced 5-HT content to a
similar extent in control and fluoxetine-exposed offspring in the cortex, hypothalamus,
hippocampus, and striatum at PD 70.
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Figure 3. Reduction in brain 5-HT content one hour following a single injection of the 5-HT
releaser PCA (5 mg/kg, i.p.) in prepubescent (/Y and adult (!J) male progeny prenatally
exposed to either saline or fluoxetine (10 mglkg/2ml, s.c. to dams from GD 13-20). Data
represent group means ± SEM from 6-8 rats per group with each rat within a group being
obtained from a different litter. There were no significant differences in the magnitude of the
PCA-induced reduction in 5-HT content in any of the brain regions between control and
fluoxetine exposed offspring at PD 28 irrespective of the brain region examined. In contrast,
in adult progeny, the magnitude of the PCA-mediated reduction in 5-HT content was
significantly lower (-42 %) in the midbrain of fluoxetine-exposed rats. Data were analyzed
by a 2-way ANOVA followed by a Newman-Keuls test. Abbreviations: Ctx, cortex; Hypo,
hypothalamus; Hipp, hippocampus; Str, striatum; MdBr, midbrain. * Significantly different
from the reduction in midbrain 5-HT content observed in adult control offspring (p < 0.05).
t Significantly different from the respective values in prepubescent control offspring
(p<0.05).
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Age-Related Changes in the Neurochemical Status of 5-HT Neurons
Basal Monoamine Content

Several differences were observed in basal monoamine content as a
consequence of normal maturation. For example, a 2-way ANOVA indicated a
significant main effect of age [F( 1,27) = 6. 75; p < 0.05] in the midbrain. As
indicated in Table 4, midbrain 5-HT levels were significantly greater in the adult
control progeny than in prepubescent control progeny ( + 61 %). In contrast, 5HIAA content was significantly lower in adult control progeny compared to values
in prepubescent animals in the hypothalamus, hippocampus, striatum, and midbrain
but not in the cortex (Table 5). These differential changes in 5-HT and 5-HIAA
levels as a consequence of maturation, resulted in significantly greater 5-HT:5HIAA ratios (an index of 5-HT turnover) in adult control animals vs. their
prepubescent counterparts in all brain regions examined (Table 6).

PCA Induced Reduction of 5-HT Content

In saline-exposed progeny, the ability of PCA to reduce 5-HT content was
significantly greater in the cortex of prepubescent offspring in comparison to their
adult counterparts (Fig. 3). In contrast, PCA reduced 5-HT content to a greater
extent in the midbrain of adult control animals. No age-related differences in
reductions in 5-HT content following PCA administration were observed in the
hypothalamus, hippocampus or striatum in saline-exposed control progeny.
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Effect of Prenatal Fluoxetine Exposure on the
Density of 5-HT Uptake Sites in Brain Homogenates
In order to assess whether global changes in serotonergic innervation
occurred as a consequence of prenatal exposure to fluoxetine, 5-HT uptake sites
were initially measured in homogenates of the cortex, hypothalamus, hippocampus
and striatum. For comparative purposes, the density of 5-HT uptake sites was
also determined in the midbrain. As shown in Table 7, prenatal exposure to
fluoxetine did not alter the density of 5-HT uptake sites in prepubescent progeny in
any of the brain regions examined. Likewise, in adult progeny, no alterations in
the density of 5-HT uptake sites were observed as a consequence of fluoxetineexposure in either the cortex, hypothalamus, hippocampus, striatum or midbrain
(Table 7). The density of 5-HT uptake sites was similar between prepubescent and
adult progeny in the cortex, hippocampus, striatum and midbrain. However, 5-HT
uptake sites were significantly lower in the hypothalamus of adult progeny in
comparison to their prepubescent counterparts.
The lack of widespread changes in the density of 5-HT uptake sites in
homogenates does not preclude the possibility of more subtle changes in 5-HT
uptake sites in discrete neuroanatomic loci. This possibility was addressed in the
autoradiographic studies discussed later in this chapter.

TABLE 7

THE DENSITY OF 5-HT UPTAKE SITES IN HOMOGENATES OF
BRAIN REGIONS IN PREPUBESCENT AND ADULT MALE PROGENY

Brain Region
Treatment Group

Frontal Cortex

Hypothalamus

Hippocampus

Striatum

Midbrain

Saline

452 ± 8 (6)

749 ± 60 (6)

332 ± 9 (8)

456 ± 21 (8)

459 ± 14 (8)

Fluoxetine

438 ± 27 (8)

819 ± 38 (6)

327 ± 15 (8)

496 ± 18 (8)

489 ± 18 (8)

Saline

394 ± 19 (8)

506 ± 4ot (7)

327 ± 27 (8)

470 ± 23 (8)

498 ± 17 (8)

Fluoxetine

429 ± 28 (8)

476 ± 26t (7)

333 ± 19 (8)

516 ± 25 (7)

474 ± 20 (8)

Pre12ubescent

Adult

Data are expressed as fmol/mg protein and represent the means ± SEM from 6-8 rats per group with each rat within a group being
obtained from a different litter. The number of rats per group is shown in parentheses. No significant differences were observed
in the density of 5-HT uptake sites as a consequence of prenatal fluoxetine exposure. Data were analyzed by a two-way ANOVA
followed by a Newman-Keuls post-hoc test. 5-HT uptake sites were labelled by using a saturating concentration (0.4nM) of
3
[ H]paroxetine and nonspecific binding was determined in the presence of 1µM citalopram.
t Significantly different than the
respective values in prepubescent progeny (p<0.05).
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Lack of Effect of Prenatal Fluoxetine Exposure on
the 5-HT 1A Mediated Increase in Hormone Secretion
Plasma ACTH
Figure 4 illustrates basal and 8-0H-DPAT induced increase in plasma levels
of ACTH in prepubescent and adult male progeny. Basal values of ACTH (saline
challenged) were unaffected in either prepubescent (Fig. 4A) or adult (Fig. 48)
progeny by prenatal exposure to fluoxetine. In both age groups, a single injection
of a maximally effective dose of the 5-HT 1A agonist 8-0H-DPAT (0.5 mg/kg)
significantly elevated plasma ACTH levels above basal values in both saline and
fluoxetine-exposed progeny. Likewise, the magnitude of the ACTH response to 8OH-DPAT was similar in control and fluoxetine-exposed progeny regardless of the
age of the animals.

Plasma Corticosterone
Consistent with the ACTH data, basal levels of corticosterone were not
significantly different between control and fluoxetine-exposed progeny (Fig. 5).
Likewise, 8-0H-DPAT significantly elevated plasma corticosterone levels above
basal values in both saline and fluoxetine-exposed progeny regardless of the age of
the offspring. Prenatal exposure to fluoxetine did not alter the magnitude of the
corticosterone response to 8-0H-DPAT in either prepubescent or adult progeny.

Plasma Renin
Figure 6 illustrates basal and stimulated levels of plasma renin in
prepubescent and adult progeny prenatally exposed to either saline or fluoxetine.
As observed for ACTH and corticosterone, basal levels of renin were unaffected by
prenatal fluoxetine exposure. In prepubescent progeny, 8-0H-DPAT significantly
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elevated plasma renin levels above basal values (Fig. 6A). The magnitude of the
renin response to 8-0H-DPAT was similar in control and fluoxetine-exposed
prepubescent progeny. In adult progeny, 8-0H-DPAT did not significantly elevate
plasma renin levels above basal values in either control or fluoxetine-exposed
progeny (Fig. 68). In addition, there were no between-group differences in the
magnitude of the renin response to 8-0H-DPAT in adult progeny.

Age-Related Changes in Plasma Hormones

A significant main effect of age was observed for plasma ACTH
[F(1,45)=5.39; p<0.05], corticosterone [F(1,46)=7.50; p<0.01) and renin
[F(1,44) = 93. 74; p < 0.01] values as shown in Figures 4 through 6. A NewmanKeuls post-hoc analysis revealed that both basal and stimulated renin values in
prepubescent progeny were significantly lower than adult values (p<0.05).
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Figure 4. Basal and stimulated plasma ACTH levels following a single injection of either
saline or a maximally effective dose of 8-0H-DPAT (0.5 mg/kg, s.c.) in prepubescent
(/V or adult (!1) male progeny prenatally exposed to either saline or fluoxetine (10
mg!kg/2ml, s.c., to dams from GD 13-20). Data represent group means ± SEM from
6-8 rats per group with each rat within a group being obtained from a different litter.
Basal levels of ACTH were not altered by prenatal fluoxetine exposure in either
prepubescent or adult progeny. 8-0H-DPAT significantly increased ACTH in all
progeny groups. The magnitude of the ACTH response to 8-0H-DPAT was not
significantly different between saline and fluoxetine-exposed progeny regardless of the
age of the offspring. * Significantly different from the corresponding saline-injected
group (p<0.05). Data were analyzed by a 3-way ANOVA followed by a NewmanKeuls test.

74

--"'O

50

A. Prepubescent
40

Saline

~ 8-0H-DPAT

O>

-

CJ

:::i.

Q)

30

c

0lo...

(].)
+-'

en

*

20

0

0

t0

10

()

0

--"'O

50

B. Adult
40

O>

-

:::i.
(].)

c

Control

30

*

Fluoxetine

*

0lo...
Q)
+-'

en

20

0

u

t

0
()

10
0

Control
Fluoxetine
Prenatal Exposure Group

Figure 5. Basal and stimulated plasma corticosterone levels following a single
injection of either saline or a maximally effective dose of 8-0H-DPA T (0. 5 mg/kg, s.c.}
in prepubescent (/j) or adult (fl} male progeny prenatally exposed to either saline or
fluoxetine (10 mglkg/2ml, s.c., to dams from GD 13-20). Data represent group means
± SEM from 6-8 rats per group with each rat within a group being obtained from a
different litter. Basal levels of corticosterone were not altered by prenatal fluoxetine
exposure in either prepubescent or adult progeny. Likewise, there were no significant
differences between groups in the magnitude of the corticosterone response to 8-0HDPAT regardless of the age of the offspring. * Significantly different from the
corresponding saline-injected group (p < 0.05). Data were subjected to a log
transformation and then analyzed by a 3-way ANOVA followed by a Newman-Keuls
test.

75

-I-

.r:.

E

120

A. Prepubescent

c=J

Saline

90

C>
c
............

c
c
Q)
0::

-I-

.r:.

E

*

*

(9

z<(

~ 8-0H-DPAT

60
30
0

120

Control

Fluoxetine

B. Adult

90

(9

z<(

C>
c
............

c
c
Q)
0::

60

#

#

30
0

Control
Fluoxetine
Prenatal Exposure Group

Figure 6. Basal and stimulated plasma renin levels following a single injection of either
saline or a maximally effective dose of 8-0H-DPAT (0.5 mg/kg, s.c.) in prepubescent
(~ or adult (fl} male progeny prenatally exposed to either saline or fluoxetine (10
mg!kg/2ml, s.c., to dams from GD 13-20). Data represent group means ± SEM from
5-8 rats per group with each rat within a group being obtained from a different litter.
Basal levels of renin were not altered by prenatal fluoxetine exposure in either
prepubescent or adult progeny. The renin response to 8-0H-DPAT was similar in
saline and fluoxetine-exposed offspring regardless of the age of the animals.
* Significantly different from the corresponding saline-injected group (p < 0.05).
#Significantly different from the respective prepubescent group (p < 0.05). Data were
subjected to a log transformation and then analyzed by a 3-way ANOVA followed by
a Newman-Keuls test.
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Reduction in 5-HT 2 AJ2 c Mediated Neuroendocrine
Function Following Prenatal Exposure to Fluoxetine
Plasma ACTH
Figure 7 illustrates basal and DOI-induced increase in plasma ACTH in
prepubescent and adult male progeny prenatally exposed to either saline or
fluoxetine. Basal levels of plasma ACTH were unaltered by prenatal exposure to
fluoxetine in prepubescent {Fig. 7 Al and adult {Fig. 78) progeny. At PD 28, a
single injection of the 5-HT 2 A12 c agonist DOI significantly elevated plasma ACTH
levels above basal values in control and fluoxetine-exposed progeny. The
magnitude of the ACTH response to DOI was similar in saline and fluoxetineexposed progeny at PD 28 {Fig. 7A). In adult progeny, DOI elevated plasma ACTH
levels in both control and fluoxetine-exposed progeny groups. However, the ACTH
response to DOI was markedly attenuated (-58%; p<0.05) in adult progeny
prenatally exposed to fluoxetine {Fig. 78) compared to the corresponding salineexposed controls.

Plasma Corticosterone
As shown in Figure 8, basal levels of corticosterone were not altered by
prenatal exposure to fluoxetine in either prepubescent {Fig. SA) or adult (Fig. 88)
progeny. DOI significantly elevated corticosterone above basal values in
prepubescent and adult progeny from both treatment groups. At PD 28, the
magnitude of the corticosterone response to DOI was not significantly altered by
prenatal exposure to fluoxetine. Likewise, in adult progeny, there were no
significant differences between groups in the magnitude of the corticosterone
response to DOI.
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Figure 7. Basal and stimulated plasma ACTH levels following a single injection of either
saline or a maximally effective dose of DOI (2 mg/kg, s. c.) in prepubescent (/Y or adult
(!1) male progeny prenatally exposed to either saline or f/uoxetine (10 mg/kg/2ml, s.c.,
to dams from GD 13-20). Data represent group means ± SEM from 6-8 rats per group
with each rat within a group being obtained from a different litter. Basal levels of
ACTH were not altered by prenatal fluoxetine exposure in either prepubescent or adult
progeny. However, the ACTH response to DOI was significantly attenuated (-58%) in
adult male progeny prenatally exposed to fluoxetine. *Significantly different from the
corresponding saline-injected group {p < 0.05). t Significantly different from the adult
vehicle-exposed/DOI-injected group {p<0.05). # Significantly different from the
respective value in prepubescent progeny. Data were analyzed by a 3-way ANOVA
followed by a Newman-Keuls test.

78

.-

-

60

A. Prepubescent

"C

O>
::J..
.._
Q)

c

0

"'-

50
40

CJ)

0

*

20

(.)

:e0

Saline
DOI

30

Q)

+-'

-

c::::::J

*

10

(.)

0

.-

-

60

"C

O>
::J..
.._
Q)

c
0

"'-

50

Control

Fluoxetine

*#

B. Adult

*

40
30

Q)

+-'

CJ)

0

20

(.)

:e0

(.)

10
0

Control
Fluoxetine
Prenatal Exposure Group

Figure 8. Basal and stimulated plasma corticosterone levels following a single injection
of either saline or a maximally effective dose of DOI (2 mg/kg, s.c.) in prepubescent
(A) or adult (8) male progeny prenatally exposed to either saline or fluoxetine (10
mg/kg/2ml, s.c., to dams from GD 13-20). Data represent group means ± SEM from
6-8 rats per group with each rat within a group being obtained from a different litter.
Basal levels of corticosterone were not altered by prenatal f luoxetine exposure in either
prepubescent or adult progeny. Likewise, there were no significant differences
between groups in the magnitude of the corticosterone response to DOI regardless of
the age of the offspring. * Significantly different from the corresponding saline-injected
group (p < 0.05). #Significantly different from the respective value in prepubescent
progeny (p<0.05). Data were subjected to a log transformation and then analyzed by
a 3-way ANOVA followed by a Newman-Keuls test.
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Figure 9. Basal and stimulated plasma renin levels following a single injection of either
saline or a maximally effective dose of DOI (2 mg/kg, s. c.) in prepubescent (A) or
adult (8) male progeny prenatally exposed to either saline or fluoxetine (10 mg!kg/2ml,
s.c., to dams from GD 13-20). Data represent group means ± SEM from 6-8 rats per
group with each rat within a group being obtained from a different litter. No
differences were observed between treatment groups in either basal levels of plasma
renin or in the ability of DOI to increase plasma renin regardless of the age of the
offspring. * Significantly different from the corresponding saline-injected group
(p < 0 .05). # Significantly different from respective values in prepubescent progeny
(p < 0.05). Data were subjected to a log transformation and then analyzed by a 3-way
ANOV A followed by a Newman-Keuls test.
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Plasma Renin

As observed for ACTH and corticosterone, basal levels of renin were
unaffected by prenatal fluoxetine exposure (Fig. 9). In prepubescent progeny, DOI
did not significantly elevate plasma renin levels above basal values in either
treatment group. Nonetheless, the renin response to DOI was not affected by
prenatal exposure to fluoxetine at PD 28. In contrast to PD 28 progeny, at PD 70,
DOI significantly elevated plasma renin levels above basal values in both control
and fluoxetine-exposed progeny. However, the magnitude of the renin response
was not significantly different between saline and fluoxetine-exposed progeny at
PD 70.

Age-Related Changes in Plasma Hormones

A significant main effect of age was observed for plasma ACTH
[F(1,46)=6.14; p<0.05], corticosterone [F(1,46)=11.23; p<0.01], and renin
[F(1,40)=12.18; p<0.01]. A comparison between Figures 9A and 98 reveals that
while basal renin values are approximately 2-fold greater at PD 28 than at PD 70,
the magnitude of the response to DOI is similar at both developmental time points.
Therefore, the higher renin basal values in prepubescent progeny could account for
the inability of DOI to significantly elevate renin above basal levels at PD 28. In
contrast, no developmental change in basal corticosterone or ACTH values were
observed between PD 28 and PD 70. However, the ACTH and corticosterone
responses to DOI were stastically significantly different between adult versus
prepubescent progeny only in the fluoxetine-exposed animals (Figs. 7 and 8).
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Effect of Prenatal Fluoxetine Exposure on 5-HT 2 A 12c
Receptors in Homogenates of Hypothalamus and Cortex
In order to discern whether global changes in the density of 5-HT zAizc
receptors occurred concomitantly with the reduction in the 5-HT 2 A, 2 c mediated
ACTH response, 5-HT 2 A12 c receptors were measured in homogenates of the
hypothalamus. As indicated in Table 8, the maximal density (Bmax) of
hypothalamic 5-HT 2 A12 c receptors in rats at PD 28 was not significantly different
between progeny of control and fluoxetine-treated dams. Likewise, no changes in
the affinity (Kd) of [ 125 1]001 for hypothalamic 5-HT 2 A12 c receptors were observed at
PD 28 following prenatal exposure to fluoxetine. In contrast to PD 28 progeny, in
adult progeny, the maximal density of hypothalamic 5-HT 2 A 12 c receptors was
significantly decreased (-35 % ; p < 0.05) in fluoxetine-exposed offspring (Table 8).
Consistent with the PD 28 data, the affinity (Kd) of [ 125 1JDOl-labelled 5-HT2 A, 2 c
receptors in adult progeny was not significantly altered by prenatal fluoxetine
exposure. In order to determine whether the reduction of 5-HT zAi 2 c receptors
observed in the hypothalamus reflected a generalized reduction in brain 5-HT zAi 2 c
receptors, these sites were also measured in cortex. As shown in Table 9,
prenatal exposure to fluoxetine did not alter [ 125 1]001 binding to cortical 5-HT 2 A12 c
receptors in either prepubescent or adult offspring.
Taken together, the changes in 5-HT 2 A12 c receptors in the hypothalamus
along with the specific attenuation of the DOI-stimulated ACTH response,
suggested that prenatal exposure to fluoxetine may have differentially affected
specific brain regions or select brain 5-HT pathways. Therefore, autoradiographic
studies were carried out to identify alterations in 5-HT recognition sites in discrete
neuroanatomic loci following prenatal fluoxetine exposure.
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TABLE 8
MAXIMAL DENSITY (Bmaxl AND AFFINITY (Kd) OF [ 125 l]DOI
LABELLED 5-HT 2 A12c RECEPTORS IN HYPOTHALAMIC HOMOGENATES
FROM PREPUBESCENT AND ADULT PROGENY

PRENATAL
EXPOSURE GROUP

5-HT 2 A 12c RECEPTORS
Bmax
(fmol/mg protein)

Prepubescent
Control

29.5 ± 2.2

0.31 ± 0.04

Fluoxetine

29.1 ± 1.6

0.45 ± 0.07

Control

23.0 ± 2.8

0.49 ± 0.07

Fluoxetine

14.9 ± 1.0 *
(-35%)

0.29 ± 0.03

Adult

Data represent the means ± SEM from 6-8 rats per group with each rat within a
group being obtained from a different litter. In prepubescent progeny, prenatal
exposure to fluoxetine ( 10 mg/kg, s.c., to dams from GD 13-20) did not alter the
maximal density (Bmaxl or the affinity (Kd) of 5-HT 2 A12c receptors in the hypothalamus.
In contrast, at PD 70, prenatal exposure to fluoxetine resulted in a significant 35 %
decrease in the maximal density (Bmaxl of hypothalamic 5-HT 2 A 12 c receptors in progeny.
Similar to PD 28 males, the affinity of [ 125 1]DOI for hypothalamic 5-HT 2 A 12c receptors
(Kd) was comparable in saline and fluoxetine-exposed progeny at PD 70. Bmax and Kd
values were determined from Scatchard analyses of [ 125 11001 saturation data using
concentrations of [ 125 1]DOI ranging from 0.15 nM - 0.6 nM. Nonspecific binding was
determined in the presence of 10 µM 5-HT. Data were analyzed by a two-way
ANOVA.
* Significantly different from age-matched saline exposed progeny
(p < 0.05).
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TABLE 9
125

1]001 LABELLED 5-HT 2 A12c RECEPTORS IN CORTICAL
HOMOGENATES FROM PREPUBESCENT AND ADULT PROGENY
[

Prenatal
Exposure Group

5-HT 2 A 12 c Receptors
(fmol/mg protein)

Prepubescent
Control

54.5 ± 3.2

Fluoxetine

64.6 ± 5.6

Adult
Control
Fluoxetine

9.3 ± 0.4
11.0 ± 0. 7

t
t

Data represent the means ± SEM from 6-8 rats per group with each rat
within a group being obtained from a different litter. In contrast to the
effects observed in the hypothalamus, prenatal exposure to fluoxetine
( 10 mg/kg, s.c., to dams from GD 13-20) did not alter the binding of
[1 25 l]DOI to cortical 5-HT 2 A12 c receptors in prepubescent or adult
progeny; indicating no difference in receptor affinity and/or density.
Data were analyzed by a two-way ANOV A. 5-HT 2 A12 c receptor density
was measured using a single concentration of [ 125 1]001 (0.05 nM). Nonspecific binding was determined in the presence of 10 µM 5-HT.
t Significantly different from respective values in prepubescent progeny
(p<0.05).
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Prenatal Fluoxetine Exposure Produces Site-Specific Alterations in
5-HT Uptake Sites: Evidence for Alterations in Serotonergic Innervation
Telencephalon
Site-specific alterations in 5-HT uptake sites in telencephalic brain regions
following prenatal exposure to fluoxetine are shown in Table 11 and illustrated in
Figure 10. In prepubescent offspring, prenatal fluoxetine exposure altered the
density of 5-HT uptake sites in select subregions of the hippocampus.

For

example, a significant increase in 5-HT uptake sites was observed in the CA2
( + 4 7 % ) and CA3 ( + 38 % ) areas of the hippocampus in fluoxetine-exposed
prepubescent offspring (Table 11 ). In contrast, in prepubescent offspring the
density of 5-HT uptake sites was not altered in either the dentate gyrus (DG) or in
the CA 1 area of the hippocampus.

5-HT uptake sites were also significantly

elevated in select nuclei of the amygdala in prepubescent offspring prenatally
exposed to fluoxetine. 5-HT uptake sites were significantly increased in the
basolateral (BLAMY; +32%) and medial (MAMY; +44%) amygdaloid nuclei.
However, 5-HT uptake sites in the central amygdala (CAMY), caudate putamen
(CPu), globus pallidus (GP) and ventral pallidum (VP) were similar between control
and fluoxetine-exposed prepubescent offspring. In contrast, in adult offspring
(Table 11 ), the density of 5-HT uptake sites was not significantly altered in any
subregion of the hippocampus (CA 1, CA2, CA3, dentate) by prenatal fluoxetine
exposure. Likewise, in adult offspring, prenatal fluoxetine exposure did not alter
the density of 5-HT uptake sites in any of the basal ganglia or amygdaloid nuclei
examined in the present study (central, basolateral, and medial amygdala; caudate
putamen, globus pallidus, and ventral pallidum). Prenatal exposure to fluoxetine
did not alter the density of 5-HT uptake sites in any of the cortical areas examined
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in either prepubescent or adult progeny [cingulate (Cg3), frontal (Fr2), entorhinal
(Ent), occipital (Oc2L), parietal (Par1 ), retrosplenial granular (RSG) and temporal
(Te 1) cortex]. Likewise, the density of 5-HT uptake sites in lateral septa I nuclei
[dorsal (LSD) and intermediate (LSI) areas] was not affected by fluoxetine exposure
in either prepubescent or adult progeny.

Diencephalon and Mesencephalon

Prenatal fluoxetine induced alterations in the density of 5-HT uptake sites in
Diencephalic and Mesencephalic brain regions are shown in Table 11 and in Figure
10. Similar to the hippocampus, in prepubescent progeny, only select subregions
of the hypothalamus were affected by prenatal fluoxetine exposure. For example,
5-HT uptake sites in the lateral hypothalamus (LH) were significantly elevated

( + 21 %) in prepubescent fluoxetine-exposed progeny. In contrast, prenatal
exposure to fluoxetine significantly reduced (-21 %) the density of 5-HT uptake
sites in the dorsomedial hypothalamic nucleus (DM) in prepubescent offspring. The
density of 5-HT uptake sites was similar between control and fluoxetine-exposed
animals in all other subregions of the hypothalamus examined [anterior (AHC),
arcuate (Arc), and ventromedial (VMH) nuclei; medial mammillary (MM) and medial
preoptic (MPA) areas] in prepubescent progeny. In addition to hypothalamic
alterations, a significant decrease in 5-HT uptake sites was observed in the
substantia nigra (SN; -19%) in prepubescent fluoxetine-exposed offspring. Despite
the alterations in 5-HT uptake sites observed in prepubescent progeny in a number
of regions receiving serotonergic innervation, 5-HT uptake sites were not altered by
fluoxetine exposure in brain regions composed primarily of serotonin perikarya [i.e.
dorsal (DR) and median (MnR) raphe nuclei]. In contrast to the changes observed
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in prepubescent offspring, in adult progeny, the density of 5-HT uptake sites was
similar between control and fluoxetine-exposed offspring across all subregions of
the hypothalamus and tegmentum examined (Table 11 ). Consistent with data
obtained in prepubescent progeny, the density of 5-HT uptake sites in the dorsal
and median raphe nuclei was not altered by prenatal fluoxetine exposure.

Changes in the Density of 5-HT Uptake Sites as a Consequence of Maturation
Figure 11 graphically illustrates the regional specificity of changes in the
density of 5-HT uptake sites as a consequence of normal maturation (i.e.
prepubescent versus adult densities of 5-HT uptake sites in control progeny). The
majority of brain areas examined in the present study possess a comparable
density of 5-HT uptake sites in prepubescent and adult animals (Table 11 ).
However, notable increases and decreases were observed in specific
neuroanatomic loci. Adult control progeny exhibited a significantly greater density
of 5-HT uptake sites than their prepubescent counterparts in the cingulate cortex
(Cg3;

+ 33%), the arcuate nucleus (Arc) of the hypothalamus ( + 56%), the

basolateral (BLAMY;

+ 58%) and medial amygdaloid nuclei (MAMY; + 66%), as

well as in CA 1 ( + 48%) and CA3 ( + 76%) areas of the hippocampus (Table 11 ).
In contrast, the density of 5-HT uptake sites was significantly lower in control adult
progeny than in prepubescent animals within the temporal cortex (Te1; -65%),
substantia nigra (SN; -26%), ventral tegmental area (VTA; -31 %), and median
raphe (MnR; -25%; Table 11 and Figure 11 ).
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TABLE 10
LIST OF ABBREVIATIONS USED IN AUTORADIOGRAPHIC STUDIES
Abbreviation

Brain Region

AHC
Arc
BLAMY
CA1
CA2
CA3
CAMY
CHP
Cg3
CPu
DG
DM
DR
Ent
Fr2
GP
LH
LSD
LSI
MAMY
MM
MnR
MPA
Oc2L
Par1
PVN
RSG
SN
Te1
VMH
VP
VTA

Anterior hypothalamic area, central
Arcuate hypothalamic nucleus
Basolateral amygdaloid area
CA 1 field of Ammon's horn
CA2 field of Ammon's horn
CA3 field of Ammon's horn
Central amygdaloid area
Choroid Plexus
Cingulate cortex, area 3
Caudate putamen
Dentate gyrus
Dorsomedial hypothalamic nucleus
Dorsal raphe nucleus
Entorhinal cortex
Frontal cortex, area 2
Globus pallidus
Lateral hypothalamic area
Lateral septal nucleus, dorsal
Lateral septal nucleus, intermediate
Medial amygdaloid area
Medial mammillary area
Median raphe nucleus
Medial preoptic area
Occipital cortex, area 2, lateral
Parietal cortex, area 1
Paraventricular hypothalamic nucleus
Retrosplenial granular cortex
Substantia nigra
Temporal cortex, area 1
Ventromedial hypothalamic nucleus
Ventral Pallidum
Ventral Tegmental Area

Abbreviations listed are in general accordance with those given in the
rat atlas by Paxinos and Watson (1986).

88

Figure 10. Autoradiograms demonstrating the effect of prenatal f/uoxetine exposure
on the density of f1HJcitalopram-labelled 5-HT uptake sites in prepubescent progeny.
Representative autoradiograms of control progeny are shown in panels A, C, £, and
G. Representative autoradiograms of fluoxetine-exposed progeny are shown in panels
~. D, f, and H. White areas indicate brain regions with a high density of 5-HT uptake
sites. Prenatal exposure to fluoxetine resulted in a significant increase (shaded red)
in the density of 5-HT uptake sites in the LH, CA2, CA3, BLAMY and MAMY. In
contrast, the density of 5-HT uptake sites was significantly decreased (shaded blue)
in SN. The density of 5-HT uptake sites in serotonergic cell body regions (DR and
MnR) was not altered by prenatal exposure to fluoxetine. Abbreviations are defined
in Table 10. 5-HT uptake sites were labelled with 0. 7 nM [ 3 H]citalopram. Nonspecific
binding was defined in the presence of 1 µM paroxetine. Abbreviations are described
in Table 10.

TABLE 11
THE DENSITY OF [ 3 HJCIT ALO PRAM-LABELLED 5-HT UPTAKE SITES
IN SELECT BRAIN REGIONS OF PREPUBESCENT AND ADULT OFFSPRING
Prepubescent Progeny
Brain Region
TelenceQhalon
Cortex
Cg3
Fr2
Ent
Oc2L
Par1
RSG
Te1
Hippocampus
CA1
CA2
CA3
DG
Septum
LSD
LSI

Saline

(N)

Fluoxetine

Adult Progeny
(N)

Saline

(N)

Fluoxetine

(N)

24
14
24
7
13
12
17

±
±
±
±
±
±
±

2
2
4
1
2
1
4

(5)
(5)
(5)
(5)
(4)
(4)
(5)

25
14
20
6
13
12
14

±
±
±
±
±
±
±

3
2
1
1
1
1
1

(5)
(5)
(4)
(4)
(5)
(5)
(4)

32
15
30
6
10
10
6

±
±
±
±
±
±
±

1t
1
1
1
1
1
1t

(5)
(5)
(5)
(5)
(5)
(4)
(5)

34
13
30
8
9
14
8

±
±
±
±
±
±
±

3t
1
5
1
1
1
1

(6)
(6)
(6)
(6)
(5)
(5)
(6)

9
19
21
7

±
±
±
±

1
1
3
1

(5)
(5)
(4)
(4)

12
28
29
10

±
±
±
±

1
1 *
1 *
1

(5)
(4)
(5)
(5)

16
29
37
10

±
±
±
±

2t
3
2t
1

(5)
(4)
(4)
(5)

17
31
37
11

±
±
±
±

2
4
2t
2

(5)
(5)
(6)
(6)

20 ± 2
60 ± 5

(5)
(5)

25 ± 1
61 ± 3

(4)
(4)

21 ± 3
57 ± 4

(4)
(5)

25 ± 3
63 ± 3

(6)
(5)

00
CD

TABLE 11 Continued

Adult Progeny

Prepubescent Progeny
Brain Region
Amygdala
BLAMY
CAMY
MAMY
Basal Ganglia
CPu
GP
VP
Dience12halon
Hypothalamus
AHC
Arc
DM
LH
MM
MPA
PVN
VMH

Saline

(N)

71 ± 5
13 ± 2
32 ± 1

(4)
(5)
(4)

38 ± 3
86 ± 5
63 ± 7

65
18
43
71
63
35
38
30

±
±
±
±
±
±
±
±

6
1
2
3
5
3
3
3

(N)

Saline

(N)

Fluoxetine

(N)

94 ± 1 *
15 ± 2
46 ± 3 *

(4)
(5)
(4)

112 ± 7t
17 ± 1
53 ± 1 t

(4)
(5)
(5)

113 ± 5
17 ± 2
50 ± 3

(5)
(6)
(6)

(5)
(3)
(4)

37 ± 2
59 ± 6
55 ± 4

(5)
(3)
(3)

33 ± 3
69 ± 2
70 ± 2

(5)
(3)
(4)

28 ± 2
56 ± 9
61 ± 6

(6)
(5)
(5)

(5)
(5)
(4)
(4)
(5)
(4)
(5)
(5)

74
24
34
86
62
31
43
34

(5)
(4)
(4)
(5)
(4)
(3)
(5)
(5)

54
28
45
62
58
37
34
35

(4)
(4)
(5)
(5)
(5)
(5)
(5)
(5)

67
22
44
72
70
34
39
28

(6)
(6)
(5)
(5)
(6)
(5)
(6)
(5)

Fluoxetine

±
±
±
±
±
±
±
±

4
1
1 *
6 *
5
5
2
1

±
±
±
±
±
±
±
±

2
2t
3
3
6
4
2
3

±
±
±
±
±
±
±
±

2
2
3t
3t
7
3
3
1

CD

0

TABLE 11 Continued

Prepubescent Progeny
Brain Region
Mesence(2halon
Tegmentum
SN
VTA
Raphe Nuclei
DR
MnR

Saline

(N)

121 ± 5
114 ± 8

(4)
(5)

155 ± 8
145 ± 10

(5)
(5)

Adult Progeny
(N)

Saline

(N)

98 ± 3 *
109 ± 6

(3)
(4)

90 ± 5t
79 ± 5t

(4)
(5)

155 ± 14
134 ± 5

(4)
(3)

138 ±4
108 ± 4t

(5)
(4)

Fluoxetine

Fluoxetine

74 ± at
86 ± 5t
149 ± 5
115 ± 5

(N)

(5)
(6)
(6)
(6)

Data are expressed as fmol of sites/mg tissue equivalent and represent the means ± SEM from 3-6 rats per group with each rat
within a group being obtained from a different litter. The number of rats per group is shown in parentheses. Prenatal exposure
to fluoxetine (10 mg/kg/2ml, s.c., to dams from GD 13-20) significantly increased the density of 5-HT uptake sites in CA2
( +47%), CA3 ( + 38%), BLAMY ( + 32%), MAMY ( +44%), and the LH ( + 21 %) in prepubescent progeny. In contrast, the density
of 5-HT uptake sites was significantly decreased in DM (-21 %), and SN (-19%) in prepubescent progeny. By PD 70, the density
of 5-HT uptake sites was similar between saline and fluoxetine-exposed offspring across all brain regions examined. 5-HT uptake
sites were labelled with 0.7 nM [ 3 H]citalopram. Nonspecific binding was determined in the presence of 1 µM paroxetine.
Quantification of autoradiograms was performed using computerized digital image analysis as described in Materials and Methods.
Anatomical abbreviations are described in Table 10. Data were analyzed using a two-way ANOVA followed by a Newman-Keuls
post hoc test. *Significantly different from the respective control values in prepubescent progeny (p<0.05). t Significantly
different than the respective values in prepubescent offspring (p < 0.05).
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Figure 11 . Representative brain regions of control progeny in which the density of
3
[ HJcitalopram-labelled 5-HT uptake sites either increased, decreased or remained
constant as a consequence of maturation. Data are expressed as fmol of sites/mg
tissue equivalent (fmol/mg TE) and represent the means ± SEM from 4-5 control rats
with each rat within a group being obtained from a different litter. Adult (PD 70)
control progeny exhibited a significantly greater density of 5-HT uptake sites in Cg3
(A; + 33%), CA 1 (f!; + 78%) and BLAMY (C; + 58%) than their prepubescent
counterparts. The density of 5-HT uptake sites was similar in prepubescent and adult
control progeny in Fr2 (D), CAMY (~) and LH (f). In contrast, the density of 5-HT
uptake sites was significantly lower in adult progeny in Te1 (G; -65%), SN (H; -26%)
and VTA (l; -31 %). 5-HT uptake sites were labelled with 0.7 nM [ 3 H]citalopram.
Nonspecific binding was determined in the presence of 1 µM paroxetine. Data were
obtained via the quantification of autoradiograms which was performed using
computerized digital image analysis as described in Materials and Methods.
Anatomical abbreviations are described in Table 10. Data were analyzed as in Table
11 using a two-way ANOVA followed by a Newman Keuls post-hoc test.
*Significantly different from prepubescent (PD 28) values (p < 0.05).
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Prenatal Fluoxetine Exposure Produces Site-Specific
Alterations in the Density of 5-HT iA Receptors
Site-specific alterations in brain 5-HT 1 A receptors in prepubescent and adult
progeny prenatally exposed to fluoxetine are shown in Table 12 and illustrated in
Figure 12. In contrast to the numerous alterations in 5-HT uptake sites observed
in fluoxetine-exposed offspring, the density of 5-HT 1 A receptors was only minimally
affected by the prenatal treatment. In prepubescent progeny, the density of 5HT 1 A receptors was significantly increased only in the paraventricular nucleus of
the hypothalamus (PVN; + 26%; p < 0.05) and in the entorhinal cortex (Ent;
+42%; p<0.05) of fluoxetine-exposed offspring. 5-HT 1 A receptor density was
comparable in control and fluoxetine-exposed prepubescent offspring in all other
cortical (Par1, RSG, Fr2, and Cg3) and hypothalamic (AHC, OM, LH, VMH) areas
examined. Likewise, prepubescent progeny did not exhibit any alterations in the
density of 5-HT 1 A receptors in any of the subregions of the hippocampus, septum,
tegmentum, or basal ganglia examined in the present study. In addition, the
density of 5-HT,A receptors was not altered in either the dorsal or median raphe
nuclei at PD 28.
In contrast to the increase in 5-HT,A receptor density observed in the
paraventricular nucleus and in the entorhinal cortex in prepubescent progeny, in
adult progeny, the density of 5-HT 1 A receptors in these two brain regions was
similar between treatment groups. However, the density of 5-HT 1 A receptors in
the ventromedial hypothalamus (VMH) was significantly reduced (-33%) in adult
progeny prenatally exposed to fluoxetine. In contrast, at PD 70, the density of 5HT 1 A receptors was not altered by prenatal fluoxetine exposure in any other
subregion of the hypothalamus examined (AHC, OM, LH, PVN). Likewise, no
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alterations in 5-HT 1A receptor density were observed in adult progeny as a
consequence of prenatal fluoxetine exposure in the hippocampus, septum,
caudate, or midbrain raphe nuclei.

Changes in the Density of 5-HT 1A Receptors as a Consequence of Maturation
Several brain regions exhibited differences in the density of 5-HT 1 A
receptors as consequence of maturation, with a majority of the changes being a
reduction in 5-HT 1 A receptors as the animals mature (Fig. 13 and Table 12). For
example, the density of 5-HT 1 A receptors was significantly lower in the caudate
putamen (-45%) and in subregions of the cortex (-56 to -65%), septum (-41 to 43%) and hypothalamus (-49 to -60%; Table 12) in adult control progeny in
comparison to their prepubescent counterparts. In contrast, in one subregion of
the hypothalamus, the ventromedial nucleus, the density of 5-HT 1A receptors was
significantly greater ( + 32%) in adult control progeny than in the prepubescent
animals. No significant alterations were observed in 5-HT 1 A receptor density as a
consequence of maturation in either the hippocampus or raphe nuclei.

D.

95

E.

F.

Figure 12. Representative autoradiograms and figures illustrating the effect of
prenatal f/uoxetine exposure on f1HJB-OH-DPA T-labelled 5-HT,A receptors. The
autoradiograms shown are representative of [ 3 H]8-0H-OPAT binding in control
' prepubescent (A, f!) and adult (C) progeny. White areas indicate brain regions with
' a high density of 5-HT uptake sites. The panels on the right are diagramatic
representations of the results from densitometric analysis of autoradiograms taken
from prepubescent (0, £) and adult (f) progeny prenatally exposed to fluoxetine.
\I Prenatal exposure to fluoxetine significantly elevated (shaded red) 5-HT 1A receptors
in the PVN (0) and in the Ent (E) in prepubescent offspring. In adult offspring, 5-HT 1 A
receptors were significantly reduced (shaded blue) in the VMH (F) following prenatal
exposure to fluoxetine. 5-HT 1A receptors were labelled with 2 nM [ 3 H]8-0ti-OPAT.
Nonspecific binding was determined in the presence of 1 µM 5-HT. Abbreviations are
described in Table 10 and in the legend to Figure 1.
1
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TABLE 12

THE DENSITY OF [ 3 H]8-0H-DPAT-LABELLED 5-HT,A RECEPTORS IN PREPUBESCENT AND ADULT OFFSPRING

Brain Region
TelenceQhalon
Cortex
Cg3
Fr2
Ent
Par1
RSG
Hippocampus
CA1
CA2
CA3
DG
Septum
LSD
LSI
Caudate
Cpu

Saline

Prepubescent Progeny
(N)
Fluoxetine

2.6
4.0
8.5
0.8
1.1

(5)
(5)
(5)
(3)
(4)

37.8
33.6
104.2
34.6
9.0

69.8±4.1
12.1 ± 2.2
51.6 ± 7.8
87.5 ± 1.7

(4)
(4)
(4)
(4)

66.1
9.9
44.2
92.2

87.9 ± 5.4
86.3 ± 3.0
1.1 ± 0.2

30.7
26.9
73.0
33.8
9.7

±
±
±
±
±

(N)

Saline

(5)
(5)
(5)
(5)
(5)

24.0
20.1
66.4
11.9
4.2

±4.6
± 1.8
± 7.8
± 3.2

(5)
(5)
(5)
(5)

(5)
(5)

83.9 ± 2.8
92.0 ± 2.8

(6)

1.4 ± 0.1

±
±
±
±
±

3.4
4.2
6.3 *
2.6
0.6

Adult Progeny
(N)
Fluoxetine

(N)

(5)
(5)
(5)
(5)
(5)

20.2
16.7
68.0
10.1
4.1

±
±
±
±
±

1.7t
1.7t
9.6t
1.2t
0.1 t

(5)
(5)
(4)
(5)
(5)

65.8 ± 5.3
7.8 ± 0.5
31.7±1.5
85.0 ± 4.3

(5)
(5)
(4)
(5)

64.7
6.9
27.2
82.8

±
±
±
±

7.6
0.8
3.4
4.8

(5)
(5)
(5)
(3)

(5)
(5)

52.1 ± 4.0t
49.3 ± 4.2t

(4)
(5)

51.0 ± 6.4t
47.1 ± 3.2t

(5)
(4)

(5)

o.6 ± o.2t

(4)

o.5 ± o.2t

(3)

±
±
±
±
±

2.1
1.6
4.7
1.3t
0.3t

1 AtsLt:. 1 ;;!. l;ontinued

Brain Region
DienceQhalon
Hypothalamus
AHC
DM
LH
PVN
VMH
Raphe Nuclei
DR
MnR

Saline

Prepubescent Progeny
(N)
Fluoxetine

(N)

Saline

Adult Progeny
(N)
Fluoxetine

17.9 ± 1.1
5.6 ± 0.4
10.7 ± 1.1
9.8 ± 1.0
22.7 ± 1.7

(4)
(6)
(4)
(6)
(4)

17.5 ± 1.3
6.2 ± 1.0
10.1 ±0.7
12.3±0.7*
21.4 ± 1.9

(5)
(5)
(5)
(5)
(5)

9.14±0.5t
5.6 ± 0.8
4.3 ± 0.3t
1.2 ± o.2t
29.9 ± 2.8t

(5)
(5)
(5)
(5)
(4)

75.6 ± 2.2
35.8 ± 5.5

(5)
(5)

83.8 ± 2.4
37.4 ± 4.5

(5)
(5)

67.2 ± 6.4
28.2±4.1

(5)
(5)

8.1
4.5
4.1
6.4
20.0

±
±
±
±
±

o.8t
0.3
o.2t
0.5t
2.2 *

69.0 ± 5.5
21.8 ± 3.9

(N)

(5)
(5)
(5)
(5)
(5)
(5)
(5)

Data are expressed as fmol of sites/mg tissue equivalent and represent the means ± SEM from 3-6 rats per group with each rat
within a group being obtained from a different litter. The number of rats per group is shown in parentheses. Prenatal exposure
to fluoxetine (10 mg/kg/2ml, s.c., to dams from GD 13-20) significantly increased the density of 5-HT,A receptors in Ent ( + 42%)
and PVN ( + 26%) in prepubescent progeny. 5-HT 1A receptors were significantly reduced in VMH (-33%) in fluoxetine-exposed
adult progeny. 5-HT,A receptors were labelled with 2.0 nM [ 3 HJ8-0H-DPAT. Nonspecific binding was determined in the presence
of 1 µM 5-HT. Quantification of autoradiograms was performed using computerized digital image analysis as described in
Materials and Methods. Anatomical abbreviations are described in Table 10. Data were analyzed using a two-way ANOVA
followed by a Newman-Keuls post hoc test. *Significantly different from the respective age-matched control values (p<0.05).
t Significantly different from the respective values in prepubescent offspring (p<0.05).
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Figure 13. Representative brain regions of control progeny in which the density of
r3HJ8-0H-DPA T labelled 5-HT7A receptors either increased, decreased or remained
constant as a consequence of maturation. Data are expressed as fmol of sites/mg
tissue equivalent {fmol/mg TE) and represent the means ± SEM from 3-5 control rats
with each rat within a group being obtained from a different litter. Adult {PD 70)
control progeny exhibited a significantly lower density of 5-HT,A receptors in Par1 {A;
-65%), RSG {];!; -49%), LSI {C; -43%), AHC {D; -49%), LH (£; -60%) and LSD (f; 41 %) than their prepubescent counterparts. In contrast, the density of 5-HT,A
receptors was significantly greater in adult progeny in VMH (G; + 32%). The density
of 5-HT,A receptors was similar in prepubescent and adult control progeny in MnR (H)
and CA 1 {!). 5-HT,A receptors were labelled with 2.0 nM [ 3 H]8-0H-DPAT. Nonspecific
binding was determined in the presence of 1 µM 5-HT. Data were obtained via the
quantification of autoradiograms which was performed using computerized digital
image analysis as described in Materials and Methods. Anatomical abbreviations are
described in Table 10. Data were analyzed as in Table 12 using a two-way ANOVA
followed by a Newman Keuls post-hoc test. *Significantly different from prepubescent
(PD 28) values (p<0.05).
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Prenatal Fluoxetine Exposure Produces Site-Specific Alterations
in the Density of [3 HJKetanserin-Labelled 5-HT 2 A Receptors

In contrast to the minimal perturbation in the density of 5-HT 1A receptors
reported above, a number of site-specific alterations were observed in the density
of [ 3 H]ketanserin-labelled 5-HT 2 A receptors in both prepubescent and adult progeny
prenatally exposed to fluoxetine (Table 13 and Fig. 14).

Telencephalon

The site-specific and age-dependent alterations in the density of
[

3

H]ketanserin-labelled 5-HT 2 A receptors in telencephaloic brain regions are reported

in Table 13. 5-HT 2 A receptors were significantly elevated in the ventral pallidum
(VP;

+ 78%), and the dorsolateral septal nucleus (LSD; + 81 %) in prepubescent

progeny prenatally exposed to fluoxetine (Table 13). In contrast, prenatal
fluoxetine exposure did not alter the density of 5-HT 2 A receptors in any other
subregion of the basal ganglia [e.g. globus pallidus (GP) and caudate putamen
(CPu)], or amygdala [basolteral (BLAMY), central (CAMY) and medial (MAMY)
nuclei] examined in prepubescent offspring. Likewise, in prepubescent offspirng,
[

3

H]ketanserin-labelled 5-HT 2 A receptor density was not affected by prenatal

fluoxetine exposure in any of the subregions of the cortex [cingulate (Cg3), frontal
(Fr2), entorhinal (Ent), occipital (0c2L), parietal (Par1), retrosplenial granular (RSG),
temporal (Te1 )] or hippocampus [CA3 and dentate gyrus (DG)] examined in the
present study. [ 3 HJKetanserin-labelled 5-HT 2 A receptors were undetectable in the
CA 1 and CA2 areas of the hippocampus. In contrast, in adult offspring, prenatal
fluoxetine exposure significantly increased the density of 5-HT 2 A receptors in the
entorhinal cortex (Ent;

+ 70%), dentate gyrus (DG; + 71 %) and basolateral
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amygdala (BLAMY; +48%). However, 5-HT 2 A receptors were significantly
reduced in the globus pallidus (GP; -70%) in adult fluoxetine-exposed offspring.
No other alterations in [ 3 H]ketanserin-labelled 5-HT 2 A receptors were observed in
telencephalic brain regions in adult progeny of fluoxetine-treated dams.

Diencephalon and Mesencephalon
Site-specific and age-dependent alerations in [ 3 H]ketanserin labelled 5-HT 2 A
receptors in diencephalic and mesencephalic brain regions are shown in Table 13.
In prepubescent offspring, a significant increase in the density of 5-HT 2 A receptors
was observed in the medial preoptic area (MPA;

+ 41 %) of the hypothalamus

following prenatal exposure to fluoxetine. In addition, in prepubescent progeny,
prenatal fluoxetine exposure also resulted in a significant reduction in the density
of [ 3 H]ketanserin-labelled 5-HT 2 A receptors in the lateral hypothalamus (LH; -38%).
[

3

H]ketanserin-labelled 5-HT 2 A receptors were not altered in any other subregion of

the hypothalamus examined in prepubescent progeny [anterior (AHC) and
dorsomedial (DM) areas; medial mammillary (MM), paraventricular (PVN) and
ventromedial (VMH) nuclei]. In contrast, in adult offspring, the paraventricular
nucleus of the hypothalamus (PVN) was the only subregion of the hypothalamus
examined that was affected (91 % increase) by prenatal fluoxetine-exposure.

No

alterations in the density of [ 3 H]ketanserin-labelled 5-HT 2 A receptors were observed
in the substantia nigra (SN), ventral tegmental area (VT A) or in midbrain raphe
nuclei [dorsal (DR) and median (MnR)] in either prepubescent or adult progeny
prenatally exposed to fluoxetine.
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Changes in the Density of [3 HJKetanserin-Labelled
5-HT 2 A Receptors as a Consequence of Maturation
In contrast to the numerous differences observed between prepubescent
and adult control progeny in the density of 5-HT uptake sites and 5-HT 1 A receptors,
minimal changes were observed in 5-HT 2 A receptors as a consequence of
maturation. As illustrated in Figure 15, 5-HT 2 A receptor density was significantly
greater in adult control progeny in the dorsomedial hypothalamus {DM;
in the basolateral amygdala {BLAMY;

+ 76%) and

+ 136%) than in their prepubescent

counterparts. In addition, 5-HT 2 A receptors were significantly lower in the lateral
hypothalamus {LH; -57%) of adult progeny in comparison to prepubescent animals.
In all other brain regions examined, the density of 5-HT 2 A receptors were
comparable in control prepubescent and adult progeny.
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D.

E.

F.

Figure 14. Representative autoradiograms and figures illustrating the effect of
prenatal fluoxetine exposure on [ 3HJketanserin-labelled 5-HT2A receptors.
The
3
autoradiograms shown are representative of [ H]ketanserin binding in control
prepubescent (A) and adult (.6., ~) progeny. White areas indicate brain regions with
a high density of 5-HT 2 A receptors. The panels on the right are diagrammatic
representations of the results of significant receptor changes from densitometric
analysis of autoradiograms taken from prepubescent (D) and adult (£, .El progeny
prenatally exposed to fluoxetine. Prenatal exposure to fluoxetine significantly elevated
(shaded red) 5-HT 2A receptors in the MPA and VP (0) in prepubescent offspring. In
adult offspring, 5-HT 2 A receptors were significantly elevated (shaded red) in the PVN
(E), CA3, and BLAMY (F) following prenatal exposure to fluoxetine. 5-HT 2 A receptors
were labelled with 0.4 nM [ 3 H]ketanserin in the presence of 30 nM prazosin.
Nonspecific binding was determined in the presence of 1 µM cinanserin.
Abbreviations are described in Table 10 and in the legend to Figure 1.
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TABLE 13
THE DENSITY OF [ 3 H]KETANSERIN-LABELLED 5-HT 2 A RECEPTORS IN PREPUBESCENT AND ADULT OFFSPRING

Brain Region

Saline

Prepubescent Progeny
(N)
Fluoxetine

(N)

Saline

Adult Progeny
(N)
Fluoxetine

(N)

Telence~halon

Cortex
Cg3
Fr2
Ent
Oc2L
Par1
RSG
Te1
Hippocampus
CA3
DG
Septum
LSD
LSI

3.9
5.8
2.2
0.9
1.8
0.4
2.2

(5)
(5)

(5)

52.2
27.8
21.6
6.2
25.6
10.5
13.0

(4)

7.9 ± 3.4
11.5 ± 2.3

(3)
(4)

(6)
(5)

27.3 ± 5.1 *
18.6 ± 3.4

(4)
(5)

(6)
(6)
(6)
(5)
(6)
(6)
(6)

58.6
10.3
18.5
9.3
26.4
10.6
14.7

4.5 ± 1.1
9.6 ± 2.2

(5)

15.1 ± 3.9
15.3 ± 1.2

50.1
16.7
16.1
9.4
26.5
7.9
12.0

±
±
±
±
±
±
±

13.1
3.3
2.8
2.4
3.0
1.8
2.6

±
±
±
±
±
±
±

15.9
1.5
4.2
3.5
3.6
0.9
3.4

(5)
(4)
(4)
(4)
(5)
(4)

(3)
(5)

66.0
25.0
36.8
9.6
23.6
6.1
17.9

11.8
5.2
3.7 *
1.9
0.9
0.9
3.4

(6)
(6)
(5)
(5)
(5)
(4)
(6)

5.0 ± 0.8
12.9 ± 1.8

(5)
(5)

10.1 ± 1.9
22.1 ± 3.9 *

(5)
(6)

10.3 ± 4.0
8.7 ± 1.0

(4)

7.6 ± 3.1t
13.0 ± 1.2

(4)
(5)

±
±
±
±
±
±
±

(4)

(5)
(4)

(5)

±
±
±
±
±
±
±

0

w

TABLE 13 Continued

Brain Region
Amygdala
BLAMY
CAMY
MAMY
Basal Ganglia
CPu
GP
VP
Dience(2halon
Hypothalamus
AHC
DM
LH
MM
MPA
PVN
VMH

Saline

Prepubescent Progeny
(N)
Fluoxetine

11.9 ± 3.3
7.8 ± 2.5
10.9 ± 2.6

(6)
(4)
(5)

53.3 ± 7.4
8.4 ± 1.8
13.4 ± 4.2

(6)
(5)
(4)

19.2
23.3
19.9
111.1
22.9
28.1
36.2

±
±
±
±
±
±
±

1.8
4.3
1.4
5.7
3.0
2.1
5.5

(6)
(6)
(5)
(5)
(4)
(5)
(6)

17.0 ± 5.0
9.7 ± 1.0
14.0 ± 3.9
93.3 ± 15.7
9.2 ± 1.4
23.9 ± 3.1 *

18.4
23.1
12.4
168.1
32.3
25.1
31.1

±
±
±
±
±
±
±

1 .2
2.8
0.5 *
11.5
3.8 *
2.8
7.4

Adult Progeny
(N)
Fluoxetine

(N)

Saline

(4)
(3)
(4)

28.1 ± 2.ot
12.1 ± 1. 1
18.0 ± 2.8

(5)
(4)
(5)

41.6 ± 3.9 *
18.8 ± 4.6
25.1 ± 1.9t

(5)
(4)
(5)

(5)
(4)
(4)

78.1 ± 9.5
10.3 ± 2.1
8.7 ± 1.3

(5)
(4)
(3)

82.3 ± 7.1
3.1 ± 0.5*t
8.7 ± 1.1t

(6)
(6)
(6)

(4)
(5)
(4)
(3)
(4)
(5)
(5)

17.6±3.6
41.1 ± 6.1 t
8.5 ± 1.9t
152.0 ± 24.4
19.2 ± 1.4
20.4 ± 3.4
22.1 ± 2.3

(4)
(5)
(4)
(3)
(4)
(4)
(5)

22.8
53.3
11.8
225.6
22.9
39.0
30.9

±
±
±
±
±
±
±

2.0
5.5
1.3
59.9
1.7t
4.0*t
4.3

(N)

(6)
(6)
(5)
(4)
(5)
(5)
(6)

TABLE 13 Continued

Brain Region
Mesence(2halon
Tegmentum
SN
VTA
Raphe Nuclei
DR
MnR

Saline

Prepubescent Progeny
(N)
Fluoxetine

(N)

Saline

Adult Progeny
(N)
Fluoxetine

(N)

10.6 ± 2.5
39.9 ± 12.3

(6)
(6)

11.8 ± 4.9
23.5 ± 5.4

(5)
(4)

8.5 ± 1.2
22.8 ± 3.3

(4)
(5)

5.7 ± 0.9
31.3 ± 2.2

(6)
(6)

27.0 ± 5.3
16.6 ± 3.7

(4)
(4)

44.0 ± 3.6
21.2 ± 2.8

(4)
(4)

42.8 ± 7.3
16.7 ± 3.0

(4)
(5)

54.9 ± 9.0
13.9 ± 3.1

(4)
(4)

Data are expressed as fmol of sites/mg tissue equivalent and represent the means ± SEM from 3-6 rats per group with each rat
within a group being obtained from a different litter. The number of rats per group is shown in parentheses. Prenatal exposure
to fluoxetine significantly increased the density of [ 3 H]ketanserin-labelled 5-HT 2 A receptors in LSD ( + 81 %), MPA ( + 41 %), and
VP ( + 78%) in prepubescent offspring. In addition, at PD 28, 5-HT 2 A receptors were significantly reduced in the LH (-38%)
following prenatal exposure to fluoxetine. In adult progeny, prenatal fluoxetine exposure produced a significant increase in 5-HT 2 A
receptors in the Ent ( + 70 % l, DG ( + 71 % l, PVN ( + 91 % ) and BLAMY ( + 48 % l. 5-HT 2 A receptors were significantly reduced in
the GP (-70%) in adult fluoxetine-exposed progeny. 5-HT 2 A receptors were labelled with 0.4 nM [ 3 H]ketanserin in the presence
of 30 nM prazosin. Nonspecific binding was determined in the presence of 1 µM cinanserin. Data are extrapolated to 100%
fractional occupancy using the experimentally determined Kd value of 2.57 nM from saturation studies in slide mounted sections
of frontal cortex. 5-HT 2 A receptors were undetectable in the CA 1 and CA2 areas of the hippocampus, and in the arcuate nucleus
of the hypothalamus. Quantification of autoradiograms was performed using computerized digital image analysis as described
in Materials and Methods. Anatomical terminology is described in Table 1. Data were analyzed using a two-way ANOVA followed
by a Newman-Keuls post hoc test. *Significantly different from the respective age-matched control values (p<0.05). t
Significantly different from the respective values in prepubescent offspring (p<0.05).
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Figure 15. Representative brain regions of control offspring in which the density of
3
H]ketanserin-labelled 5-HT2A receptors either increased, decreased or remained
constant as a consequence of maturation. Data are expressed as fmol of sites/mg
tissue equivalent (fmol/mg TE) and represent the means ± SEM from 4-6 control rats
with each rat within a group being obtained from a different litter. Adult (PD 70)
control progeny exhibited a significantly greater density of 5-HT 2 A receptors in DM (A;
+ 76%) and BLAMY (!!; + 36%) than their prepubescent counterparts. In contrast,
the density of 5-HT 2 A receptors was significantly lower in adult progeny in LH (C; 43%). The density of 5-HT 2 A receptors was similar in prepubescent and adult control
progeny in CA3 (!;) and MPA (f). 5-HT 2 A receptors were labelled with 0.4 nM
3
[ H]ketanserin in the presence of 30 nM prazosin. Nonspecific binding was determined
in the presence of 1 µM cinanserin. Data were obtained via the quantification of
autoradiograms which was performed using computerized digital image analysis as
described in Materials and Methods. Data are extrapolated to 100% fractional
occupancy using the experimentally determined Kd value of 2.57 nM. Anatomical
abbreviations are described in Table 10. Data were analyzed as in Table 13 using a
two-way ANOVA followed by a Newman Keuls post-hoc test. *Significantly different
from prepubescent (PD 28) values (p < 0.05).
[
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Prenatal Fluoxetine Exposure Produces Site-Specific Alterations
in the Density of [ 12511001-Labelled High Affinity 5-HT 2 A Receptors
Telencephalon
Site-specific alterations in the density of high affinity 5-HT 2 A receptors were
observed following prenatal exposure to fluoxetine are shown in Table 14 and
illustrated in Figure 16. Similar to observations made regarding [ 3 H]ketanserin
labelled 5-HT 2 A receptors, high affinity 5-HT 2 A receptors were not altered by
prenatal fluoxetine exposure in the subregions of the cortex [cingulate (Cg3),
frontal (Fr2), entorhinal (Ent), occipital (0c2L), parietal (Par1 ), retrosplenial granular
(RSG), and temporal (Te1 )] and hippocampus [CA 1, CA2, CA3, and dentate gyrus
(DG)J examined in prepubescent progeny. However, prenatal fluoxetine exposure
resulted in a 6-fold increase in the density of 5-HT 2 A receptors in the caudate
putamen (CPu) of prepubescent rats. No other alterations in the density of high
affinity 5-HT 2 A receptors were observed in telencephalic areas in prepubescent
progeny. In adult progeny exposed to fluoxetine, the density of 5-HT 2 A receptors
was significantly elevated in the basolateral amygdala (BLAMY;
dorsolateral septal nucleus (LSD;

+ 109), the

+ 306%), and in the CA3 region of the

hippocampus ( + 118%). Similar to prepubescent progeny, prenatal exposure to
fluoxetine did not alter the density of the high affinity 5-HT 2 A receptors in any of
the cortical areas examined (Table 14).

Diencephalon and Mesencephalon
In contrast to the alterations observed in the density of [ 3 H]ketanserin
labelled 5-HT 2 A receptors in the hypothalamus, high affinity 5-HT 2 A receptors were
not altered in any of the subregions of the hypothalamus examined in
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prepubescent progeny prenatally exposed to fluoxetine. In adult progeny, high
affinity 5-HT 2 A receptors were significantly elevated only in the medial mammillary
nucleus {MM; + 73%) of the hypothalamus following prenatal exposure to
fluoxetine. Prenatal exposure to fluoxetine did not alter the density of 5-HT 2 A
receptors in the tegmentum regardless of the age of the offspring.

Changes in the Density of [125 11001-Labelled
5-HT 2A Receptors as a Consequence of Maturation
In contrast to the minimal effects of maturation on [ 3 H]ketanserin- labelled
5-HT 2 A receptors (i.e. the total population) in control progeny, a greater number of
differences were observed in the density of high affinity 5-HT 2 A receptors as a
consequence of maturation (Fig. 17, Table 14). 5-HT 2 A receptors were
significantly lower in adult control progeny than in their prepubescent counterparts
in the occipital (Oc2L; -59%), parietal (Par1; -71 %) and retrosplenial granular
(RSG; -43%) areas of the cortex, areas which exhibited no maturation effects on
[

3

H]ketanserin binding. 5-HT 2 A receptors were also significantly lower in the medial

preoptic area (MPA; -58%) in adult control progeny versus the prepubescent
group. In contrast, 5-HT 2 A receptors were significantly greater in adult progeny
than in prepubescent progeny in the caudate putamen (CPu; + 371 %) and in the
anterior (AHC; + 111 %), arcuate (Arc; +482%) and dorsomedial (DM; + 70%)
nuclei of the hypothalamus.
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c.

D.

Figure 16. Representative autoradiograms and figures illustrating the effect of
prenatal f/uoxetine exposure on f 25/JDO/-labelled high affinity 5-HT2A receptors.
The autoradiograms shown are representative of [ 1251)001 binding in control
prepubescent (A) and adult (.6.) progeny. White areas indicate brain regions with a
high density of 5-HT uptake sites. The panels on the right are diagrammatic
representations of the results from densitometric analysis of autoradiograms taken
from prepubescent (,~) and adult (0) progeny prenatally exposed to fluoxetine.
Prenatal exposure to fluoxetine significantly increased (shaded red) the number of
high affinity 5-HT 2A receptors in the CPu (C) in prepubescent offspring. In adult
offspring, high affinity 5-HT 2A receptors were significantly elevated (shaded red) in
CA3 and BLAMY (0) following prenatal exposure to fluoxetine . High Affinity 5HT2A receptors were labelled with 0.2 nM [ 1251)001. Nonspecific binding was
determined in the presence of 100 nM spiperone to preclude binding to 5-HT 2c
receptors. Abbreviations are described in Table 10 and in the legend to Figure 1.

TABLE 14

THE DENSITY OF HIGH AFFINITY [ 125 1]001-LABELLED 5-HT 2 A RECEPTORS IN PREPUBESCENT AND ADULT OFFSPRING

Brain Region
TelenceQhalon
Cortex
Cg3
Fr2
Ent
Oc2L
Par1
RSG
Te1
Hippocampus
CA1
CA2
CA3
DG
Septum
LSD
LSI

Prepubescent Progeny
(N)
Saline
Fluoxetine

(N)

Saline

Adult Progeny
(N)
Fluoxetine

(N)

(5)
(6)
(6)
(6)
(6)
(6)
(6)

5.27
5.70
1.34
2.53
16.09
2.37
4.52

±
±
±
±
±
±
±

0.23
0.45
0.40
0.53
1.24
0.45
0.72

(5)
(5)
(4)
(5)
(5)
(5)
(5)

5.20
4.90
3.28
1.21
4.99
1.21
3.72

±
±
±
±
±
±
±

0.91
0.61
0.24
0.33t
0.71 t
0.23t
0.60

(5)
(5)
(5)
(5)
(5)
(5)
(5)

6.19
6.55
4.09
1.69
7.26
1.15
5.40

0.32
0.75
0.94
0.26
1.53t
0.25
0.91

(6)
(5)
(6)
(6)
(5)
(4)
(6)

0.03
0.21
0.02
0.09

(6)
(6)
(5)
(5)

0.38
0.57
0.66
0.58

±
±
±
±

0.08
0.12
0.13
0.22

(4)
(5)
(5)
(5)

0.41
0.41
0.57
0.44

±
±
±
±

0.15
0.22
0.10
0.08

(3)
(4)
(4)
(4)

0.66±0.14
0.95 ± 0.22
1.24 ± 0.27*
1.00 ± 0.22

(5)
(5)
(6)
(6)

0.48 ± 0.16
0.49 ± 0.12

(5)
(5)

0.48 ± 0.13
0.47 ± 0.04

(5)
(5)

0.18 ± 0.03
0.79 ± 0.18

(4)
(5)

0.73 ± 0.13*
1.19 ± 0.28

(6)
(6)

6.02 ± 0.56
6.28 ± 0.59
1.25 ± 0.13
2.95 ± 0.38
17.18 ± 1.67
2.14±0.24
6.14±0.99
0.20
0.60
0.45
0.43

±
±
±
±

±
±
±
±
±
±
±

0

TABLE 14 Continued

Brain Region
Amygdala
BLAMY
CAMY
MAMY
Basal Ganglia
CPu
GP
VP
Dience12halon
Hypothalamus
AHC
Arc
DM
LH
MM
MPA
PVN
VMH

Saline

Prepubescent Progeny
(N)
Fluoxetine

(N)

Saline

Adult Progeny
(N)
Fluoxetine

4.47 ± 0.38
0.68 ± 0.11
3.66 ± 0.47

(6)
(6)
(6)

3.53 ± 0.27
0.96 ± 0.25
3.09 ± 0.29

(5)
(5)
(5)

5.74 ± 0.87
0.91 ± 0.22
2.16 ± 0.20

(5)

0.51 ± 0.20
0.33 ± 0.07
0.63 ± 0.07

(5)
(6)
(6)

3.06 ± 0.16*
0.24±0.10
0.62 ± 0.12

(5)
(5)
(5)

2.40 ± 0.14t
nd
nd

(4)

1.69
0.28
1.12
2.25
17.27
1.50
1.33
5.61

±
±
±
±
±
±
±
±

0.24
0.03
0.27
0.17
1.34
0.25
0.16
0.63

(6)
(4)
(6)
(5)
(6)
(6)
(5)
(6)

1.97
0.38
0.70
2.04
17.99
1.44
1.81
4.71

±
±
±
±
±
±
±
±

0.78
0.05
0.04
0.20
1.34
0.11
0.48
0.53

(3)
(5)
(4)
(5)
(4)
(4)
(5)
(5)

3.56
1.63
1.90
2.08
17.46
0.63
1.02
4.58

±
±
±
±
±
±
±
±

0.30t
0.41 t
0.26t
0.28
3.10
0.04t
0.25
1.02

(4)
(4)

(6)
(4)
(5)
(5)
(4)
(5)
(4)
(5)

(N)

12.00 ± 1.03*t
1.41 ±0.23
3.32 ± 0.46

(6)
(6)
(6)

2.96 ± 0.82
nd
nd

(6)

3.42
1.16
2.11
2.60
30.19
0.68
1.27
5.29

±
±
±
±
±
±
±
±

0.31 t
0.38
o.18t
0.37
3.65*t
0.17t
0.22
0.69

(5)
(6)
(5)
(5)
(4)
(6)
(3)
(6)

TABLE 14 Continued

Brain Region
Mesenceghalon
Tegmentum
SN
VTA

Prepubescent Progeny
(N)
Saline
Fluoxetine

0.30 ± 0.05
1.43 ± 0.31

(6)
(6)

0.19 ± 0.04
2.01 ± 0.36

(N)

Saline

(4)
(5)

0.59 ± 0.07
1.35 ± 0.12

Adult Progeny
(N)
Fluoxetine

(N)

(5)
(5)

(5)
(5)

0.96 ± 0.35
2.06 ± 0.26

Data are expressed as fmol of sites/mg tissue equivalent and represent the means ± SEM from 3-6 rats per group with each rat
within a group being obtained from a different litter. The number of rats per group is shown in parentheses. Prenatal exposure
to fluoxetine ( 10 mg/kg/2ml, s.c., to dams from GD 13-20) significantly increased the density of high affinity 5-HT zA receptors
in CPu ( + 500%) in prepubescent progeny. In adult progeny, 5-HT 2 A receptors were significantly elevated in CA3 ( + 118%), MM
( + 73%), BLAMY ( + 109%), and LSD ( + 300%). High affinity 5-HT 2 A receptors were labelled with 0.2 nM [ 125 11001. Nonspecific
binding was determined in the presence of 100 nM spiperone to preclude binding to 5-HT zc receptors. Quantification of
autoradiograms was performed using computerized digital image analysis as described in Materials and Methods. Data are
extrapolated to 100% fractional occupancy using the experimentally determined Kd value of 0.68 nM for prepubescent and 1. 74
nM for adult progeny. Anatomical abbreviations are described in Table 10. High affinity 5-HT zA receptors were undetectable in
the raphe nuclei and in the GP and VP only in adult progeny. Therefore, in the GP and VP, prepubescent data were analyzed by
a Students' t-test. All other data were analyzed using a two-way ANOVA followed by a Newman-Keuls post hoc test.
*Significantly different from the respective age-matched control values (p<0.05). t Significantly different from the respective
values in prepubescent offspring (p < 0.05). nd indicates not determined.
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Figure 17. Representative brain regions of control progeny in which the density of
high affinity f 25/JDOJ-labelled 5-HT2A receptors either increased, decreased or remained
constant as a consequence of maturation. Data are expressed as fmol of sites/mg
tissue equivalent (fmol/mg TE) and represent the means ± SEM from 4-6 control rats
with each rat within a group being obtained from a different litter. Adult (PD 70)
control progeny exhibited a significantly lower density of 5-HT 2 A receptors in Oc2L (A;
-59%), Par1 (~; -71 %) and MPA (C; -58%) than their prepubescent counterparts. The
density of 5-HT 2 A receptors was similar in prepubescent and adult control progeny in
MM (D), VTA (~)and BLAMY (f). In contrast, the density of 5-HT 2 A receptors was
significantly greater in adult progeny in CPU (G; + 371 %), AHC (H; + 111 %), and Arc
(l; +482%) than in prepubescent offspring. High affinity 5-HT 2 A receptors were
labelled with 0.2 nM [ 125 1JDOI. Nonspecific binding was determined in the presence
of 100 nM spiperone to preclude binding to 5-HT 2 c receptors. Data were obtained via
the quantification of autoradiograms which was performed using computerized digital
image analysis as described in Materials and Methods. Data are extrapolated to 100%
fractional occupancy using the experimentally determined Kd value of 0.68 nM for
prepubescent and 1. 74 nM for adult offspring. Anatomical abbreviations are described
in Table 10. Data were analyzed as in Table 14 using a two-way ANOVA followed
by a Newman Keuls post-hoc test. *Significantly different from prepubescent (PD 28)
values (p<0.05).
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Prenatal Fluoxetine Exposure Produces Site-Specific Alterations
in the Percentage of High Affinity 5-HT 2 A Receptors
The number of high affinity 5-HT 2 A receptors to the number of
[3H]ketanserin-labelled receptors was calculated to provide an index of the percent
of 5-HT 2 A receptors able to couple to their respective guanine nucleotide regulatory
proteins. In order to calculate the percentage of high affinity 5-HT 2 A receptors, the
density of [ 3 H]ketanserin and [ 125 1]001-labelled 5-HT 2 A receptors representing 100
% fractional occupancy was determined using the experimentally derived affinity
for the radioligands reported in Table 15. The percentage of high affinity 5-HT 2 A
receptors calculated for each brain region is shown in Table 16. The percentage of
high affinity sites was significantly greater in the caudate putamen (CPu;

+ 300%)

in fluoxetine-exposed prepubescent offspring. In adult progeny, the percentage of
high affinity 5-HT 2 A receptors was significantly elevated in the dorsolateral septa I
nucleus (LSD;

+ 275%) following prenatal exposure to fluoxetine. The percentage

of high affinity sites was similar in control and fluoxetine-exposed offspring in all
other brain regions examined.

Changes in the Percentage of High Affinity
5-HT 2 A Receptors as a Consequence of Maturation
As shown in Table 16, the percentage of high affinity 5-HT 2 A receptors was
significantly greater in adult controls than in prepubescent progeny in the
intermediate zone of the lateral septal nucleus (LSI;
putamen (CPu;

+ 125 %) and in the caudate

+ 200%). In contrast, the percentage of high affinity 5-HT 2A

receptors was significantly lower in the parietal (Par1; -83 %) and retrosplenial
granular (RSG; -70%) areas of the cortex and in the anterior hypothalamus (AHC; 77%) and medial preoptic area (MPA; -57%) in adult progeny.

TABLE 15
[

125

11001 AND [3 HJKETANSERIN AFFINITY CONSTANTS IN CORTICAL SLICES

Kd of [ 3 H]ketanserin for 5-HT 2 A receptors
(high and low)
Prenatal
Exposure Group

Kd of [ 125 1JDOI for 5-HT 2 A receptors
(high)

Prepubescent Progeny

Adult Progeny

Prepubescent Progeny

Adult Progeny

Saline

2.54 ± 0.11 (3)

2.33 ± 0.29 (3)

0.61 ± 0.12 (5)

1.90 ± 0.26

t

(5)

Fluoxetine

2.49 ± 0.61 (3)

2.90 ± 0.64 (5)

0. 75 ± 0.16 (5)

1.58 ± 0.40

t

(5)

Data represent the means ± SEM from 3-5 rats per group with each rat within a group being obtained from different litter.
The number of rats per group is shown in parentheses. Affinity values were derived from scatchard analysis of saturation
studies carried out in cortical brain sections which were wiped from the slides into scintillation vials as described in the
Materials and Methods section. Prenatal exposure to fluoxetine did not alter the affinity of [3 H]ketanserin or [ 125 1]DOI for 5HT 2 A receptors in either prepubescent or adult offspring. Average Kd for [ 3 H]ketanserin = 2.57 nM; Average Kd for [ 125 11001
in prepubescent offspring = 0.68 nM; Average Kd for [ 125 IJDOI in adult progeny = 1. 74 nM. Data were analyzed using a
two-way ANOVA followed by a Newman-Keuls post-hoc test. tSignificantly different from respective values in prepubescent
progeny (p<0.05).

TABLE 16
THE PERCENTAGE OF HIGH AFFINITY 5-HT 2 A RECEPTORS IN PREPUBESCENT AND ADULT OFFSPRING

Brain Region
Telence(Jhalon
Cortex
CG3
Fr2
Ent
Oc2L
Par1
RSG
Te1
Hippocampus
CA3
DG
Septum
LSD
LSI
Amygdala
BLAMY
CAMY
MAMY
Caudate
CPu

Saline

13
49
9
52
48
23
49

±
±
±
±
±
±
±

2
12
2
12
7
5
9

Prepubescent Progeny
(N)
Fluoxetine

(6)
(6)
(6)
(5)
(6)
(6)
(5)

11
47
8
49
43
16
44

±
±
±
±
±
±
±

2
12
2
11
3
2
5

(N)

Saline

(5)
(5)
(4)
(3)
(5)
(4)
(4)

10
28
16
20
8
7
29

13 ± 3
3 ± 0

±
±
±
±
±
±
±

2
9
1
6
2t
4t
3

Adult Progeny
(N)
Fluoxetine

(N)

(5)
(5)
(4)
(5)
(5)
(4)
(5)

10 ± 1
28 ± 6
13 ± 4
26 ± 7
11 ± 2t
5 ± 0
34 ± 8

(6)
(6)
(5)
(6)
(5)
(3)
(6)

(4)
(4)

16 ± 3
5 ± 1

(6)
(6)

10 ± 3
8 ± 4

(4)
(5)

9 ± 2
3 ± 1

(3)
(4)

3 ± 1
4 ± 2

(6)
(6)

3 ± 1
3 ± 1

(5)
(5)

42 ± 12
14 ± 7
40 ± 12

(5)
(4)
(5)

26 ± 7
16 ± 2
30 ± 10

(4)
(4)
(4)

21 ± 4
7 ± 3
18 ± 5

(5)
(3)
(5)

35 ± 5
27 ± 11
14 ± 3

(6)
(6)
(5)

1 ± 0

(6)

4 ± 1*

(5)

3 ± 1t

(5)

3.5 ± 0.9

(6)

4 ± 1
9 ± 2t

(4)
(5)

15 ± 6 *t
7 ± 1

(4)
(5)

....
....

TABLE 16 Continued

Brain Region
Dience12halon
Hypothalamus
AHC
DM
LH
MPA
PVN
VMH
Mesence12halon
Tegmentum
SN
VTA

Saline

Prepubescent Progeny
(N)
Fluoxetine

2
1
1
1
1
1

(6)
(5)
(5)
(5)
(6)
(5)

3 ± 1
5 ± 1

(6)
(6)

13
4
7
7
5
13

±
±
±
±
±
±

(N)

2
0
2
1
1
5

(5)
(4)
(5)
(4)
(4)
(5)

3 ± 1
5 ± 1

(4)
(4)

12
3
10
4
5
19

±
±
±
±
±
±

Saline

1t

Adult Progeny
(N)
Fluoxetine

5 ± 3t

± 2
± 6

(4)
(5)
(5)
(4)
(3)
(5)

4
9
4
7
21

8 ± 2
7 ± 1

(4)
(5)

14 ± 5t
6 ± 1

3
5
7
3
5
22

±
±
±
±

1
2
ot

±
±
±
±
±

1
2
1
3
3

(N)

(3)
(5)
(5)
(6)
(3)
(5)

(5)
(6)

Data are expressed as fmol of sites/mg tissue equivalent and represent the means ± SEM from 3-6 rats per group with each rat
within a group being obtained from a different litter. The number of rats per group is shown in parentheses. Prenatal exposure
to fluoxetine ( 10 mg/kg/2ml, s.c., to dams from GD 13-20) significantly increased the percentage of high affinity 5-HT 2 A receptors
in CPU (+300%) in prepubescent progeny. The percentage of high affinity 5-HT 2 A receptors was significantly elevated in LSD
( + 275%) in adult offspring prenatally exposed to fluoxetine. The percentage of high affinity 5-HT 2 A receptors represents the
percentage of [ 125 1]001-labelled receptors relative to the total density of 5-HT 2 A receptors as labelled by [ 3 H]ketanserin. Anatomical
abbreviations are described in Table 10. Data were analyzed using a two-way ANOVA followed by a Newman-Keuls post hoc
test. *Significantly different from the age-matched control values (p<0.05). t Significantly different from the respective values
in prepubescent offspring (p < 0.05).
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Figure 18. Regional specificity of statistically significant alterations in the percentage
of high affinity 5-HT2A receptors as a consequence of normal maturation. Data are
expressed as the percentage of high affinity 5-HT 2 A receptors present (% High
Affinity) and represent the means ± SEM from 4-6 control rats with each rat within
a group being obtained from a different litter. Adult (PD 70) control progeny exhibited
a significantly greater percentage of high affinity 5-HT 2 A receptors in LSI (A; + 125%)
and CPu (§.; + 200%) than their prepubescent counterparts.
In contrast, the
percentage of high affinity 5-HT 2 A receptors was significantly lower in adult progeny
in Par1 (C; -83%), RSG (D; -70%), AHC (£; -77%), and MPA (f; -57%) than in
prepubescent offspring. The percentage of high affinity 5-HT 2 A receptors was similar
in prepubescent and adult control progeny in CA3 (G), VTA (H) and Cg3 (!).
Anatomical abbreviations are described in Table 10. Data were analyzed as in Table
1 6 using a two-way ANOVA followed by a Newman Keuls post-hoc test.
* Significantly different from prepubescent (PD 28) values (p < 0.05).
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Summary of Results
Prenatal exposure to fluoxetine results in site-specific and age-dependent
alterations in the neurochemical and functional status of brain 5-HT pathways in
offspring in the absence of physical abnormalities. The results are summarized in
Tables 17-18 and in Figures 9-22.

Neurochemical Status of 5-HT Neurons
5-HT content was significantly reduced in the frontal cortex of
prepubescent progeny but was similar to control values by adulthood (Table 17).
In contrast, midbrain 5-HT content was significantly reduced only in fluoxetineexposed adult progeny. Prenatal fluoxetine exposure did not alter the density of 5HT uptake sites in homogenates of cortex, hypothalamus, hippocampus, striatum
or midbrain. However, more detailed autoradiographic analysis in discrete
neuroanatomic loci detected numerous localized alterations in the density of 5-HT
uptake sites in prepubescent, but not in adult offspring, prenatally exposed to
fluoxetine (Figure 19). In addition, most of the changes in 5-HT uptake sites were
localized to limbic areas of the brain.

Functional Status of 5-HT Neurons
The magnitude of the reduction in 5-HT content following the administration
of a 5-HT releasing drug was attenuated only in midbrain of adult progeny exposed
prenatally to fluoxetine (Table 17).

Neurochemical Status of 5-HT Receptor Systems
5-HT,A receptor density was minimally altered by prenatal exposure to
fluoxetine (Fig. 20). 5-HT 1 A receptors were significantly elevated only in the
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entorhinal cortex and the paraventricular nucleus of the hypothalamus of
prepubescent but not adult progeny prenatally exposed to fluoxetine. However, 5HT 1 A receptors were significantly reduced in the ventromedial hypothalamus of
adult but not prepubescent progeny. These were the only alterations in 5-HT 1 A
receptor density observed following prenatal fluoxetine exposure.
In contrast, a greater number of alterations in 5-HT 2 A receptor density were
observed in both prepubescent and adult progeny following prenatal exposure to
fluoxetine (Figs. 21 and 22). The majority of the alterations in the density of
[

3

H]ketanserin and [ 125 1]DOl-labelled 5-HT 2 A receptors were observed in adult

progeny prenatally exposed to fluoxetine. In addition, the majority of 5-HT 2 A
receptor density alterations were observed in limbic areas of the brain.

Functional Status of Postsynaptic 5-HT Receptor Systems

The magnitude of the neuroendocrine responses (ACTH, corticosterone, and
renin) to a maximally effective dose of the 5-HT 1A agonist 8-0H-DPAT were not
altered by prenatal exposure to fluoxetine (Table 18). In contrast, the magnitude
of the ACTH response to the 5-HT 2 A 12c agonist DOI was significantly attenuated in
adult but not in prepubescent progeny prenatally exposed to fluoxetine (Table 18).
Neither the corticosterone nor renin responses to DOI were altered by prenatal
exposure to fluoxetine.

Effects of Maturation on the Neurochemical and
Functional Status of 5-HT Pathways

In addition to investigating the effects of prenatal exposure to fluoxetine on
5-HT pathways, the experimental design allowed us to detect alterations in
neurochemical and functional status of brain 5-HT pathways as a consequence of
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normal maturation (summarized in Table 19). The densities of all the 5-HT
recognition sites examined in the present study (5-HT uptake sites, 5-HT,A and 5HT 2 A receptors) were affected to some degree by maturation. Overall, the greater
number of changes which occurred as a consequence of maturation were changes
in the density of 5-HT uptake sites.

TABLE 17
SUMMARY OF CHANGES IN THE NEUROCHEMICAL AND FUNCTIONAL STATUS OF 5-HT NEURONS
Brain Region
Neurochemical Parameter

Frontal Cortex

Hypothalamus

Hippocampus

Striatum

Midbrain

~

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

5-HT Content
Prepubescent progeny
Adult progeny

~

Extent of Reduction in
5-HT Content Following PCA
n.s.

Prepubescent Progeny
Adult Progeny

~

ti.

= Significant reduction in fluoxetine-exposed progeny
= Significantly attenuated response to PCA observed in fluoxetine-exposed progeny

n.s.

=

No significant effect of fluoxetine exposure on this parameter

JJ.
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TABLE 18
SUMMARY OF DIFFERENTIAL 5-HT AGONIST MEDIATED
NEUROENDOCRINE RESPONSES IN PROGENY PRENATALLY
EXPOSED TO FLUOXETINE

Treatment Group

ACTH

Hormone
CORT

Renin

5-HT 1A (8-0H-DPA T)
Prepubescent progeny

n.s.

n.s.

n.s.

Adult progeny

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

5-HT 2 A 12c (001)
Prepubescent progeny
Adult progeny

i

CORT = Corticosterone
n.s.
= No significant effect of fluoxetine exposure on this parameter
i
= Significant attenuation of the ACTH response to DOI in fluoxetine-exposed
offspring
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A.

RSG

Par1

~~·· ·~

B.
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LH

r@'
Prepubescent Progeny

c.

Prepubescent Progeny

D.

DM

~

.·

..

. ·.·

1->repubescent Progeny

Prepubescent Progeny

Figure 19. Summary of alterations in the density of [ 3 HJcitalopram-labelled 5-HT
uptake sites in prepubescent progeny prenatally exposed to fluoxetine. Significant
increases (A,~; + 21 to + 4 7) in the density of 5-HT uptake sites were observed
following prenatal exposure to fluoxetine in the brain regions shaded in red (lateral
hypothalamus, CA2 and CA3 subregions of the hippocampus, and the medial and
basal amygdaloid nuclei). Significant decreases (C,D; -19% to -21 %) in the density
of 5-HT uptake sites were observed in brain regions shaded in blue (dorsomedial
hypothalamus, and substantia nigra). Abbreviations are described in Table 10 and in
the legend to Figure 1 .
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A.

B.

PVN

~@..____...Prepubescent Progeny

C.

Prepubescent Progeny

CA1

Adult Progeny

Figure 20. Summary of alterations in the density of fHJB-OH-DPA T-labelled 5-HT7A
receptors in prepubescent (!l,!J) and adult (g rat progeny prenatally exposed to
fluoxetine. Significant increases ( + 26% to + 42%) in the density of 5-HT 1A receptors
were observed in prepubescent progeny prenatally exposed to fluoxetine in the brain
regions shaded in red (paraventricular nucleus, entorhinal cortex). In contrast, in adult
progeny, a significant decrease (-33%) in the density of 5-HT 1 A receptors was
observed in the brain region shaded in blue (ventromedial hypothalamus).
Abbreviations are described in Table 10 and in the legend to Figure 1.
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B.

A.

Prepubescent Progeny

c.

Adult Progeny

D.

Adult Progeny

Adult Progeny

Figure 21. Summary of alterations in the density off 251JDOl-labelled 5-HT2A receptors
in prepubescent (/l) and adult (ftf;,Q) rat progeny prenatally exposed to fluoxetine.
Significant increases (red; + 73% to + 500%) in the density of high affinity 5-HT 2 A
receptors were observed in progeny prenatally exposed to fluoxetine. In prepubescent
progeny, 5-HT 2 A receptors were significantly elevated only in the caudate putamen.
In adult progeny, high affinity 5-HT2 A receptors were significantly elevated in the
dorsolateral septa I nucleus, CA3 subregion of the hippocampus, basolateral ainygdala,
and medial mammillary nucleus. Abbreviations are described in Table 10 and in the
legend to Figure 1 .
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A.

Prepubescent Progeny

Prepubescent Progeny

c.

Prepubescent Progeny

Figure 22. Summary of alterations in the density of r3HJketanserin-labelled 5-HT2A
receptors in prepubescent (~{l.,g and adult (!J.,g,f) rat progeny prenatally exposed to
fluoxetine.
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0.

E.

PVN

CP~

f@;®----Adult Progeny

Adult Progeny

F.

Adult Progeny

Adult Progeny

Figure 22 Continued. Summary of alterations in the densitv. of [ 3 H]ketanserin-labelled
5-HT2A receptors in prepubescent fAf!..,g and adult ({l,f,~ rat progeny prenatally
exposed to fluoxetine. Significant increases (red; + 41 % to + 91 %) and decreases
(blue; -38% to -70%) in the density of 5-HT 2 A receptors were observed in progeny
prenatally exposed to fluoxetine. In prepubescent progeny, 5-HT 2 A receptors were
significantly elevated in the (dorsolateral septa! nucleus, medial preoptic area and
ventral pallidum). In addition, 5-HT 2 A receptors were significantly reduced in the lateral
hypothalamus in prepubescent fluoxetine-exposed progeny. In adult progeny, 5-HT 2 A
receptors were significantly elevated in the paraventricular nucleus, dentate gyrus,
basolateral amygdala and entorhinal cortex and significantly reduced in the globus
pallidus. Abbreviations are described in Table 10 and in the legend to Figure 1.

129
TABLE 19

SUMMARY OF ALTERATIONS IN 5-HT RECOGNITION SITES AS DETERMINED BY
AUTORADIOGRAPHIC ANALYSES IN PREPUBESCENT AND ADULT PROGENY
PRENATALLY EXPOSED TO FLUOXETINE

Brain Region

Prepubescent Progeny
CIT DPT
KET
DOI

CIT

Adult Progeny
DPT
KET

DOI

ns
ns
ns
ns
ns
ns
ns

Telence(;!halon
Cortex

Cg3
Fr2
Ent
Oc2L
Par1
RSG
Te1

nd
ns
ns
nd

ns
ns
ns
ns
ns
ns
ns

ns
ns
ns
ns
ns
ns
ns

ns
ns
ns
ns
ns
ns
ns

ns
ns
ns
nd
ns
ns
nd

bd
bd
ns
ns

ns
ns
ns
ns

ns
ns
ns
ns

ns
ns
ns
ns

bd
bd
ns

ns
ns

ns

ns
ns
ns
ns

t

ns

ns
ns

ns
ns

t

ns
ns

ns
ns

ns
ns

t

ns

ns
ns

t

ns
ns
ns

ns
ns
ns

ns
ns
ns

nd
nd
nd

t

t

t

nd
nd
nd

ns
ns

ns
ns

ns
ns
ns

ns
nd
nd

ns
ns

t

ns
ns
ns

ns
nd
nd

ns

ns
bd
bd

ns
ns
ns
ns
ns
ns
ns

ns
ns
t

ns
ns
t

ns
ns
ns
ns

Hippocampus

CA1
CA2
CA3
DG

ns
t
t

t

Septum

LSD
LSI

ns

Amygdala

BLAMY
CAMY
MAMY

nd

Basal Ganglia

CPu
GP
VP

t

ns
ns

i

ns
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TABLE 19 Continued

Brain Region
Dience12halon
Hypothalamus
AHC
ARC
DM
LH
MM
MPA
PVN
VMH
Mesence12halon
Tegmentum
SN
VTA
Raphe Nuclei
DR
MnR

Prepubescent Progeny
CIT
DPT
DOI
KET

CIT

Adult Progeny
DPT
KET

DOI

ns
ns
i
t
ns
ns
ns
ns

ns
nd
ns
ns
nd
nd
t
ns

ns
bd
ns
i
ns
t
ns
ns

ns
ns
ns
ns
ns
ns
ns
ns

ns
ns
ns
ns
ns
ns
ns
ns

ns
nd
ns
ns
nd
nd
ns
i

ns
bd
ns
ns
ns
ns
t
ns

ns
ns
ns
ns
t
ns
ns
ns

i
ns

nd
nd

ns
ns

ns
ns

ns
ns

nd
nd

ns
ns

ns
ns

ns
ns

ns
ns

ns
ns

bd
bd

ns
ns

ns
ns

ns
ns

bd
bd

t = This parameter was significantly increased (p < 0.05) in fluoxetine-exposed
progeny. i = This parameter was significantly reduced (p < 0.05) in fluoxetineexposed progeny. Abbreviations: [ 3 H]CIT, citalopram-labelled 5-HT uptake sites; DPT,
3
[ H]8-0H-DPA T-labelled
5-HT 1 A receptors; KET, [ 3 H]ketanserin-labelled 5-HT 2 A
125
receptors; DOI, [ l]DOl-labelled 5-HT 2A receptors; ns, no significant alteration in this
parameter was observed in fluoxetine-exposed progeny; nd, not determined; bd, value
was beyond the detectable limits of the assay.

TABLE 20

SUMMARY OF CHANGES IN NEUROCHEMICAL AND FUNCTIONAL
INDICES OF BRAIN SEROTONIN SYSTEMS IN CONTROL
PROGENY AS A CONSEQUENCE OF MATURATION

Index

Significant Changes as a Consequence of Maturation

5-HT

t
t
t
t

5-HIAA
5-HT/5-HIAA
PCA Response

Mdbr
Hypo, Hipp, Str, Mdbr
FCtx, Hypo, Hipp, Str, Mdbr
Mdbr;

ACTH, corticosterone and renin responses to 8-0H-DPAT

+ renin
+ renin

ACTH, corticosterone and renin responses to DOI

n.s.

Basal ACTH, corticosterone, renin

[
[
[
[

3

H]citalopram-labelled 5-HT uptake sites

3

H]8-0H-DPAT-labelled 5-HT 1A receptors

125
3

1]DOl-labelled 5-HT 2 A receptors

H]ketanserin-labelled 5-HT 2 A receptors

Percentage of high affinity 5-HT 2 A receptors

t
t
t
t
t

+ FCtx

Cg3, CA1, CA3, BLAMY, MAMY, Arc;
VMH;

+ Par1,

LSI, CPu;

SN, MnR

RSG, LSD, LSI, CPu, AHC, LH, PVN

CPu, AHC, Arc, DM;
BLAMY, DM;

+ Te1,

+ OC2L,

Par1, RSG, MPA,

+ LH

+ Par1,

RSG, AHC, MPA

t = Significantly greater in adult control progeny in comparison to their prepubescent counterparts.
+ = Significantly lower in adult control progeny in comparison to their prepubescent counterparts.
n.s. = No significant difference observed between adult and prepubescent control progeny.
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CHAPTERV
DISCUSSION
The studies reported herein provide data demonstrating that prenatal
exposure to fluoxetine produces alterations in both pre- and postsynaptic
components of brain 5-HT pathways in offspring in the absence of visually
apparent physical abnormalities. The neurochemical alterations are not
widespread, as they occur only in specific neuroanatomic loci. In particular,
serotonergic pathways to limbic and motor areas of the brain are selectively altered
in offspring prenatally exposed to fluoxetine. In addition, the nature {i.e. location,
magnitude and direction) of the observed neurochemical changes are dependent on
the age of the offspring. Some of the statistically significant alterations in brain
serotonergic pathways are observed only in prepubescent animals, while other
alterations are manifested only upon maturation of the offspring prenatally exposed
to fluoxetine. Additional studies are required to determine whether these "delayed"
alterations persist or may be accentuated in senescent offspring. Overall, the data
presented in this dissertation support the hypothesis that fluoxetine-induced
disruption of the regulation of 5-HT systems during fetal brain development can
produce neurochemical and functional alterations in brain 5-HT pathways in
offspring. The implications of the specific effects of prenatal fluoxetine exposure
on the neurochemical and functional status of pre- and postsynaptic components of
brain 5-HT pathways will be discussed individually in the following paragraphs.
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Neurochemical Status of Brain 5-HT Neurons
Monoamine Content

The present data indicate that alterations in brain 5-HT content in progeny
prenatally exposed to fluoxetine can occur in both terminal (i.e. cortex) and cell
body regions (i.e. midbrain). Deficits in the frontal cortex are present in
prepubescent offspring and return to control values by adulthood. In contrast,
midbrain 5-HT content is reduced (-28%; p < 0.05) only following maturation in
rats prenatally exposed to fluoxetine suggesting a delayed effect or compensatory
response to other alterations. 5-HT content was not reduced in any other brain
regions examined (striatum, hippocampus and hypothalamus) regardless of the age
of the offspring. Thus, these experiments indicate that the reductions in 5-HT
content are region-specific and age-dependent rather than widespread in progeny
prenatally exposed to fluoxetine. However, the data do not preclude the possibility
that in brain regions where global changes in 5-HT content were not detected,
more localized alterations in 5-HT content and/or 5-HT innervation may have
occurred either in specific neuroanatomic loci and/or in specific 5-HT pathways.
For example, Akbari et al. ( 1992) was not able to detect changes in [ 3 H]paroxetine
binding to 5-HT uptake sites in hippocampal homogenates in prepubescent
offspring prenatally exposed to cocaine, despite observing a loss of 5-HT
immunoreactive fibers in the hippocampus in slide-mounted sections. These data
suggest compensatory changes in 5-HT uptake sies may have occured during
development or that the changes in 5-HT innervation were too subtle to detect in
homogenate binding assays. Likewise, in the present dissertation studies, changes
in 5-HT uptake sites in several brain regions evident by in vitro autoradiography
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were not detected in homogenate binding assays. Therefore, subsequent studies
using more sensitive immunohistochemical techniques may be more applicable to
detect changes in 5-HT content in discrete brain nuclei.
Reductions in 5-HT content were observed in fluoxetine-exposed offspring
in the absence of any significant alterations in brain 5-HIAA content, suggesting
that the observed reductions in 5-HT content are the result of a decrease in
regional 5-HT synthesis. The decreased 5-HT synthesis could be the result of
either ( 1) alterations in the availability of the 5-HT precursor L-tryptophan, or (2)
alterations in the amount and/or function of synthetic enzymes or their required
cofactors (see appendix 1 ). Individual values of brain 5-HT content were divided
by their respective 5-HIAA values as an index of 5-HT turnover for each animal.
As brain 5-HIAA content was not significantly altered by prenatal fluoxetine
exposure, no significant alterations in the 5-HT /5-HIAA ratios were observed in
progeny prenatally exposed to fluoxetine.
The studies discussed thus far examined the effect of prenatal fluoxetine
exposure on serotonergic neurochemical markers in the cortex, hypothalamus,
striatum, hippocampus and midbrain. These brain regions were chosen to represent
( 1 ) areas which complete synapse formation at differing postnatal ages (Lauder et

al., 1982; Lidov and Molliver, 1982a,b; Wallace and Lauder, 1983; D' Amato et al.,
1987) and/or (2) areas receiving varying degrees of serotonergic innervation from
the dorsal and median raphe nuclei. For example, the midbrain dorsal raphe
synapses become apparent prior to birth, and synapse formation continues to
increase for several weeks postnatally (Lauder and Bloom, 1975). Similarly, the
establishment of the extent and pattern of serotonergic innervation of the cortex
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takes place from gestational day 19 through postnatal day 21 (D' Amato et al.,
1987). In contrast, the striatum does not begin to receive substantial 5-HT
innervation until 2 weeks after birth {Wallace and Lauder, 1983), and serotonergic
innervation in the hippocampus continues to increase as long as 3 months
postnatally {Azmitia et al., 1983). The two brain regions in which 5-HT was
significantly reduced {cortex and midbrain) follow developmental time courses
which are similar to each other, but differ somewhat from the other brain regions
examined, with respect to the initiation and completion of serotonergic innervation
in these areas. Therefore, the data suggest that the differential sensitivity of
developing brain regions to late-term prenatal fluoxetine exposure may be related,
at least in part, to the extent of serotonergic innervation of a particular brain region
at the time of the prenatal insult. Fluoxetine administration throughout the preweanling period may have produced additional changes in brain regions receiving
significant 5-HT innervation after birth.
The examination of brain regions with differential sources of serotonergic
innervation facilitates evaluating whether prenatal fluoxetine exposure may
selectively alter a specific ascending serotonergic pathway. With respect to
differential sources of innervation, the hippocampus receives serotonergic
innervation primarily from the median raphe nucleus while the striatum receives
serotonergic projections primarily from the dorsal raphe nucleus {Lorens and
Guldberg, 1974; Van de Kar and Lorens, 1979). In contrast, the cortex as well as
the hypothalamus receive extensive serotonergic innervation from both the dorsal
and median raphe nuclei (Van de Kar and Lorens, 1979). The lack of changes in 5HT in these regions suggests little difference between 5-HT pathways. The
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presence of changes in 5-HT content in an area which contains both dorsal and
median raphe cell bodies (i.e. midbrain) and in an area which receives 5-HT
projections from both dorsal and median raphe nuclei (i.e. cortex) suggests that
both ascending pathways may be sensitive to the effects of prenatal fluoxetine
exposure. Furthermore, the vulnerability of these 5-HT pathways may be due to
the time of drug exposure. The lack of alterations in 5-HT content in striatum,
hippocampus, and hypothalamus indicate that sensitivity to prenatal fluoxetine
exposure appears to be region-specific rather than dependent on the specific
serotonergic projections which innervate the particular area. Therefore, the data
from the experiments discussed thus far do not provide any evidence for a
differential susceptibility of ascending median or dorsal raphe serotonergic
pathways.

Comparison Between Prepubescent and Adult Control Progeny

Relatively few studies have quantitatively examined age-dependent changes
in monoamine content. Consistent with the data presented in this dissertation,
Schwabe et al. (1992) reported lower 5-HIAA but not 5-HT values in the striatum
of adult rats in comparison to prepubescent animals. In addition, data from this
dissertation indicate that in adult rats, basal 5-HIAA content is significantly lower
in the hypothalamus, hippocampus, and midbrain than in prepubescent animals
(Table 5). In the present studies, as the animals matured, a selective increase in 5HT content was observed only in the midbrain. This general lack of changes in 5HT content with maturation is consistent with previous reports in which 5-HT was
measured in whole rat brain (Nomura et al., 1976).
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5-HT Uptake Sites
Radioligand Binding Assays in Homogenates
In regions where changes in 5-HT content were observed in fluoxetineexposed offspring, there were no accompanying alterations in the density of 5-HT
uptake sites as measured by radioligand binding assay in homogenates. The
radioligand binding data in homogenates of specific brain regions indicate that
widespread global changes in the density of 5-HT uptake sites were not present in
offspring prenatally exposed to fluoxetine. In contrast to these homogenate
studies, Montero et al. (1990) reported that prenatal exposure to either fluoxetine
or clomipramine (a tricyclic antidepressant which selectively inhibits 5-HT uptake)
resulted in decreased [ 3 H]imipramine binding to cortical 5-HT uptake sites in
prepubescent but not in adult offspring. This same group also reported that
prenatal exposure to the monoamine oxidase inhibitors clorgyline or deprenyl
resulted in decreased [ 3 H]imipramine binding to cortical 5-HT uptake sites in both
prepubescent and adult offspring. Several differences between the procedures
used in the present dissertation studies and that of Montero et al. (1990) may
account for the divergent observations: ( 1) the study by Montero et al. (1990)
employed a lower dose of fluoxetine (2.5 mg/kg/day), but for a longer duration (15
days); (2) this group also administered fluoxetine in the drinking water; and (3)
while no more than 1 pup per litter was utilized in each treatment group in the
present dissertation studies, similar protocols were not specified by Montero et al.
( 1990). Nevertheless, the Montero study demonstrates age-dependent changes in
the density of 5-HT uptake sites as a result of prenatal exposure to fluoxetine.
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Autoradiographic Studies

As discussed above for 5-HT content, the lack of alterations in the density
of 5-HT uptake sites in homogenates does not preclude the possibility that
changes limited to discrete neuroanatomic loci may have occurred in progeny
prenatally exposed to fluoxetine. This possibility was addressed as part of this
dissertation project using quantitative in vitro autoradiographic analysis of 5-HT
uptake sites in slide-mounted brain tissue sections, where changes in discrete
neuroanatomic loci could be determined. In contrast to the lack of changes in 5HT uptake sites observed in homogenates, region-specific alterations (increases
and decreases) in the density of 5-HT uptake sites were observed in slide-mounted
sections taken from prepubescent offspring prenatally exposed to fluoxetine. The
alterations in the density of 5-HT uptake sites appear to be "short-lived" as, in
adult offspring, the density of 5-HT uptake sites is similar between the control and
fluoxetine-exposed treatment groups. In this regard, the present dissertation
studies are consistent with the age-dependent changes in the density of 5-HT
uptake sites reported by Montero et al. (1 990) following prenatal exposure to
fluoxetine. In addition, the autoradiographic analysis of 5-HT uptake sites supports
the suggestion that prenatal fluoxetine exposure produces subtle region-specific
alterations that may not be detected with less sensitive methods such as
homogenate binding assays.
The density of 5-HT uptake sites was markedly altered in several brain
regions which are integral components of the limbic system in offspring prenatally
exposed to fluoxetine. For example, 5-HT uptake sites were significantly increased
in CA2 and CA3 areas of the hippocampus, in the basolateral and medial
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subregions of the amygdala, and in the lateral hypothalamus of prepubescent
offspring, prenatally exposed to fluoxetine (Table 11 ). In addition, 5-HT uptake
sites were also significantly reduced in the dorsomedial nucleus of the
hypothalamus in prepubescent fluoxetine-exposed offspring. The alterations in the
density of 5-HT uptake sites may be indicative of alterations in serotonergic
innervation to the affected brain regions (Descarries et al., 1995). Studies suggest
that serotonergic neurons projecting to the basolateral amygdala and the prefrontal
cortex are involved in mediating emotional or cognitive states in response to
psychological stressors (Kawahara et al., 1993). In addition, serotonergic
neurotransmission in the lateral hypothalamus has been suggested to be involved
in regulating food satiety and reward. Extracellular 5-HT increases in the lateral
hypothalamus during feeding, and when the hungry rats are aroused by the smell
of food (Hoebel et al., 1989; Schwartz et al., 1989a,c). In addition, excess 5-HT
in the lateral hypothalamus has been demonstrated to produce anorexia in rats
(West et al., 1989). Consistent with this idea, local injection of the anorectic drug
d-fenfluramine into the lateral hypothalamus increased extracellular concentrations
of 5-HT (Schwartz et al., 1989b). In addition, a peripheral dose of tryptophan
known to cause anorexia increased extracellular 5-HT in the dialysates of the
lateral hypothalamus (Schwartz et al., 1988). In contrast, the peripheral
administration of 8-0H-DPAT reduced satiety and promoted obesity in rats
(Dourish et al., 1985). The 8-0H-DPAT induced obesity was attributed to a
reduction in 5-HT neurotransmission via activation of 5-HT 1A autoreceptors. In
summary, activation of the limbic system mediates emotional responses, "fight or
flight" reactions, as well as food finding and sexual behaviors. Therefore,
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alterations in the extent of serotonergic innervation to limbic areas and/or
alterations in serotonergic function (i.e. via regulation of 5-HT by 5-HT
transporters) in limbic areas may be of clinical significance to human offspring
prenatally exposed to fluoxetine. Furthermore, the significant reduction in 5-HT
uptake sites in the substantia nigra in prepubescent progeny prenatally exposed to
fluoxetine suggest a consequent effect of prenatal fluoxetine on dopaminergic
systems. As serotonergic neurotransmission in the substantia nigra has been
suggested to exert a seizure suppressing action (Pasini et al., 1992), alterations in
the extent of serotonergic innervation and/or function in the substantia nigra may
also be of clinical significance in human offspring. In order to more accurately
determine whether changes in the density of 5-HT uptake sites reflect changes in
serotonergic innervation and/or function, further studies which can visualize 5-HT
axons and terminals by utilizing an antibody which recognizes the serotonin
transporter and studies of 5-HT uptake need to be carried out.
Prenatal fluoxetine exposure did not alter the density of 5-HT uptake sites in
brain regions rich in 5-HT perikarya (dorsal and median raphe). Since 5-HT uptake
sites in the dorsal and median raphe are located primarily on 5-HT perikarya rather
than on 5-HT axons or terminals, as is the case for most limbic areas of the brain
(D' Amato et al., 1987), these data indicate little effect on 5-HT cell bodies.
However, a significant increase in 5-HT uptake sites was observed in the lateral
hypothalamus, an area in which many of the 5-HT uptake sites may be located on
axons of passage in the median forebrain bundle. The significance of these latter
findings is not yet apparent.
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Fluoxetine-induced alterations in the extent of serotonergic innervation of
various brain regions may result in, or occur concomitantly with, changes in the
density of 5-HT receptors. Alterations in either the extent of serotonergic
innervation or the density of 5-HT receptors can markedly alter the functioning of
specific brain regions and, consequently, alter the physiologic or behavioral
responses which are subserved by these serotonergic neurons. For example,
Guimaraes et al. (1993) reported that 5-HT,A receptors in the hippocampus, which
receive serotonergic innervation from the median raphe nucleus, participate in the
organisms ability to tolerate or adapt to aversive events. Thus, alterations in the
extent of serotonergic innervation to the hippocampus or in the functional status of
midbrain 5-HT neurons will disrupt the normal pattern of serotonergic stimulation
of postsynaptic 5-HT,A receptors in the hippocampus. A disruption in 5-HT,A
receptor function could ultimately impact the animals' responsiveness to aversive
stimuli. Alterations in receptor-mediated events may also occur consequent to
changes in the density of the 5-HT receptor subtype itself. Region specific
changes in the density of 5-HT 1A and 5-HT 2 A receptors were observed in the
present dissertation studies. The implications of these receptor changes will be
discussed in greater detail in a subsequent section of the discussion (page 132).
Although the density of 5-HT uptake sites was not altered in adult offspring
prenatally exposed to fluoxetine, it is likely that functional deficits in 5-HT nerve
terminals may be present in the absence of any alterations in the density of 5-HT
uptake sites. Evidence that functional alterations in 5-HT neurons can occur in the
absence of alterations in the density of 5-HT uptake sites includes reports by
Battaglia et al. ( 1988, 1990) demonstrating that, in cortex of rats recovering from
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MOMA-induced lesion of serotonergic axons, 5-HT uptake sites reached control
levels at 1 year, yet, 5-HT levels remained markedly below control values
suggesting a functional alteration in the presynaptic 5-HT neurons. Therefore, it is
likely that prenatal fluoxetine exposure which affects 5-HT systems during prenatal
development, may produce functional alterations in 5-HT neurons in adult offspring
even when the density of 5-HT uptake sites has returned to control values.
Consistent with this idea, in the present studies, midbrain 5-HT content was
significantly reduced in adult progeny prenatally exposed to fluoxetine despite the
lack of changes in the density of dorsal and median raphe 5-HT uptake sites. In
addition, the significant attenuation in the ability of the 5-HT releasing drug PCA to
reduce 5-HT content in midbrain of adult offspring prenatally exposed to fluoxetine
provides supportive evidence of a functional impairment in this region. The
investigation into the functional status of brain 5-HT neurons following prenatal
exposure to fluoxetine is discussed below on page 144.

Comparison Between Prepubescent and Adult Control Progeny
With respect to postnatal development, initial studies in homogenates of
control progeny indicated that 5-HT uptake sites did not change in either the
cortex, hippocampus, striatum or midbrain as a consequence of maturation.
However, as these measurements were carried out in homogenates, selective
alterations in discrete neuroanatomic loci could not be detected. Using more
sensitive autoradiographic techniques, subsequent studies indicated that 5-HT
uptake sites are significantly greater in adult control offspring in subregions of the
basal ganglia and hippocampus as well as in the arcuate nucleus of the
hypothalamus and the cingulate cortex. In contrast to prepubescent offspring, in
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adult control offspring, 5-HT uptake sites were significantly lower in the temporal
cortex and the median raphe nucleus. While differences in the degree of tritium
quenching (i.e. differences in the grey and white matter composition of the brain)
between prepubescent and adult progeny could result in artifactual differences
between these groups, this possibility is unlikely to have significantly contributed
to the autoradiographic results described in these dissertation studies. This
contention is supported by the absence of a consistent pattern of quenching
across the two age groups in any specific brain region irrespective of the tritiated
radioligand used. Thus, the differential autoradiographic signals between
prepubescent and adult progeny represent differential densities of 5-HT recognition
sites.
In humans, Andersson et al. (1992) did not observe any age-related
changes in [ 3 H]paroxetine binding to 5-HT uptake sites in homogenates of
cingulate cortex, amygdala, frontal cortex, or hypothalamus. These authors
suggested that brain 5-HT terminals are stable with increasing age in humans.
However, as our autoradiographic measurements (which can reveal changes in
discrete neuro-anatomic loci which are beyond the detection limit of homogenate
radioligand binding assays) revealed age-dependent alterations, it is likely that agerelated changes in 5-HT uptake sites in humans may have existed and would have
been detectable using comparable techniques. In rats, consistent with the results
obtained in the present dissertation studies, Whitaker-Azmitia et al. (1990c) did
not report any differences between prepubescent and adult progeny in the density
of 5-HT uptake sites in brainstem homogenates. In contrast, Whitaker-Azmitia et

al. (1990c) reported that [ 3 H]paroxetine-labelled 5-HT uptake sites were
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significantly greater at PD 60 than at either PD 30 or at PD 90 in frontal cortex
homogenates. The values obtained for the densities of 5-HT uptake sites in
homogenates in the present study are similar to those obtained by WhitakerAzmitia et al. at PD 30 and PD 90. Therefore, it appears that 5-HT uptake sites in
the frontal cortex peak at PD 60, then rapidly decrease to adult values as early as
PD 70. In addition to examining the effects of maturation on 5-HT uptake sites in
homogenates, the present dissertation studies demonstrate changes in 5-HT
uptake sites in several discrete neuroanatomic loci as a consequence of
maturation. Some of the changes in the density of 5-HT uptake sites in the
mesencephalon were reductions which were detected in adult progeny. This agedependent reduction in 5-HT uptake sites has been suggested to be a normal
phase of development related to the removal or pruning of excess 5-HT terminals
(Whitaker-Azmitia et al., 1990c).

Functional Status of Brain 5-HT Neurons
The functional status of brain 5-HT neurons was assessed by measuring the
ability of the 5-HT releasing drug PCA to reduce 5-HT content in the frontal cortex,
hypothalamus, hippocampus, striatum and midbrain. The magnitude of the
reduction in 5-HT content was significantly attenuated only in the midbrain of adult
progeny prenatally exposed to fluoxetine (Figure 3) where basal 5-HT content was
also significantly reduced (-28%). In contrast, despite an identical reduction (28 % ) in basal 5-HT content in the frontal cortex of prepubescent fluoxetineexposed offspring, the magnitude of the PCA-induced reduction in frontal cortical
5-HT content was similar in control and fluoxetine-exposed offspring. As
previously mentioned, PCA enters 5-HT neurons via the 5-HT transporter and
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facilitates the release of 5-HT (Kuhn et al., 1985; Rudnick and Wall, 1992).
Evidence suggests that PCA releases 5-HT primarily from the cytoplasmic pool of
5-HT found within 5-HT terminals (Rudnick and Wall, 1992; Kuhn et al., 1985;
Adell et al., 1989). For example, Sanders-Bush and Martin ( 1982) demonstrated
that the PCA-mediated release of 5-HT was ca+ 2 independent, and therefore, did
not involve the exocytosis of 5-HT from storage vesicles. Rudnick and Wall
(1992) more recently proposed that PCA releases 5-HT via a PCA-mediated
exchange mechanism involving the reversal of the 5-HT transporter. Once inside
the serotonergic neuron, PCA has also been demonstrated to inhibit 5-HT synthesis
by inhibiting the rate limiting enzyme in the synthesis of 5-HT, tryptophan
hydroxylase (Sanders-Bush et al., 1972). Therefore, alterations in the ability of
PCA to reduce 5-HT content are indicative of ( 1) alterations in the size of the
releasable pool of 5-HT or (2) alterations in the 5-HT uptake or release processes
within the serotonergic neurons. With this in mind, there are several possible
explanations for the dichotomous results obtained in the frontal cortex and
midbrain. With respect to the midbrain, the PCA-mediated reduction in 5-HT
content was significantly attenuated, suggesting that the cytoplasmic pool of 5-HT
is reduced in the midbrain. This reduction in the releasable form of 5-HT may
occur in the absence or presence of changes in the amount of 5-HT stored in
secretory vesicles. Alternatively, prenatal fluoxetine exposure may have altered
either the ability of PCA to enter midbrain 5-HT neurons or to facilitate the release
of neuronal 5-HT into the extracellular space within the midbrain. Alterations
leading to a reduced ability of PCA to enter 5-HT terminals can include ( 1) changes
in the density of 5-HT uptake sites (either collectively or the number of
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sites/neuron), (2) changes in the affinity (Km) of PCA for the 5-HT transporter, or
(3) changes in maximal transport velocity of PCA (V maxl· Likewise, as PCAmediated 5-HT release is believed to be affected primarily via a reversal of the 5HT transport mechanism, changes in the kinetic parameters for 5-HT transport
(Vmax• Km), as well as changes in the number of 5-HT uptake sites may also affect

the release of 5-HT from serotonergic neurons. As decreases in midbrain 5-HT
uptake sites were not observed in fluoxetine-exposed progeny, changes in 5-HT
uptake sites do not appear to be the reason for the attenuated PCA-induced effect.
In order to determine which of the other aforementioned scenarios may be
responsible for the attenuated response to PCA in the midbrain, additional
experiments investigating the active uptake of 5-HT would have to be carried out
in synaptosomal preparations. Similar to observations made in the midbrain, basal
5-HT content was also significantly reduced in the cortex of fluoxetine-exposed
offspring. However, in contrast to the midbrain, the ability of PCA to reduce 5-HT
content in cortex was similar in control and fluoxetine-exposed rats. Therefore,
despite comparable reductions in 5-HT content in midbrain and cortex, the nature
of the changes in 5-HT neurons in cortex appears to be different from that
produced in the midbrain. The most parsimonious explanation for these findings is
that the cytoplasmic (releasable) pool of 5-HT in the cortex is not affected by
prenatal fluoxetine exposure. Rather, the reduction in basal cortical 5-HT content
may be due to a reduction in the amount of 5-HT stored in secretory vesicles.
Alternatively, the differential effects of the PCA-induced reduction in 5-HT in
midbrain versus terminal brain regions may reflect an age-dependent effect of
prenatal fluoxetine exposure on terminal versus dendritic 5-HT uptake and release
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processes. In cortex, the inability of fluoxetine exposure to alter the magnitude of
the PCA-mediated reduction in 5-HT content also suggests that cortical 5-HT
uptake and release processes have not been altered by fluoxetine exposure.
Likewise, in the other brain regions examined (hypothalamus, hippocampus, and
striatum), the lack of alterations in basal 5-HT values or in the PCA-mediated
reduction in 5-HT content indicates that neither the amount of cytoplasmic 5-HT
nor the uptake or release processes were altered by fluoxetine exposure in these
areas.

Comparison Between Prepubescent and Adult Control Progeny
In addition to the age-dependent changes in basal monoamine levels
previously discussed, the present study represents the first published report of
age-dependent differences in the ability of the serotonin releaser PCA to reduce 5HT content in rat cortical and midbrain tissue. In adult control progeny, a
significant increase in basal midbrain 5-HT content occurred concomitantly with a
significantly greater response to PCA. These data suggest that the releasable pool
of 5-HT in the midbrain is greater in adult animals than in their prepubescent
counterparts. Consistent with this idea, differences in resting 5-HT release from
raphe neurons between prepubescent and adult rat progeny were recently reported
by Knoll et al. (1995).

Neurochemical Status of 5-HT Receptor Systems
The densities of 5-HT ,A and 5-HT 2 A receptors were determined
autoradiographically in select brain regions following prenatal exposure to
fluoxetine. Autoradiographic studies were limited to these two 5-HT receptor
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subtypes for the following reasons: (1) both 5-HT,A and 5-HT 2 A receptors have
been demonstrated to be present and functional during fetal rat brain development
(Daval et al., 1987; Whitaker-Azmitia et al., 1987; Roth et al., 1991; Becquet et

al., 1992; Hi Ilion et al., 1994); (2) studies suggest that the administration of
fluoxetine in adult animals can disrupt the neurochemical and/or functional status
of these receptor systems (Dumbrille-Ross and Tang, 1983; Wong et al., 1985;
Eison et al., 1991; Li et al., 1993a,b); and (3) alterations in both 5-HT,A and 5HT 2 A receptors have been implicated in the etiology of and/or have been the target
receptors for treatment of various psychiatric disorders (Mita et al., 1986; Deakin,
1988; Cheetham et al., 1990; Pandey et al., 1990; Fuller, 1991; Molcho et al.,
1 991 ; Siever et al., 1 991). In addition, 5-HT 1 A and 5-HT 2 A receptors are the most
well characterized of the 5-HT receptor subtypes, and radioligands are readily
available to study the presence of these receptors in slide-mounted sections
(Gozlan et al., 1983; Middlemiss and Fozard, 1983; Pazos and Palacios, 1985;
Appel et al., 1990). Finally, activation of postsynaptic 5-HT,A and 5-HT 2 A
receptors mediate the release of plasma hormones (see Van de Kar, 1991 for
review). Measurement of 5-HT agonist-stimulated plasma hormones can then
serve as a peripheral index of the status of hypothalamic postsynaptic 5-HT
receptor systems.
Evidence suggests that, in the dorsal and median raphe nuclei, 5-HT,A
receptors are located primarily on 5-HT perikarya where they serve as
autoreceptors (Verge et al., 1985, 1986; Weissmann-Nanopoulos et al., 1985;
Sotelo et al., 1 990). The stimulation of these autoreceptors decreases the firing
rate of 5-HT neurons reducing serotonergic neurotransmission (Adell et al., 1993;
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Hajos et al., 1995). In contrast, neuronal 5-HT,A receptors located in all other
brain regions measured in the present studies are exclusively postsynaptic
receptors (Verge et al., 1986) located on non-serotonergic neurons. Evidence
suggests that 8-0H-DPAT administration elevates plasma ACTH and corticosterone
via stimulation of postsynaptic 5-HT 1 A receptors located in the paraventricular
nucleus of the hypothalamus (Karteszi et al., 1982; Van de Kar et al., 1985a; Van
de Kar, 1991 ). In rat brain, neuronal 5-HT 2 A receptors are exclusively postsynaptic
receptors (Fischette et al., 1987).

5-HT iA Receptors
Autoradiographic studies revealed that the density of 5-HT 1 A receptors in
various neuroanatomic loci was minimally affected by prenatal fluoxetine exposure.
5-HT 1 A receptors were significantly elevated only in the paraventricular nucleus of
the hypothalamus and in the entorhinal cortex in prepubescent fluoxetine-exposed
offspring. In contrast, in adult progeny, a significant reduction in 5-HT 1 A receptors
was observed only in the ventromedial hypothalamus in fluoxetine-exposed
offspring. No other changes in the density of 5-HT 1 A receptors were observed in
16 other brain regions examined in prepubescent and adult rats prenatally exposed
to fluoxetine. The entorhinal cortex plays a pivotal role in the control of
hippocampal function (Jones, 1993). Changes in the density of 5-HT 1 A receptors
in the entorhinal cortex may, therefore, affect the relay of information from the
entorhinal cortex to the hippocampus and back through the entorhinal cortex to
other areas of the brain. The ventromedial nucleus of the hypothalamus plays an
important role in modulating weight and energy balance (Parkinson and
Weingarten, 1990; Tokunaga et al., 1986), thermoregulation (Amir, 1990), and
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sexual behavior (Schulze and Gorzacka, 1991 ). In addition, the ventromedial
nucleus of the hypothalamus may play a role in modulating cardiovascular function
(Valladao et al., 1990). Therefore, alterations in the density of 5-HT 1 A receptors in
the ventromedial nucleus may affect one or more of the aforementioned functions
which may result in significant consequences in offspring. The paraventricular
nucleus of the hypothalamus plays a key role in regulating the secretion of ACTH
(Van de Kar, 1991 ), corticosterone, vasopressin and oxytocin (Swanson and
Sawchenko, 1983), cardiovascular function (Ciriello et al., 1984; Zhang and
Ciriello, 1985; Herzig et al., 1991; Takeda et al., 1991) and neuroendocrine
response to various stressors (Richardson Morton et al., 1989; Van de Kar et al.,
1 991 ) . Despite a significant increase in 5-HT 1 A receptors in the paraventricular
nucleus of the hypothalamus of prepubescent fluoxetine-exposed offspring,
neuroendocrine responses to a maximally effective dose of the 5-HT,A agonist 80H-DPAT were not significantly altered in this group. This observation of changes
in receptor number without concomitant changes in the receptor-mediated
responses could occur as a result of maximally stimulating the 5-HT,A receptor.
Thus, it is possible that significant differences in the neuroendocrine response to 80H-DPA T may be observed at submaximal levels of the drug. Alternatively, the
lack of a significant change in 5-HT 1 A mediated neuroendocrine responses could be
the result of an influence of 5-HT 1 A receptor activation in the dorsal raphe.
Consistent with this idea, 5-HT 1 A receptors in the dorsal raphe have recently been
demonstrated to partially mediate the 8-0H-DPAT induced elevation of plasma
ACTH (Pajot et al., 1995). Lastly, recent evidence suggests that unlike other
radiolabeled agonists, [ 3 H]8-0H-DPAT may exhibit a moderate affinity for the
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uncoupled (i.e. not G-protein linked) state of the 5-HT 1A receptor such that both
the uncoupled and coupled states of the receptor can be radiolabelled (Butkerait et

al., 1995). Thus, changes in the density of [3 HJ8-0H-DPAT binding may reflect
changes in the number of coupled and uncoupled receptors rather than a change in
the absolute number of receptors present in a given tissue. Such shifts between
affinity states would alter the observed radioligand affinity and result in differential
autoradiographic signals between control and fluoxetine-exposed offspring. Thus,
should the change in [ 3 H]8-0H-DPAT binding in the paraventricular nucleus may
not represent an increase in the absolute number of 5-HT 1 A receptors; and would
therefore not appear to be inconsistent with the lack of alterations in the 5-HT 1 A
agonist-mediated neuroendocrine responses.
To date, no other published reports have examined the effect of prenatal
exposure to fluoxetine or other selective 5-HT uptake inhibitors on 5-HT 1A receptor
density. However, we previously reported that prenatal exposure to cocaine (a
non-selective monoamine uptake inhibitor) did not alter the density of 5-HT 1 A
receptors in homogenates of the hypothalamus, cortex, or midbrain of
prepubescent offspring despite a potentiation in 5-HT 1 A receptor-mediated
neuroendocrine responses (Battaglia and Cabrera, 1994). The chronic (21 d)
administration of fluoxetine to adult male rats has been reported to decrease 5HT 1 A receptors in the dorsal raphe (Welner et al., 1989). In contrast, 5-HT 1 A
receptor density in cortical or hypothalamic homogenates was not altered by
chronic fluoxetine administration to adult rats (Li et al., 1993b), despite reductions
in 5-HT 1A mediated ACTH and corticosterone responses in drug-treated animals.
In the present dissertation studies, it is of interest to note that the density
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of 5-HT,A receptors was altered in specific brain regions (Ent, VMH, and PVN)
where 5-HT uptake sites were not affected by fluoxetine exposure. According to
the generally accepted, yet relatively simplistic view of receptor regulation,
changes in the density of receptors generally occur secondary to changes in the
presynaptic stimulus (which can include changes in the number and/or function of
5-HT terminals). However, this hypothesis has been developed from observations
in adult animals where homeostasis has been achieved. The correspondence
between presynaptic innervation (and/or receptor stimulation) and changes in
postsynaptic receptors may be somewhat different during developmental stages.
For example, prenatal exposure to the dopaminergic receptor blocker haloperidol
resulted in a reduction in 0 2 dopamine receptors in neonatal offspring (Rosengarten
and Friedhoff, 1979). However, the administration of haloperidol to adult rats,
produces the opposite effect (Rosengarten and Friedhoff, 1979). Nonetheless,
while receptor regulation does not always follow the simple theoretical model, it is
possible that alterations in 5-HT,A receptor density in the entorhinal cortex,
paraventricular nucleus, and ventromedial hypothalamus did occur as a
consequence of localized alterations in the functional status of serotonergic
neurons projecting to these brain regions. As previously mentioned, alterations in
the functional status of serotonergic neurons may occur in the absence of changes
in the density of 5-HT uptake sites. Furthermore, the detection of discrete
changes in the functional status of 5-HT neurons requires the use of more sensitive
techniques than were employed in the present studies. Alternatively, the extent of
serotonergic innervation (as measured by 5-HT uptake site density) may have been
altered at time points other than those examined in the present dissertation studies
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(i.e. prior to PD 28, or between PD 28 and PD 70). Again, changes in the extent
of serotonergic innervation to these particular brain regions could result in
alterations in the density of 5-HT 1A receptors. Finally, it is also possible that
fluoxetine administration during fetal brain development resulted in a disruption of
other neurotransmitter systems or growth factors required for the normal
development of 5-HT target tissues containing 5-HT 1 A receptors. Consistent with
this idea Rubinstein et al. (1993) reported that prenatal exposure to cocaine (a
non-selective monoamine uptake inhibitor) reduced the glial derived growth factor
S-1008 immunoreactivity in the adult hippocampus.

5-HT 2A Receptors
In addition to the changes observed in the density of 5-HT 1A receptors,
prenatal fluoxetine exposure altered the density of [ 125 l]DOI and [ 3 H]ketanserinlabelled 5-HT 2 A receptors in a manner which was dependent on both the brain
region examined and the age of the offspring. In some brain regions, only the
density of high affinity G-protein coupled ([ 125 l]DOl-labelled) 5-HT 2 A receptors was
significantly altered by prenatal fluoxetine exposure. In other areas, fluoxetineinduced alterations in the total population of 5-HT 2 A receptors (high and low
affinity; labelled by [ 3 H]ketanserin) occurred either in the presence or absence of
changes in the density of high affinity coupled receptors (i.e. those labelled by
[

125

1]DOI). For example, in prepubescent progeny, high affinity ([ 125 l]DOl-labelled)

5-HT 2 A receptors were increased in the caudate putamen. Likewise, in adult
progeny, high affinity 5-HT 2 A receptor density was increased by fluoxetineexposure in the CA3 region of the hippocampus, the lateral septal nucleus, and the
medial mammillary nucleus. Despite the increase in the number of coupled 5-HT 2 A
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receptors in these brain regions, fluoxetine-exposure did not alter the total number
of receptors present. Therefore, the selective increase in the number of high
affinity 5-HT 2 A receptors in these brain regions is indicative of an increase in the
number of 5-HT 2 A receptors which are coupled to G-proteins in fluoxetine-exposed
offspring. Since the density of the total 5-HT 2 A receptor population was
unchanged, the increase in [ 125 1)001-labelled sites should result in a significant
increase in the percentage of high affinity 5-HT 2 A receptors in these brain regions.
Consistent with this, the calculated percentage of high affinity 5-HT 2 A receptors
was significantly elevated in the caudate putamen in prepubescent offspring, and
in the lateral septal nucleus in adult fluoxetine-exposed progeny {Table 16).
However, despite the significant increase in [ 125 1)001-labelled 5-HT 2 A receptors in
the absence of changes in the total receptor population, the calculated percentage
of high affinity 5-HT 2 A receptors was determined to be not significantly different in
the CA3 region of the hippocampus (despite a 23 % difference between groups) in
adult fluoxetine-exposed progeny.
In contrast to the aforementioned selective increases in the number of high
affinity 5-HT 2 A receptors, the total number of 5-HT2 A receptors ([ 3 H]ketanserinlabelled) was significantly elevated in the lateral septal nucleus, ventral pallidum,
and medial preoptic area in prepubescent fluoxetine-exposed progeny. None of
these changes in the total receptor population were accompanied by significant
changes in the absolute number of [ 125 1)001-!abelled receptors. Thus, although
fluoxetine exposure increased the total number of 5-HT 2 A receptors present in
these brain regions, the prenatal treatment did not result in a corresponding
significant increase in the number of 5-HT 2 A receptors which are coupled to G-
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proteins. Thus, it can be concluded that the percentage of high affinity receptors
to the total receptor population should have been altered by fluoxetine exposure in
these regions. However, the percentage of high affinity receptors as calculated in
Table 16 was determined to be not significantly different in response to prenatal
fluoxetine exposure. In adult progeny, the total number of 5-HT 2 A receptors was
significantly elevated in the entorhinal cortex, dentate gyrus, and paraventricular
nucleus of the hypothalamus in fluoxetine-exposed progeny in the absence of any
alterations in the density of [ 125 1)001-labelled high affinity 5-HT 2 A receptors.
Consequently, the percentage of high affinity 5-HT 2 A receptors in these regions
should also be reduced. However, as mentioned above, the percentage of high
affinity receptors as calculated in Table 16 was determined to not be significantly
different in response to prenatal fluoxetine exposure.
Lastly, in adult progeny, concomitant significant elevations in both [ 125 1)001
and [ 3 H]ketanserin-labelled receptors were only observed in the basolateral
amygdala as a consequence of prenatal exposure to fluoxetine. As the percentage
of high affinity 5-HT 2 A receptors was not statistically different between treatment
groups in the amygdala, the increase in total receptor population in the basolateral
amygdala resulted in an increase in the absolute number of 5-HT 2 A receptors which
are coupled to G-proteins.
Only two other studies have examined the consequence of prenatal
exposure to selective 5-HT uptake inhibitors on the density of brain 5-HT 2 A
receptors. Consistent with the present dissertation studies, Romero et al. (1994)
did not observe any changes in the density of [ 3 H]ketanserin-labelled 5-HT 2 A
receptors in cortical homogenates from either prepubescent or adult offspring
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prenatally exposed to fluoxetine. In contrast, prenatal exposure to the 5-HT
uptake inhibitor clomipramine has been reported to result in a significant decrease
in [ 3 H]spiperone-labelled 5-HT 2 A receptors in prepubescent but not in adult
offspring (De Ceballos et al., 1985).
Again, according to the simple model of receptor regulation, the alterations
in 5-HT 2 A receptor density could have occurred secondary to changes in the
presynaptic stimulus (e.g. the extent of 5-HT innervation). Consistent with this
model, in the present studies the density of 5-HT uptake sites was significantly
elevated in the lateral hypothalamus in prepubescent offspring prenatally exposed
to fluoxetine and a concomitant decrease in [ 3 H]ketanserin-labelled 5-HT 2 A
receptors was also observed in the lateral hypothalamus in these offspring.
Therefore, the observed reduction in these hypothalamic 5-HT 2 A receptors, may in
fact, represent compensatory changes in postsynaptic 5-HT receptors consequent
to changes in the serotonergic innervation of this area. However, in all other
instances where 5-HT 2 A receptor densities (labelled either by [ 125 1]001 or
[

3

H]ketanserin) were significantly altered by fluoxetine exposure, no concomitant

changes were observed in the density of 5-HT uptake sites following prenatal
exposure to fluoxetine. As indicated for the 5-HT,A receptors, the data do not
preclude the possibility that the changes in 5-HT 2 A receptors were ( 1 ) secondary to
localized alterations in the functional status of serotonergic neurons, (2) secondary
to changes in the extent of serotonergic innervation which occurred at time points
other than those examined in the present studies particularly during pre- or
postnatal development or (3) consequent to changes in other neurotransmitter
systems and/or necessary growth factors.
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Similar to the observations made regarding fluoxetine-induced perturbations
in 5-HT uptake sites, changes in the density of 5-HT 2 A receptors were observed
primarily in limbic and motor areas of the brain. In addition, 5-HT 2 A receptor
density was not affected in either the dorsal or median raphe (areas rich in 5-HT
perikarya). Alterations in the density of 5-HT 2 A receptors in limbic areas may be of
clinical significance to human offspring prenatally exposed to fluoxetine; as
activation of the limbic system mediates emotional responses, "fight or flight"
reactions, as well as food finding, and sexual behaviors. In addition, alterations in
5-HT 2 receptor density have been reported in suicide victims (Mann et al., 1986;
and Arora and Meltzer, 1989) and in patients suffering from various psychiatric
disorders such as depression (Yates et al., 1990), schizophrenia (Bleich et al.,
1988), and senile dementia of the Alzheimer's type (Reynolds et al., 1984; Crow

et al., 1984; Marcussen et al., 1984; Cheng et al., 1991 ). Thus, human offspring
prenatally exposed to fluoxetine may exhibit altered susceptibility to developing
these psychiatric disorders or to therapeutic interventions which modulate 5-HT 2 A
receptors. Alternatively, since 5-HT 2 receptors represent one potential target site
for the pharmacologic treatment of psychiatric patients (Kellar et al., 1 981 , 1 983;
Clements-Jewery and Robson, 1982; Snyder and Peroutka, 1982; Closse and
Jaton, 1984, Stockmeir and Kellar, 1985; Andree et al., 1986; Leysen et al.,
1986; Matsubara and Meltzer, 1989; Meltzer et al., 1989), human offspring
prenatally exposed to fluoxetine may exhibit a differential sensitivity or
responsiveness to therapeutic interventions which modulate brain 5-HT 2 A receptor
systems. Finally, changes in the efficiency of 5-HT 2 A receptors to couple to their
respective G-proteins, may alter the 5-HT 2 A receptor-mediated function including
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the receptor-mediated stimulation of plasma hormones. This possibility was
addressed in the present dissertation studies and is discussed on page 1 64.

Differential Sensitivity of 5-HT 1A and 5-HT 2 A Receptor Systems
In contrast to the limited alterations observed in 5-HT,A receptor density, a
greater number of alterations in 5-HT 2 A receptor density were observed in both preand postpubescent fluoxetine-exposed offspring. However, as the density of 5HT,A receptors was examined in fewer brain regions than 5-HT 2 A receptors, any
conclusion that 5-HT,A receptors may be "less sensitive" to perturbation than 5HT 2 A receptor systems must be made with caution. More widespread changes in
the density of 5-HT,A receptors may have occurred in the amygdala or in
subregions of the cortex or hypothalamus which were not examined in the present
studies (e.g. Oc2L, Te1, MPA). However, 5-HT,A receptors are virtually absent
from the substantia nigra or globus pallid us (Verge et al., 1986) and therefore, it is
unlikely that an examination of these brain regions would result in detectable
differences between control and fluoxetine-exposed offspring. In general, the
presence of minimal changes in the density of 5-HT,A receptors in fluoxetineexposed offspring is consistent with the lack of significant alterations in 5-HT,A
receptor-mediated neuroendocrine responses in offspring prenatally exposed to
fluoxetine. The apparent resistance of 5-HT,A receptor systems to disruption of
brain 5-HT pathways during development is consistent with published reports
(Pranzatelli and Martens, 1992; Pranzatelli et al., 1994). Pranzatelli and his
colleagues demonstrated that neonatal administration of the 5-HT neurotoxin 5, 7dihydroxytryptamine (5,7-DHT) did not alter the density of 5-HT,A receptors across
several brain regions despite marked reductions in 5-HT uptake sites and 5-HT
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content. These authors suggested that 5-HT 1 A receptors and the 5-HT transporter
binding sites exhibited differential plasticity following the neonatal insult.
Likewise, the present dissertation studies also reported marked alterations in 5-HT
uptake sites, but minimal changes in 5-HT 1 A receptor density.

Functional Status of 5-HT Receptor Systems
G-Protein Coupling to 5-HT 2 A Receptors
As an index of the ability of 5-HT 2 A receptors to couple to their respective
G-proteins (Gq), the percentage of high affinity agonist ([ 125 1)001) labelled 5-HT 2 A
receptors was calculated in each brain region for each of the animals. As
previously mentioned, the effects of prenatal fluoxetine exposure on the calculated
percentage of high affinity receptors frequently did not match what would be
expected based on the data from significant changes in [ 125 1)001 and
[

3

H] ketanserin-labelled 5-HT 2 A receptors. This discrepancy between theoretical

expectations and statistically significant alterations in the calculated percentage of
5-HT 2 A receptors is likely due to the degree of variability inherent in such a
calculation. In order to experimentally calculate the percentage of high affinity 5HT 2 A receptors, several factors need to be determined. The process is described
below. The autoradiographic studies presented in this dissertation were carried out
using a single concentration of each radioligand to label the respective 5-HT
receptor subtypes. This technique is commonly used, and allows for the detection
of changes in either the affinity or density of the receptors. As most drug
treatments do not alter the affinity of receptors, in autoradiographic studies, it is
generally presumed that changes in the density of the radiolabelled signal are
indicative of changes in the density of the receptor being labelled rather than

160
changes in the affinity of the radioactive label. The fraction of receptors occupied
by a given concentration of radioligand in a particular brain region is exclusively
dependent on the affinity of the ligand for the receptor and the concentration of
the radiolabelled drug used in the assay according to the following equation:
Fractional Occupancy = 1 I [1

+

K0 *;0·1

In this equation, K0 * equals the affinity of the radioligand for the recognition site
and

o· equals the

concentration of the radioligand used in the assay. Saturation

studies were carried out in slide mounted cortical sections to determine the actual

Kd values of [ 125 1]001 and [ 3 H]ketanserin for 5-HT 2 A receptors in slide-mounted
sections (Table 15). The fraction of receptors occupied by the concentration of
radioligand used in the assays was calculated using the above equation. The mean
affinity of [ 3 H]ketanserin was determined to be 2.57 nM. Therefore, 13% of the
total receptor population was labelled by the concentration of [ 3 H]ketanserin used
in the autoradiographic studies (0.4 nM). The affinity of [ 125 1]001 was
experimentally determined to be 0.68 nM in prepubescent rats and 1. 74 nM in
adult rats. Therefore, the concentration of radioligand used in the present studies
(0.2 nM) labelled 23% of the high affinity receptors present in prepubescent rats
and 10% of the high affinity 5-HT 2 A receptors present in adult rats. In order to
calculate the percentage of high affinity 5-HT 2A receptors, all the experimentally
derived values for the density of [ 125 1]001 and [ 3 H]ketanserin-labelled 5-HT 2 A
receptors (representing different fractional occupancies) were normalized to 100 %
fractional occupancy by multiplying the experimentally derived values by the
appropriate factor for each ligand (Appel et al., 1990). Therefore, any small errors
inherent in the experimentally determined values may be magnified by such a
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multiplication factor. Lastly, the maximal density of [ 125 1]001-labelled receptors is
divided by the maximal density of [ 3 H]ketanserin-labelled receptors to obtain the
fraction of high affinity receptors for each rat. Therefore, the percentage
determination is calculated for each rat using 2 values which each have some
degree of magnified inherent error in their measurement. Thus, as can be seen in
Table 17, the values for the percentage of high affinity 5-HT 2 A receptors have
larger error values than either the [ 125 1]001 or [ 3 H]ketanserin data alone. Therefore
a more accurate depiction of changes in the coupling efficiency of 5-HT 2 A receptors
is obtained by examining the consequences of prenatal fluoxetine-exposure on 5HT 2 A receptors directly labelled by [ 125 1]001 and [ 3 H]ketanserin (as discussed in the
previous section) without any mathematical transformations to calculate the
percentage of high affinity receptors present.
We initially reported that the density but not the affinity of 5-HT 2 A12c
receptors was significantly reduced in hypothalamic homogenates from adult
progeny prenatally exposed to fluoxetine (Cabrera and Battaglia, 1994). This
reduction in 5-HT 2 A12c receptors was consistent with the attenuated ACTH
response to the 5-HT 2 A12 c agonist DOI observed in the same group of animals.
Autoradiographic studies indicated that prenatal exposure to fluoxetine did not
alter the density of high affinity 5-HT 2 A receptors in the majority of the subregions
of hypothalamus that were measured. In particular, the density of high affinity 5HT 2 A receptors was not significantly altered in the paraventricular nucleus of the
hypothalamus in adult progeny. As the 5-HT 2 A receptors located in the
paraventricular nucleus are thought to mediate, in part, the 5-HT-induced secretion
of ACTH, this finding was unexpected. On the other hand, autoradiographic

162
studies also revealed that in adult progeny [ 3 H]ketanserin-labelled 5-HT 2 A receptors
were significantly elevated in the paraventricular nucleus of the hypothalamus
following prenatal exposure to fluoxetine. At first, this appeared to be
contradictory to our earlier findings in homogenates and somewhat inconsistent
with the reduction in the magnitude of the ACTH response to the 5-HT 2 A12c agonist
DOI. In our initial studies, we did not directly determine the density of
[

3

H]ketanserin-labelled 5-HT 2 A receptors in hypothalamic homogenates due to the

limited amount of tissue available. However, the density of [ 3 H]ketanserin labelled
receptors determined in cortex and midbrain homogenates (Cabrera and Battaglia,
1994) in adult progeny, revealed no significant differences in the density of
[

3

H]ketanserin-labelled receptors in these brain regions following prenatal exposure

to fluoxetine. Therefore, it is also likely that in hypothalamus homogenates in
adult progeny the density of [ 3 H]ketanserin-labelled receptors was likewise
unaffected by prenatal fluoxetine exposure. Assuming that the density of
[

3

H]ketanserin labelled receptors in the hypothalamus did not change in our

previous studies, despite the decrease in hypothalamic [ 125 1]001 labelled receptors,
then the percentage of high affinity 5-HT 2 A receptors in the hypothalamus would
have been reduced in hypothalmic homogenates in our initial studies. In the
autoradiographic studies, while the density of [ 125 1]001 labelled receptors did not
change in the paraventricular nucleus of fluoxetine-exposed adult progeny, the
number of [ 3 H]ketanserin labelled receptors increased, resulting in an overall
reduction in the percentage of high affinity receptors present. Therefore, it is
possible that the functional responsiveness of the 5-HT 2 A receptors (in particular,
those localized to the paraventricular nucleus of the hypothalamus) is more closely
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related to the percentage of high affinity receptors present rather than the absolute
number of high affinity 5-HT 2A receptors. Alternatively, discrepancies between the
two studies (homogenates vs. autoradiography) may be attributable to 5-HT 2c
receptors. [ 125 1]001 possesses a high affinity for both 5-HT 2A (Kd = 0.4 nM) and 5HT2c (Kd = 1.6 nM; Leonhardt et al., 1992) receptors. In the protocol previously
used in homogenates, a partial labelling of 5-HT 2c receptors by [ 125 1]001 could have
contributed to the differences between the two studies. However, the present
autoradiographic studies were carried out using a methodology in which 5-HT 2A
receptors were selectively labelled (see Materials and Methods section). However,
since [ 125 1)001 has a lower affinity for 5-HT 2c receptors, 5-HT 2c receptors would
have represented only a minimal fraction of the radiolabelled population in the
homogenate assay. As a result, it is unlikely that the discrepancies between our
initial studies in homogenates and the autoradiographic studies result from a
significant involvement of 5-HT 2c receptors.
Autoradiographic studies revealed alterations in the efficiency of 5-HT 2A
receptor coupling in several brain regions in both prepubescent and adult offspring
prenatally exposed to fluoxetine. Consistent with the presence of alteration in 5HT 2 receptor systems, Romero et al. (1994) recently reported a reduction in 5-HT 2mediated stimulation of phosphoinositide hydrolysis in the cortex of prepubescent
offspring prenatally exposed to fluoxetine. Changes in the number and/or
efficiency of 5-HT 2 receptors coupled to G-proteins could alter physiologic
responses (e.g. regulation of body temperature and food intake; Aulakh et al.,
1994) mediated by this receptor subtype including 5-HT 2-mediated increases in
plasma hormones (Van de Kar, 1991 ). Studies which were carried out to assess
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the functional status of 5-HT receptor systems are discussed below.

Neuroendocrine Responses to Directly Acting Agonists
Prenatal exposure to fluoxetine did not alter the basal levels of any of the
hormones measured in the present studies (ACTH, corticosterone,and renin)
regardless of the age of the offspring. This lack of effect on basal endocrine
status indicates that prenatal fluoxetine exposure did not produce an overall
disruption of the homeostatic balance of the circulating hormones ACTH,
corticosterone and renin. As other neurotransmitters are involved in the
homeostatic regulation of these hormones (e.g. GABA,NE, DA and Ach), any
disruption in the 5-HT system could be compensated by alterations in other
neurotransmitter systems, thereby maintaining steady state basal levels. In the
present studies, deficits in neuroendocrine function were revealed in adult progeny
only following the administration of a pharmacological challenge. The attenuated
ACTH response to a maximal dose of DOI, observed in adult fluoxetine-exposed
progeny, indicates a change in the Emax for the DOI-mediated elevation of plasma
renin. In addition, the attenuated endocrine response cannot be considered
"persistent" as it was not observed in prepubescent offspring. Rather, the
decrease in DOI-mediated ACTH response was only manifested at a postpubescent
age. The most parsimonious explanation for the appearance of deficits at PD 70 is
that hormonal changes occurring during maturation unmask or contribute to the
functional deficits observed later in development. Consistent with this idea,
several studies have demonstrated that sex steroids can influence brain 5-HT
receptor systems (Biegon et al., 1982; Kendall et al., 1982; Beck et al., 1989;
Clarke et al., 1989; Mendelson and McEwen, 1990a,b). This possibility remains to

165
be investigated. No significant alterations in 5-HT 2 A12c mediated corticosterone or
renin responses were observed in adult progeny prenatally exposed to fluoxetine.
Likewise, no significant disruptions in 5-HT 2 A12c mediated neuroendocrine function
(ACTH, corticosterone, renin) were observed in prepubescent progeny prenatally
exposed to fluoxetine. These data suggest that the Emax for DOI-mediated
elevation of plasma renin and corticosterone was not altered by prenatal exposure
to fluoxetine regardless of the age of the offspring.
The selective attenuation of the ACTH response to the 5-HT 2 A 12c agonist
requires some discussion. In particular, the lack of differences between treatment
groups in the corticosterone response to DOI may at first appear to be inconsistent
with the observed attenuation of the ACTH response. However, despite the
markedly attenuated (-58%) ACTH response in fluoxetine-exposed male progeny in
comparison to controls, DOI maintained an elevation of plasma ACTH ( > 200
pg/ml) in both treatment groups. This concentration of plasma ACTH has been
reported to be sufficient to saturate adrenal gland corticotropin receptors and elicit
a maximal corticosterone response (Bagdy et al., 1989; Engeland et al., 1981;
Kaneko et al., 1980, 1981; Van de Kar et al., 1992). These data suggest that the
prenatal administration of fluoxetine does not affect the adrenal gland's production
of corticosterone. This dichotomy of alterations in ACTH responsiveness but not
in corticosterone responses has been observed in male progeny following prenatal
exposure to cocaine (Cabrera et al., 1993). However, in female progeny prenatal
cocaine exposure reduced both ACTH and corticosterone suggesting a possible
discrepancy of the adrenal corticosterone response (Cabrera et al., 1994). In
situations (i.e. environmental or pharmacological) where the ACTH elevations are
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below that necessary to produce a maximal corticosterone responses, it would be
expected that the ACTH impairment observed in fluoxetine progeny would result in
an attenuated corticosterone response relative to non-fluoxetine exposed controls.
In addition, since the effect of DOI on plasma corticosterone is mediated both by
central and peripheral mechanisms (Alper, 1990; Calogero et al., 1990) the effect
of fluoxetine exposure on the corticosterone response to DOI could be masked by
changes in peripheral mechanisms. As serotonergic pathways mediate, in part, the
neuroendocrine response to stressors (Van de Kar et al., 1991), offspring
prenatally exposed to fluoxetine may exhibit compromised endocrine responses to
various environmental or psychological stressors.
Another possible explanation for the selective ACTH attenuation is that
corticotropin releasing hormone (CRH) or CRH receptors are affected by prenatal
fluoxetine exposure. If CRH and/or CRH receptors were altered, one would expect
attenuated ACTH responses to other 5-HT receptor agonists which also stimulate
ACTH release via a common CRH pathway. However, in adult progeny, the
magnitude of the ACTH response to the 5-HT 1 A agonist, 8-0H-DPAT was not
altered in fluoxetine-exposed progeny. These data suggest that alterations at the
level of CRH or CRH receptors are not likely responsible for the attenuated ACTH
response to DOI. Rather, the simplest explanation is that the attenuated ACTH
response to DOI is the result of a reduction in the functional responsiveness at the
level of the 5-HT 2 A receptor. Presumably, this may involve the decrease in the
percentage of high affinity 5-HT 2 A receptors reported in the paraventricular nucleus
of the hypothalamus.
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Similar to the lack of effect on plasma corticosterone, the plasma renin
response to DOI was unaltered in fluoxetine progeny at either prepubescent or
adult developmental times. Also, similar to corticosterone, it has previously been
reported that the effect of DOI on plasma renin involves both central and peripheral
mechanisms (Rittenhouse et al., 1991 ). Therefore, any potential effect of prenatal
fluoxetine exposure on the renin response to DOI mediated via central mechanisms
could be masked by the peripheral effects of DOI on blood pressure (Alper, 1990,
Rittenhouse et al., 1991).
In contrast to the disruption in 5-HT 2 A12 c receptor-mediated ACTH response
observed following prenatal fluoxetine exposure, neuroendocrine responses to a
maximally effective dose of 8-0H-DPAT were unaffected by the prenatal
treatment. This lack of significant alterations in 5-HT 1A receptor-mediated ACTH,
corticosterone, or renin responses suggests that the functional status of 5-HT 1A
receptor systems is less sensitive to perturbation by prenatal fluoxetine
administration than that of 5-HT 2 A receptor systems. These data are consistent
with the minimal changes observed in the density of 5-HT IA receptors as a
consequence of fluoxetine exposure.
While we have not found any other published data on the neuroendocrine
effects of in utero exposure to fluoxetine or other selective 5-HT uptake inhibitors,
differences do exist between the present data and the neuroendocrine responses
following chronic fluoxetine administration to adult male rats (Li et al., 1993a,b).
For example, in contrast to the marked attenuation of the ACTH response to DOI
following in utero exposure to fluoxetine, long-term administration of fluoxetine (10
mg/kg, i.p. x 21 d) to adult males results in a potentiated ACTH response to DOI (Li
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et al., 1993a). Consistent with the potentiation of the ACTH response to DOI, Li
et al. (1993a) reported a 38 % increase in hypothalamic 5-HT 2 A12c receptors
following chronic fluoxetine. More recent studies, further indicate that the
increase in hypothalamic 5-HT 2 A12c receptors occurs after as little as 7 days of
fluoxetine administration, and is not accompanied by alterations in the density of
hypothalamic [ 3 H]ketanserin-labelled receptors (unpublished observations). These
data suggest that the potentiated hormone responses in adults, may result from
increases in the percentage of high affinity hypothalamic 5-HT 2 A 12 c receptors just as
the attenuated ACTH response in the present study may result from a decrease in
the percentage of high affinity hypothalamic 5-HT 2 A 12c receptors. Furthermore, in
contrast to the present lack of effect of prenatal fluoxetine exposure on corticosterone responses to DOI, the chronic administration of fluoxetine in adult male rats
resulted in a potentiation of the corticosterone response to DOI suggesting an
effect of adult fluoxetine exposure directly on adrenal gland modulation of
corticosterone. Lastly, consistent with the lack of effect of prenatal fluoxetine on
renin responses that we have observed, Li et al. (1993a) report that the renin
response to DOI was unaffected by chronic administration of fluoxetine to adult
males. Taken together, the contrasting effects of prenatal versus adult exposure
to fluoxetine suggest that the effects of prenatal administration of fluoxetine
represents a unique effect resulting from disruption of serotonergic systems during
a critical period of brain development and are distinct from fluoxetine-induced
changes in adult animals which represent the effects of the drug on 5-HT systems
at homeostasis.
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Comparison Between Prepubescent and Adult Control Progeny

Endocrine studies carried out in adult male rats indicate that the stimulation
of 5-HT 2 A12 c receptors mediates, in part, the stimulation of plasma renin. In
contrast, endocrine studies also indicate that 5-HT,A receptors do not mediate
renin secretion. Thus, the administration of a 5-HT,A agonist to adult rats has not
been demonstrated to produce a significant elevation in plasma renin above basal
values. Results from the present dissertation studies that were carried out in adult
progeny are in agreement with the published data (Lorens and Van de Kar, 1987).
However, the present studies also administered 5-HT,A and 5-HT 2 A12 c agonists to
prepubescent animals with surprising results. First, basal renin values were
significantly higher in prepubescent animals than in their adult counterparts,
regardless of the prenatal treatment (Figs. 6 and 9). As a result, DOI
administration did not significantly elevate plasma renin levels above basal values
in prepubescent progeny. In contrast, while the 5-HT,A agonist 8-0H-DPAT
administration did not significantly elevate plasma renin in adult animals as
previously reported (Van de Kar, 1991 ). 8-0H-DPAT administration to
prepubescent rats resulted in a significant increase in renin levels above basal
values. These data suggest that 5-HT,A receptor systems may indeed play a role
in regulating the secretion of plasma renin in prepubescent animals and possibly in
adults as well. Therefore, in adults, either 5-HT,A receptor systems cease to play a
role in renin secretion or the 5-HT,A receptor-mediated stimulation of plasma renin
is "suppressed" in adults by the presence of other neurotransmitter systems which
follow a later developmental time course. Alternatively, in prepubescent offspring,
8-0H-DPAT may be interacting with non-serotonergic receptors early in
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development. The stimulation of these non-serotonergic receptors may then result
in an increase in plasma renin secretion. This possibility could result from
differences in the affinity of "immature" vs. "mature" receptors for 8-0H-DPAT.
This latter suggestion is supported by the fact that 8-0H-DPA T can significantly
and markedly elevate plasma renin in adult rats following a 90% inactivation of 5HT1A receptors (unpublished observations). However, saturation studies of 8-0HDPA T carried out in several brain regions of developing rats (ages ranging from PD

1 2 - PD 26) suggests that 8-0H-DPAT interacts with a single population of sites
with no significant change in affinity.

Growth Parameters

The inability of fluoxetine to alter nutritional intake in the pregnant rats
suggests that the effects observed in the progeny are not the result of druginduced malnutrition. Likewise, deficits in progeny 5-HT systems cannot be
attributed to drug-induced differences in nurturing because the offspring were
fostered to untreated lactating dams at birth. In utero exposure to fluoxetine
during the last week of gestation did not produce any visually apparent terata, and
the only evidence of alterations in the physical maturation of offspring were the
significant changes observed in body weight in fluoxetine-exposed offspring at
birth and at PD 70. Our data are consistent with other studies that report an
absence of effects of prenatal fluoxetine administration on the general physical
appearance and development of offspring (Vorhees et al., 1994; Byrd and
Markham, 1994) despite the fact that the prenatal treatment procedures used in
most other studies were generally of longer duration (GD 8 through GD 20-22).
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Conclusions

Prenatal exposure to fluoxetine alters both pre- (e.g. 5-HT content, 5-HT
uptake sites) and postsynaptic (e.g. 5-HT 2 receptor number and function)
components of brain 5-HT pathways in offspring. Marked neurochemical and
functional changes in central 5-HT systems occur in progeny prenatally exposed to
fluoxetine in the absence of visually apparent physical abnormalities. In addition,
the nature of the neurochemical and functional alterations are age-specific;
indicating that the examination of multiple age groups is required to obtain a more
comprehensive profile of alterations in brain 5-HT systems in progeny which may
be produced by prenatal exposure to drugs which can disrupt brain development.
These dissertation studies indicate that prenatal fluoxetine exposure does
not produce widespread or global changes in central 5-HT systems. Rather, the
alterations are localized to discrete neuroanatomic nuclei. In particular, 5-HT
pathways which are integral components of the limbic system appear to be
particularly vulnerable to the disruption of brain 5-HT concentrations produced by
fluoxetine administration during the last week of pregnancy. This conclusion is
supported by the early onset of alterations in the number of 5-HT uptake sites (an
index of the extent of serotonergic innervation) in several limbic brain regions (e.g.
hippocampus, hypothalamus, and amygdala). In addition, a number of limbic areas
exhibited marked alterations in the number of 5-HT 2 receptors present in both
prepubescent and adult offspring prenatally exposed to fluoxetine. Activation of
the limbic system mediates emotional responses, "fight or flight" reactions, as well
as food finding and sexual behaviors. Thus, alterations in the functional capacity
of serotonergic projections to limbic areas may be of clinical significance to human
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offspring prenatally exposed to fluoxetine. These data also indicate that brain 5HT pathways remain compromised long-after the initial prenatal insult (i.e. up to 70
days postnatal).
As alterations in brain 5-HT pathways have been implicated in the etiology
of a variety of clinical disorders (e.g. depression, aggression, anxiety), human
offspring exhibiting neurochemical alterations similar to those described in these
dissertation studies may be particularly susceptible to developing psychiatric
disorders which involve dysfunctional 5-HT pathways. Alternatively, human
offspring exposed prenatally to fluoxetine may exhibit a differential sensitivity or
responsiveness to therapeutic interventions which modulate brain 5-HT systems.
The data from the present studies also suggest that offspring prenatally exposed to
fluoxetine may exhibit altered responses to physiologic or environmental stressors
which involve the activation of specific 5-HT pathways. As neuroendocrine
challenge tests can be performed in humans, the present data indicate the potential
clinical utility of this approach to provide peripheral markers that can be used to
identify changes in brain 5-HT pathways in human offspring exposed in utero to
fluoxetine. The differential profile of alterations in brain 5-HT pathways observed
in young versus adult progeny, suggests that prepubescent and adult offspring
may manifest differential behavioral, psychological or neuroendocrine
abnormalities. In addition, as brain 5-HT pathways modulate the release of other
neurotransmitters (e.g. norepinephrine, dopamine, acetylcholine), alterations in
specific brain 5-HT pathways, as a consequence of prenatal fluoxetine exposure,
may indirectly affect the functional status of non-serotonergic neuronal pathways.
Finally, as the alterations observed in the present studies may be generalizable to
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other selective serotonin reuptake inhibitors, the implications of these findings may
be of greater clinical significance than if these effects were attributed exclusively
to fluoxetine.
Future Directions of Research

While the studies put forth in this dissertation represent the first
comprehensive examination and demonstration of changes in brain 5-HT systems
following prenatal fluoxetine exposure, a number of questions remain to be
addressed. For example, the absence of global changes in 5-HT content in a
number of brain regions as reported herein does not preclude the possibility that
more discrete changes in neuronal 5-HT content may have occurred which were
beyond the detection limit of the homogenate assays used in the present studies.
Therefore, future studies could follow a similar prenatal protocol as outlined in this
document, but use immunohistochemical techniques to determine whether 5-HT
immunoreactivity is altered in more discrete loci. In addition, these studies could
be carried out in offspring representing several age-groups in order to provide a
more comprehensive investigation of age-dependent alterations in 5-HT content.
In addition, while evidence suggests that changes in 5-HT uptake sites (as reported
herein) reflect alterations in the extent of serotonergic innervation, one cannot
preclude the possibility that the changes in 5-HT uptake sites represent
compensatory changes in the number of transporters per terminal, independent of
changes in terminal density. Future studies could more directly determine whether
the extent innervation and/or the number of transporters per neuron is altered by
prenatal fluoxetine exposure. This could be accomplished by using
immunohistochemical techniques using antibodies which selectively recognize the
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5-HT transporter in combination with 5-HT immunocytochemistry or electron
microscopy to visualize the extent of innervation density in specific brain regions.
Also, additional studies could be carried out in synaptosomal preparations in order
to elucidate whether transporter function (e.g. 5-HT uptake or release) is altered in
various brain regions. These studies would be particularly important to carry out in
the median raphe as the present studies suggest abnormal neuron function in this
area.

Fluoxetine was administered only during the last week of gestation in the

current dissertation studies. Thus, these studies may represent the minimal degree
of disruption present in brain 5-HT systems following prenatal exposure to
fluoxetine. Future studies could include changes in the prenatal treatment
paradigm in order to more closely reflect the human condition and to determine a
wider spectrum of possible alterations following prenatal fluoxetine exposure. For
example, future studies could administer the drug orally or prior to conception and
continue throughout pregnancy. These studies could also include continuing the
fluoxetine treatment postnatally.
Although the focus of these dissertation studies was to investigate changes
in brain 5-HT systems, additional studies could be carried out to assess
neurochemical and functional changes in other neurotransmitter systems (e.g. the
catecholamines) consequent to the 5-HT alterations or directly attributed to
prenatal fluoxetine exposure.
Future directions of research might also include studies which will
investigate some of the potential functional implications of the changes in brain 5HT pathways outlined in this dissertation. For example, the dissertation studies
suggest that offspring prenatally exposed to fluoxetine may exhibit abnormal
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neuroendocrine responses to stressful or aversive stimuli. Therefore, future
studies could assess whether such stimuli result in abnormal responses in offspring
prenatally exposed to fluoxetine. In order to assess whether prenatal fluoxetineexposed offspring exhibit altered neurochemical responses to therapeutic
interventions which modulate brain 5-HT systems, offspring could be subjected to
repeated drug administration protocols which are known to affect 5-HT receptor
function. In addition to investigations which can be carried out in animal models,
clinical studies using neuroendocrine challenge tests could be carried in human
offspring known to have been exposed to fluoxetine in utero in order to determine
whether animal models are in fact predictive of changes which may occur in
human offspring. Lastly, all the aforementioned studies, including those described
within this dissertation, can also be carried out with other selective serotonin
reuptake inhibitors to assess whether the changes observed in this dissertation are
in fact generalizable to other drugs within the same class.
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Appendix 1 . Metabolic pathway for serotonin synthesis and degradation in 5-HT
neurons. L-tryptophan is taken up into the 5-HT neuron via an amino acid transporter.
Once inside the neuron, in the rate limiting step, tryptophan is converted to 5hydroxytryptophan via tryptophan hydroxylase.
5-hydroxytryptophan is then
converted to 5-HT via amino acid decarboxylase. 5-HT is either stored in secretory
vesicles where it is protected from enzymatic breakdown or it is metabolized to 5HIAA via monoamine oxidase.
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Appendix 2. Mechanistic illustration of the PCA-mediated reduction in 5-HT content.
PCA enters 5-HT terminals via the 5-HT transporter (filled hexagon) and facilitates the
release of the cytoplasmic pool of 5-HT by a reversal of the 5-HT transporter.
Subsequently, the reuptake of 5-HT back into the nerve terminal is inhibited in the
presence of PCA. In addition, once inside the neuron, PCA inhibits the synthesis of
5-HT by inhibiting the enzyme tryptophan hydroxylase. Over time, brain 5-HT content
is reduced. The extent of the reduction is dependent on the brain region examined.
Short term, alterations in the ability of PCA to reduce brain 5-HT content are in.dicative
of: ( 1) alterations in the size of the releasable pool of 5-HT; or (2) alterations in the 5HT uptake or release processes within the serotonergic neurons.
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Appendix 3. Schematic drawing of brain 5-HT pathways. 5-HT cell bodies located
in the dorsal and median raphe nuclei project to various forebrain regions including the
hypothalamus. 5-HT neurons directly innervate corticotropin releasing hormone (CRH)
containing cells in the hypothalamus (Hypo). Activation of these 5-HT neurons
stimulates the release of CRH. CRH acts at the anterior pituitary to stimulate the
release of ACTH, which increases plasma ACTH levels and subsequently stimulates
the release of corticosterone from the adrenal gland. Evidence suggests that
activation of midbrain serotonergic neurons may result in the secretion of a putative
renin releasing factor (RRF) from the hypothalamus. This RRF may then act on the
juxtaglomerular cells of the kidney to stimulate the release of renin which catalyzes
the conversion of angiotensinogen to angiotensin I.
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Aooendix 4. Schematic representation of 5-HT synapse in the hypothalamus.
Activation of serotonergic projections to the hypothalamus results in the release of
endogenous stores of 5-HT into the synaptic cleft. 5-HT can then interact with
postsynaptic 5-HT,A and/or 5-HT 2 A12 c receptors. The stimulation of 5-HT,A receptors
either by endogenous 5-HT or by the 5-HT,A agonist 8-0H-DPAT elicits an increase
in plasma ACTH and consequently corticosterone. The stimulation of 5-HT 2 A12 c
receptors either by the endogenous ligand or by the 5-HT 2 A12 c agonist DOI elicits an
increase in plasma ACTH, cortiocosterone and renin. Changes in the magnitude of the
agonist-stimulated elevations in plasma hormones are indicative of alterations in the
respective receptor systems activated.

180
OOOOOQOOLJOQQOOOOO
I I I I I I I I
I I I I I I I I
11111111

11~11

00000000

00~0::5

GDP

3H-Ketanserin
00000000
00000000~00000000
I I I I I I I I

11111111

00000000

L

I I I I I I I I
1~111@5

o

a

oo

y

I I I
I

I

I
I

I

I I I I
I

I

I

I

1251-DOI
H

00000000

00000

~

GT Pase

GTP

~

GTP GDP
00000000[)00000000

I I I I I I I I

I I I I 11 I I
1111~11

11111111

00000000

o/"::'p
~

y

oo

a y

~GDP

J

GTP

t

Adenylyl cyclase
Phospholipase C

(00

A + R

¢.

A• RL + T

¢.

A • RH• T

)

Appendix 5. Schematic drawing of the steps involved in the 5-HT1A and 5-HT2A
receptor activation of second messenger systems. The 5-HT 1A and 5-HT zA receptors
are membrane bound proteins. The interaction of the ligand with the receptor
facilitates the coupling of the receptor with its respective G-protein, forming the
ternary complex which is a transient intermediate in vivo but stabilized in vitro in the
absence of exogenous GTP. GTP displaces GDP from the a subunit of the G-protein;
the a subunit dissociates from the agonistereceptor complex freeing the 15y subunits
of the G-protein, the receptor and agonist. The activated a subunit interacts with
intracellular proteins to elicit a physiologic response and the receptor is converted to
the low affinity state for agonists. The GTPase activity of the a subunit converts the
GTP to GDP; then the a and 15y subunits reassociate. [ 125 1]001 labels the coupled (high
affinity) state of the 5-HT zA receptor. [ 3 H]ketanserin labels both the coupled (high
affinity) and uncoupled (low affinity) state of the receptor. Panel Bis a mathematical
representation of the ternary complex model illustrated in panel A. Abbreviations: A,
endogenous ligand or directly acting agonist; H receptor high affinity state; L, receptor
low affinity state; RH receptor high affinity state; RL, receptor low affinity state; T,
transducer. a, 15, and y indicate different subunits of the guanine nucleotide regulatory
protein. The shaded inverted triangle represents the endogenous neurotransmitter or
receptor agonist.

APPENDIX 6

P VALUES FROM 3-WAY ANALYSIS OF VARIANCE OF SEROTONIN LEVELS ACROSS SEVERAL BRAIN REGIONS

Brain Region
Factor

Frontal Cortex

Hypothalamus

Hippocampus

Striatum

Mid brain

0.0000

0.0674

0.0006

0.6843

0.4304

Prenatal Exposure

.9680

.5858

.9150

.4011

.2429

Postnatal PCA Challenge

.0000

.0014

.0000

.0000

.0092

Age X Prenatal
Exposure

.0002

.6831

.2278

.7315

.3891

Age X Postnatal
PCA Challenge

.7381

.7330

.0852

.2091

.0073

Prenatal Exposure X
Postnatal PCA Challenge

.2356

.8253

.3888

.8628

.5209

Age X Prenatal
Exposure X
Postnatal PCA Challenge

0.4955

0.8676

0.8830

0.5623

0.0261

Age

00
~

APPENDIX 7

P VALUES FROM 3-WAY ANALYSIS OF VARIANCE OF 5-HYDROXY
INDOLE ACETIC ACID LEVELS ACROSS SEVERAL BRAIN REGIONS

Brain Region
Factor
Age

Frontal Cortex

Hypothalamus

Hippocampus

Striatum

Midbrain

0.0047

0.0000

0.0000

0.0000

0.0000

Prenatal Exposure

.4968

.0530

.4300

.4749

.2635

Postnatal PCA Challenge

.7816

.0001

.4992

.5386

.0000

Age X Prenatal
Exposure

.2751

.5460

.9379

.6612

.4729

Age X Postnatal
PCA Challenge

.4855

.8223

.2297

.6068

.6139

Prenatal Exposure X
Postnatal PCA Challenge

.1308

.2023

.7143

.3550

.6544

Age X Prenatal
Exposure X
Postnatal PCA Challenge

0.8260

0.5137

0.9916

0.4950

0.5050

OJ
N
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APPENDIX 8
DESCRIPTION OF DRUGS

Citalopram . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Antidepressant, 5-HT uptake inhibitor
Clomipramine . . . . . . . . . . . . . . . . . . . . . . . Tricyclic antidepressant, 5-HT uptake inhibitor
Desipramine . . . . . . . . . . . . . . . . . .

Tricyclic antidepressant, noradrenergic uptake inhibitor

DOI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5-HT2N2C agonist
Fluoxetine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Antidepressant, 5-HT uptake inhibitor
lpsapirone

......................................... Anxiolytic, 5-HT1A agonist

lsoproterenol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Beta adrenergic agonist
Ketanserin ............................................... 5-HT2 antagonist
5-MT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Nonselective 5-HT agonist
Nialamide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Monoamine oxidase inhibitor
8-0H-DPAT ................................................ 5-HT1A agonist
Paroxetine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Antidepressant, 5-HT uptake inhibitor
PCA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5-HT releaser
Sertraline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Antidepressant, 5-HT uptake inhibitor
Spiperone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5-HT2 antagonist
TFMPP

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5-HT18 agonist

Zimelidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Antidepressant, 5-HT uptake inhibitor

APPENDIX 9

PHARMACOLOGIC PROFILE OF 5-HT UPTAKE BLOCKERS AT VARIOUS NEUROTRANSMITTER RECEPTORS

Fluoxetine 1

>10,000

>10,000

>5,000

>6000

>7000

>1000

.!::!.1

Muscarinic

Tissue
Source

>700

>1300

Rat cortex

Reference

Thomas et al,
1987

Rat cortex
Peroutka and
Snyder, 1980
Sertraline2

4000

12,000

38,000

Paroxetine 1

>10,000

>10,000

>5,000

7700

Citalopram 1

4500

>10,000

>5,000

>10,000

1

Data represent Kd values (nM)

2

Data represent IC 50 values (nM)

10,000

>10,000

19,000

whole brain

Koe, 1990

>10,000

>1000

>1000

89

Rat cortex

Thomas et al,
1987

>10,000

>1000

>1000

2900

Rat cortex

Thomas et al,
1987

APPENDIX 10
SELECTIVITY OF 5-HT UPTAKE BLOCKERS TO INHIBIT [3H]MONOAMINE UPTAKE IN RAT SYNAPTOSOMAL PREPARATIONS

Fluoxetine

Desmethyl-fluoxetineA

Sertraline

3

H]5-HT

NE/5-HT

Reference

14 - 30

500

20 - 26.5

170

4500

20.5

Bolden-Watson &
Richelson, 1993
Thomas et al, 1987
Wong et al, 1985
Fuller et al, 1978

25
220

410
10,000

16.4
45.5

Bolden-Watson &
Richelson, 1993
Fuller et al, 1978

3.4 - 7.3

220 - 1400

65 - 192

Tulloch & Johnson, 1992
Van Harten, 1993
Bolden-Watson &
Richelson, 1993

76

420

5.5

Bolden-Watson &
Richelson, 1993

1.1 - 3.2

350

320

Thomas et al, 1987
Wong et al, 1991

3100

370

ND

Haddock et al, 1989

>10,000

>10,000

ND

Haddock et al, 1989

2.6 - 11.2

3900

1500

Thomas et al, 1987
Wong et al, 1991

1.8

8800

4889

Milne & Goa, 1991

Desmethyl-sertralineA

Paroxetine
Metabolite I sulphate
Metabolite I glucuronide

Citalopram
Desmethyl-citalopramA· 1

3

H]NE

[

Data represent K; values (nM); AActive metabolite;

1

[

Data represent IC50 values (nM).

--"
(X)

CJ"1
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APPENDIX 11

AFFINITIES OF 5-HT UPTAKE BLOCKERS FOR THE 5-HT TRANSPORTER

Drug

K; (nM)

Tissue Source

Reference

Fluoxetine

1.2

rat cerebral cortex

Marcusson et al, 1992

Sertraline

0.57

rat whole brain

Koe et al, 1990

Paroxetine

0.01

rat cerebral cortex

Battaglia et al, 1988

Citalopram

0.63

rat cerebral cortex

Marcusson et al, 1992

APPENDIX 12
SUMMARY OF STATISTICAL ANALYSES PERFORMED IN THE DISSERTATION STUDIES
Parameter

Growth & Maturation Parameters
Maternal weight gain
Male:Female ratio
Litter Size
Crown-Rump Length
Anogenital distance
Birth weight
Radioligand Binding Assays
5-HT Uptake sites in homogenates
5-HT zAizc receptors in homogenates
Autoradiography
5-HT uptake site autoradiography
5-HT,A receptor autoradiography
5-HT zA receptor autoradiography (High)
5-HT zA receptor autoradiography (High & Low)
Saturation tests for 5-HT zA (high) receptors
Saturation tests for 5-HT zA (high & low) receptors
Percentage High Affinity 5-HT zA receptors
HPLC Determinations**
Basal levels of 5-HT
Basal levels of 5-HIAA
5-HT /5-HIAA
Reduction in regional
5-HT content following PCA

Statistical
Analysis

Post-Hoc
Test

Factors

1-way
t-test
t-test
2-way
2-way
2-way

NK
N/A
N/A
NK
NK
NK

In
In
In
In
In
In

2-way
2-way

NK
NK

In utero exposure group X age
In utero exposure group X age

2-way
2-way
2-way
2-way
2-way
2-way
2-way

NK
NK
NK
NK
NK
NK
NK

In
In
In
In
In
In
In

utero
utero
utero
utero
utero
utero
utero

exposure
exposure
exposure
exposure
exposure
exposure
exposure

group
group
group
group
group
group
group

X
X
X
X
X
X
X

age
age
age
age
age
age
age

2-way
2-way
2-way
2-way

NK
NK
NK
NK

In
In
In
In

utero
utero
utero
utero

exposure
exposure
exposure
exposure

group
group
group
group

X
X
X
X

age
age
age
age

utero
utero
utero
utero
utero
utero

exposure
exposure
exposure
exposure
exposure
exposure

group
group
group
group X gender
group X gender
group X gender

00
-...J

APPENDIX 12 Continued
Parameter

Statistical
Analysis

Post-hoc
Test

Factors

Functional Assays
ACTH response to 8-0H-DPA T
3-way
NK
In utero exposure group
Corticosterone response to 8-0H-DPAT 3-way
NK
In utero exposure group
3-way
Renin response to 8-0H-DPAT
NK
In utero exposure group
3-way
ACTH response to DOI
NK
In utero exposure group
3-way
Corticosterone response to DOI
NK
In utero exposure group
3-way
Renin response to DOI
NK
In utero exposure group
Abbrev1at1ons: 1-way, 1-way analysis of variance; 2-way, 2-way analysis of variance; 3-way,
Newman-Keuls post-hoc test; N/A, not applicable.

X age X postnatal challenge
X age X postnatal challenge
X age X postnatal challenge
X age X postnatal challenge
X age X postnatal challenge
X age X postnatal challenge
3-way analysis of variance; NK,

Note: Each brain region will be analyzed independently

* * Initially, a 3-way ANOVA will be carried out for each parameter with In Utero treatment group X age X postnatal challenge as
the factors.

(X)
(X)
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